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Summary
Viral vectors are playing an increasingly important role in the vaccine and gene
therapy fields. The broad spectrum of potential applications, together with
expanding medical markets, drives the efforts to improve the production processes
for viral vaccines and viral vectors. Developing countries, in particular, are
becoming the main vaccine market. It is thus critical to decrease the cost per
dose, which is only achievable by improving the production process. In particular
advances in the upstream processing have substantially increased bioreactor yields,
shifting the bioprocess bottlenecks towards the downstream processing. The
work presented in this thesis aimed to develop new processes for adenoviruses
purification. The use of state-of-the-art technology combined with innovative
continuous processes contributed to build robust and cost-effective strategies for
purification of complex biopharmaceuticals.
An introduction in chapter 1 reviews the current advances in the purification
development for viral vectors and viral vaccines. Emphasis is given to novel
strategies for process intensification, such as continuous or semi-continuous systems
based on multicolumn technology, opening up process efficiency. Part II of the
thesis focuses on the understanding and improving the performance of unit
operation, such as ultrafiltration and anion exchange chromatography. Chapter
2 describes the development of a novel class of ultrafiltration (UF) cassettes for
virus concentration/diafiltration. A detailed study was conducted to evaluate the
effects of (i) membrane materials, namely polyethersulfone (PES), regenerated
cellulose (RC), and highly cross-linked RC (xRC), (ii) nominal cut-off, and (iii)
UF device geometry at different production scales. The results indicate that
the xRC cassettes with a cut-off of approximately 500 kDa are able to achieve a
10-fold concentration factor with 100% recovery of particles with a process time
twice as fast as that of a commercially available hollow fiber.
Chapter 3 reports the impacts of quaternary amine ligand density and matrix
structure, namely hydrogel-grafted and directly-grafted, on state-of-the-art chro-
matographic membranes operated in bind-and-elute mode for the purification of
adenovirus serotype 5. The results show that the hydrogel-grafted membranes are
xxiii
more suitable for virus purification than the directly grafted ones. By reducing
the number of grafted ligands to low (1.7 µmol/cm2) or medium (2.4 µmol/cm2)
density, it is possible to increase the recovery of purified virus by 60% compared
to a highly charged membrane (3.3 µmol/cm2) that yielded a recovery rate lower
than 30%. Overall, this work gives an outstanding contribution to the under-
standing and development of new membrane adsorbers specifically designed for
virus purification.
In part III we step into the design of a new processes. Chapter 4 reports
the design and experimental validation of a simple quasi-continuous, open-loop,
two-column countercurrent chromatographic process for size-exclusion purification
of adenovirus serotype 5 (Ad5). The pilot-scale run yielded a virus recovery of 86%,
and a clearance of 90% and 89% for DNA and HCP, respectively, without any fine
tunning of the predetermined operating parameters. These figures compare very
favorably against single-column batch chromatography for the same volume of
size-exclusion resin. However, and most importantly, the virus yield was increased
from 57% for the batch system to 86% for the two-column SEC process because
of internal recycling of the mixed fractions of contaminated Ad5, even though
the two-column process was operated strictly in an open-loop configuration. And
last, but not least, the productivity was increased by 6-fold with the two-column
process. Chapter 5 validates the robustness of the 2-column process described
in chapter 4. A general procedure for robust design evaluation under parameter
uncertainty is described. The robust design is exemplified on the case where the
column volume and interparticle porosity are subject to uncertainty. As expected,
to increase the robustness of the 2CSMB-SEC process it is necessary to reduce
its productivity and increase its solvent consumption. Nevertheless, the design
solution given by the proposed robust approach is the least detrimental of all
possible feasible candidate solutions.
Finally in chapter 6 a rational design of a flowthrough process was implemented
by using Surface plasmon resonance (SPR) as scale down tools. The design space
predicted by SPR experiments was employed to design a flowthourgh process
using a salt tolerant membrane adsorber (STIC) from Sartorius Stedim Biotech
and Capto Core 700 resin from Ge Healthercare connected in series. The full
process development showed that the DNA clearance achieved is roughly 4 logs
reduction. Also, virus recovery is boosted, especially in the first chromatographic
unit operation (STIC membranes) where summing up the virus in FT and the
virus eluted the recovery is close to 100%. As for HCP reduction is 5 logs,
however while most of the DNA clearance is achieved in the STIC membrane, the
xxiv
HCP reduction is mainly achieved by using the Capto Core 700. This thesis has
contributed to fields of gene therapy, vaccination and bioengineering of complex
pharmaceuticals by developing innovative downstream processes. This was possible
by combining state-of-the-art materials and matrices, with computer aided process
and simulation. We firmly believe that strategies developed herein pave the way




Os vectores virais têm uma importância crescente na área das vacinas e da terapia
génica.Um vasto conjunto de aplicações assim como novos mercados resultam
num interesse crescente na optimizao dos respectivos processos de produo. Os
pases em vias de desenvolvimento so um dos principais alvos, sendo por isso
crtico a diminuição do custo por dose. Nas últimas décadas foram efectuados
grandes avanos na rea de produção tendo o passo limitante sido desviado para a
purificação dos respectivos biofármacos. O trabalho desenvolvido e apresentado
nesta tese teve como objectivo o desenvolvimento de novos processos de purificação
para adenovirus através de novas tecnologias e combinando processos continuos,
integrados e economicamente sustentáveis para a purificação de biofármacos
complexos. No captulo I são descritos os principais avanços e desafios tecnológicos
com que se depara a purificao de vacinas e vectores virais. O ênfase é colocado
em novas estratégias para intensificação de processo como o uso de sistemas
continuos ou de várias colunas de forma a aumentar a eficiência. Na segunda parte
da tese o objectivo é compreendere melhorar cada uma das operações unitárias
tais como a ultrafiltração ou a cromatografia de troca aniónica. No caṕıtulo 2
descreve-se o desenvolvimento de uma nova classe de cassetes de ultrafiltração para
concentração e diafiltração de virus. Um estudo detalhado foi conduzido por forma
a avaliar o efeito dos materiais, nomeadamente polietersulfona, celulose regenerada
e diferentes tamanhos e geometrias de poro. No caṕıtulo 3 descreve-se o impacto
da densidade de um ligando com amina quaternária e da densidade da matriz,
nomeadamente com implantes de hidrogel ou implantes directos. Os resultados
mostram que as menbranas com implantes de hidrogel são mais apropriadas para
purificação de vrus. Por redução do número de ligando implantado é posśıvel
aumentar o rendimento de v́ırus purificados para 60% comparando com as que têm
alta densidade de ligando em que o rendimento é menor do que 30%. Globalmente
este trabalho contribui para o aprofundar do conhecimento e desenvolvimento
the novas membranas de cromatografia desenhadas especificamente para v́ırus.
Na parte III inicia-se o desenho de novos processos. No caṕıtulo 4 reporta-se o
desenho e a validação experimental de um sistema de quase continuo de duas
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colunas em contra corrente para a purificação por exclusão molecular de adenovrus.
O processo piloto teve um rendimento de 86% e uma remoção de DNA de 90% e
de protéına de 89%. O resultado mais significativo foi o aumento do rendimento
de 57% para 86% quando se passou do tradicional leito fixo para para o sistema
de duas colunas de exclusão molecular. Por fim um aumento de 6 vezes da
produtividade do sistema foi conseguido. No caṕıtulo 5 validou-se a robustez do
sistema descrito no caṕıtulo anterior. É também descrito um procedimento geral
para o desenho robusto através da inclusão de incerteza em parâmetros como o
volume de coluna e a porosidade intraparticular.
Como seria expectvel, o incremento da robustez do processo 2CSMB-SEC
feito custa da reduo da produtividade e do aumento do consumo de eluente. No
entanto, a soluo obtida atravs desta metodologia a menos penalizante do conjunto
de solues possveis.
Por fim, no caṕıtulo 6 o desenho racional de um processo em que não há
ligação do produto à matriz foi implementado usando SPR em escala reduzida.
Foram usadas membranas tolerantes ao sal (STIC) da Sartorius Stedim e a resina
Capto Core 700 da GE ligadas em série. O desenvolvimento completo do processo
mostra que se consegue reduzir 4 logs de DNA assim como um aumento na recolha
de v́ırus. Tal como a redução de protéınas das células hospedeiras é 5 logs. A
maior parte do DNA é removido na primeira membrana e as protéınas na resina.
Globalmente esta tese contribui para a área da terapia génica, vacinas e bioengen-
haria de fármacos complexos através do desenvolvimento de inovadores processos
de purificação. Isto só foi possvel através da combinação de materiais e matrizes
inovadoras, com o suporte de modelação matemática e simulação. Acreditamos
que as estratégias desenvolvidas neste trabalho contribuem significativamente
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Downstream processing of virus particles for vaccination or gene therapy is becom-
ing critical as upstream titers keep improving. Moreover, the growing pressure to
develop cost-efficient processes has brought forward new downstream trains. This
review aims at analyzing the state-of-the-art in viral downstream purification
processes, encompassing the classical unit operations and their recent develop-
ments. Emphasis is given to novel strategies for process intensification, such as
continuous or semi-continuous systems based on multicolumn technology, opening
up process efficiency. Process understanding in the light of the pharmaceutical
quality by design (QbD) initiative is also discussed. Finally, an outlook of the
upcoming breakthrough technologies is presented.




Viral vectors are playing an increasingly important role in the vaccine and gene
therapy fields (Morenweiser, 2005). Vaccines are entering a renaissance period
after thirty years where few changes were introduced. They continue to be an
attractive health care tool as well as sustainable business for several reasons:
(i) vaccine demand has grown rapidly over the past decade in particular due to
emerging markets, (ii) many important medical needs are unmet where vaccines
may play a decisive role; (iii) previously intractable targets may now be within
reach for vaccination because of advances in immunology and microbiology and a
better understanding of pathogenesis (Smith et al., 2011). Moreover, the vaccine
sector is not so prone to sharp revenue declines from expiration of patents unlike
the rest of the pharmaceutical industry. Finally, high complexity of the vaccine
products is a barrier to the entry of new competitors, which new technologies can
overcome (Josefsberg and Buckland, 2012).
The first vaccines consisted mainly in live attenuated viruses (e.g., smallpox,
rabies) or inactivated bacteria (e.g., pertussis). Nowadays new technologies
are employed, such as the development of purified and inactivated viruses (e.g.,
hepatitis A), virus-like particles (e.g, hepatitis B,human papilloma virus and
influenza) (Margine et al., 2012; Pushko et al., 2011; Kang et al., 2012a; Chackerian,
2007), and polysaccharides (e.g., pneumococcal vaccines) (Miller et al., 2011).
Amongst these new trends, viral vectors are becoming important, as they allow
the simultaneous expression of multiple antigens while avoiding the safety risks
associated with the use of the whole pathogenic virus (Liniger et al., 2007).
Viral vectors that have been used in the past include poxvirus, herpesvirus,
and adenovirus (Geels and Ye, 2010). In particular, adenoviruses are considered
one of the most suitable platforms for vaccine development because they are
efficient at delivering DNA to the target cells (McConnell, 2009). Different human
serotypes are under evaluation for developing effective vaccines: Ad26, Ad35, and
Ad5, for HIV and Malaria (Zak et al., 2012; Baden et al., 2013; Ouédraogo et al.,
2013; Majhen et al., 2014) and, more recently, chimpanzee adenovirus (Ewer et al.,
2013; Nébié et al., 2014).
In the gene therapy field, although nonviral delivery approaches are becoming
common, viral vectors remain by far the most used tools, employed in over two-
thirds of the clinical trials performed to date (Ginn et al., 2013). Adenovirus has
been the most used vector (23.3% of the clinical trials carried out worldwide),
followed by retrovirus (19.9%) and then other less widely adopted viruses, such as
6
1.1. INTRODUCTION
poxvirus (5.0%), adeno-associated virus (4.9%), and herpes simplex virus (3.1%)
(Ginn et al., 2013). Nevertheless, so far the first approved gene therapy product is
Glybera R©, based on adeno-associated virus, which is indicated for the treatment of
familial lipoprotein lipase deficiency, an ultra-rare disease that leads to potentially
fatal pancreatisis (Salmon et al., 2014).
The broad spectrum of potential applications, together with expanding medical
markets, drives the efforts to improve the production processes for viral vaccines
and gene therapy vectors (Wolff and Reichl, 2008). Developing countries, in
particular, are becoming the main vaccine market (Makinen et al., 2012; Oyston
and Robinson, 2012). It is thus critical to decrease the cost per dose, which is
only achievable by improving the production process.
Advances in upstream processing have substantially increased the bioreactor
yields. For example, cell densities of 108 cells/ml have been recently obtained using
PER.C6 in a perfusion bioreactor (Vellinga et al., 2014). With such cell density,
a 1000-liter perfusion bioreactor could theoretically yield up to 1019 adenovirus
particles (105 VP/cell× 1011 cells/liter× 1000 liters). Such reported yields are
shifting the process bottlenecks towards the downstream processing (DSP) part.
Moreover, because DSP accounts for up to 70% of the overall production cost, its
improvement will establish more cost effective processes (Morenweiser, 2005).
The main aim of downstream processing is to eliminate contaminants, ei-
ther process related (e.g., bovine serum albumin, Benzonase, extractables, and
leachables) or product related (e.g., host cell proteins, DNA, proteoglycans, and
glycosaminoglycans); other product-related impurities include free proteins, ag-
gregates, and empty capsids. The ultimate goal is to obtain a product with
high purity, potency, and quality, which can meet the stringent guidelines of the
regulatory authorities, such as the FDA and EMA (Table 1.1).
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Virus and viral vectors are complex biopharmaceutical products, which vary
in size, shape, and surface structures. The isoelectric point (pI), the surface
hydrophobicity, presence or absence of an envelope, and the particle lability, can
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play important roles in the design of the downstream train (Wolff and Reichl,
2011). Given this complexity, an effective purification of the bioproduct can only
be achieved by a combination of several unit operations (Fig. 1.1).
This review focuses on the available downstream processing strategies for viral
vaccines and gene therapy vectors, including technological advances and emerging
industrial trends. To be more precise, the classical unit operations, namely
precipitation, flocculation, centrifugation, micro and ultrafiltration, bead-based
chromatography, and convective chromatographic matrices are reviewed. Emphasis
is given to (semi-)continuous purification trains employing simulated moving bed
(SMB) or SMB-type technologies, negative mode chromatography with novel
matrices, and the discussion of relevant case studies. Process characterization and
understanding in light of the pharmaceutical Quality by Design (QbD) initiative
is also addressed.
1.2 Harvest
The first steps of the purification train are heavily influenced by the characteristics
of the bioreactor bulk, namely cell density and viability or by the nature of the
product release, either secreted by budding or cell lysis.
In cases of a lytic virus production, such as adenovirus (Ad) or adeno-associated
(AVV) virus, the viruses are recovered by collecting both the intra- and extra-
cellular fractions, and thus, an additional step is taken to release the virus (Altaras
et al., 2005; Silva et al., 2010a). The cell lysis can be performed using different
methods, such as freeze-thaw, detergents, homogenizer, or sonication. Among the
non-ionic detergents, TritonTM X-100 has often been the preferred choice (Altaras
et al., 2005; Peixoto et al., 2008; Fernandes et al., 2012). Incubating the bulk
with detergent is efficient, fast, robust, easily scalable, cost-effective, and does not
require any investment in equipment; however, removal of such additives has to
be confirmed.
Although cell lysis enables the recovery of intra-celullar virus it also releases
the host cell DNA and proteins, which need to be removed from the final product.
Host cell DNA is of special concern because it not only substantially increases
the viscosity of the bioreaction bulk, but, more importantly, the regulatory
requirements set the DNA acceptable levels between 10 ng and 10 pg per dose,
depending on the type of product, medical indication, production host, and
administration route. Therefore, the majority of published research work and





 #1 Ultra ltration/Dia ltration 
#2 Ultra ltration/Dia ltration 
 #1  Chromatography (Capture)
 #2  Chromatography (Polishing)
Inactivation UV or chemically
     (only for some vaccines)
Figure 1.1: Standard flow chart of unit operations required for viral purification trains.




either simultaneously with cell lysis or after clarification (Altaras et al., 2005;
Peixoto et al., 2008; Fernandes et al., 2012; Segura et al., 2011). For enveloped
virus, such as retrovirus, baculovirus, lentivirus, influenza, or enveloped VLP, cell
lysis is not required since the virus is secreted by the producer cell through a
budding process.
Selective precipitation has been suggested as an alternative to nuclease treat-
ment for the removal of host cell DNA (Goerke et al., 2005; Konz et al., 2005).
Cationic detergents, such as domiphen bromide, are able to precipitate DNA as
well as adenoviral particles (both negatively charged and mildly hydrophobic).
For example it was demonstrated that fine adjustment of the precipitant con-
centration enables up to 90 % DNA removal with more than 90 % adenovirus
recovery (Goerke et al., 2005).
Kröber et al. (2010) implemented a DNA precipitation method for influenza
vaccine: polyethyleneimine (PEI) was used, and the optimal conditions were
obtained through a DoE approach achieving DNA removal of 85%. Selective DNA
precipitation has the advantage of being inexpensive, easily scalable (precipitated
DNA can be removed by depth filter), and suitable for high cell density processes.
Indeed, it has been shown that replacing Benzonase endonuclease with precipita-
tion results in savings of 0.5 million USD for 100 liters of high cell density culture
(Vellinga et al., 2014). Nevertheless, for the sake of completeness, it should be
mentioned that Benzonase is witnessing a patent cliff, and several competitors are
now appearing: Denerase (Sartorius Stedim Biotech), Cyanase (RiboSolution),
Pierce Universal Nuclease (Thermo Scientific), just to name a few. This will likely
cause a substantial decrease in nuclease price and, thus, be beneficial for process
cost improvement.
1.3 Clarification
A suitable clarification step should efficiently remove cell debris and large aggre-
gates (product or process-related), while maintaining and protecting the quality
of the product in the flowthrough stream (Vicente et al., 2011b). The ultimate
goal is to prepare the bioreactor bulk for further downstream processing, such as
chromatography and ultrafiltration. Centrifugation and membrane filtration are
the two most common unit operations utilized in this initial step.
Centrifugation is a unit operation widely used at laboratory scale to clarify
bioreactor bulks. At industrial scale, continuous flow centrifugation is the process
of choice. The most commonly utilized centrifuge configurations are tube cen-
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trifuge, chamber centrifuge, and disc centrifuge. Only disc-stack centrifugation
can operate in a semi-continuous way; these centrifuges are continuously fed
with suspensions, clarified liquid is continuously removed, and solids are intermit-
tently ejected (Jungbauer, 2013). The scalability of these centrifuges, particularly
scaling down, is important for optimizing continuous processes. The smallest,
commercially-available, continuous disc-stack centrifuge with intermittent solid
removal must be fed at a minimum rate of 1 L/min. This rate is far too high
for laboratory-scale optimization experiments, particularly when a continuous
operation must be tested for several hours or days. A laboratory scaled-down
continuous operation should mimic the shear stress conditions experienced by the
fluid in regular conventional centrifuge. Thus, attempts are justified to develop
scale-down tools for small-scale, continuous centrifuges (Boychyn et al., 2001;
Westoby et al., 2011; Chatel et al., 2014).
On the other hand, microfiltration (MF) has been gaining favour as an al-
ternative to centrifugation, and can be easily scaled up and implemented in a
cGMP setting. MF membranes have pore sizes in the 0.1–10 µm range and can be
classified as depth filters or “regular” filters depending on whether the solids are
retained across the filter depth or only at its surface. Additionally, depth filters
may include the use of filter aids, e.g., diatomaceous earth (DE), to modify their
structure and charge (Ostreicher et al., 2008). Depth filters have been used for a
wide variety of VLPs and viruses (enveloped and non-enveloped) with recovery
yields reaching 90 % (Peixoto et al., 2008; Fernandes et al., 2012; Vicente et al.,
2009; Kalbfuss et al., 2007; Peixoto et al., 2007). Depth filters are usually preferred
for feed streams with high biomass content, sometimes lysed bulk, due to their
ability to remove solids and impurities by different mechanisms (size exclusion
and hydrophobic and/or electrostatic interactions) (Yigzaw et al., 2006).
Careful selection of the filter (pore size, filter material, and number and
sequence of filter units) and operational parameters (inlet flow rate, pressure drop,
conductivity, and pH) must be assessed in order to avoid virus loss and to retain
solids and soluble impurities along the whole depth of the filter and not only at
its surface. Essentially, the trade-off between feed flow rate/throughput and filter
capacity/impurity removal should be evaluated (Singh et al., 2013; Roush and Lu,
2008).
Membrane microfiltration has also been performed either in normal (dead-end)
or tangential flow (TFF) mode (Rodrigues et al., 2007b; Kalbfuss et al., 2007).
Microfiltration is usually performed under low pressure, especially TFF (less than
0.7 bar), and is better suited for low-cell density bulks fermentation bulks (Liu
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et al., 2010). However, membrane fouling or shear stress-induced cell lysis can
become an issue for virus filtration (van Reis and Zydney, 2007).
The latest advances in upstream processing in terms of high cell density and
increased protein titers are challenging the above-mentioned unit operations. As
noted above, it has been recently reported that PER.C6 cell line is able to reach
up to 108 cell/mL for HIV vaccine candidate productions , (Vellinga et al., 2014),
and MDCK were infected with influenza virus (A/PR/8/34 (H1N1)) at 50× 106
viable cell density (Genzel et al., 2014). Both results were obtained by employing
a novel alternating tangential flow (ATF) perfusion system.
To cope with such high cell densities, novel microfilter configurations based
on old established filter aids has been proposed in several patents. First, a
thin protective layer of filter aid, called the precoat, is built up on the filter
septum by recirculating a filter aid slurry. After precoating, small amounts of
filter aid (body feed) are regularly added to the bioreaction bulk to be filtered.
As filtering progresses, the filter aid, mixed with the suspended solids from the
unfiltered bioreaction bulk, is deposited on the precoat. Thus, a new filtering
surface is continuously formed. Such configuration reportedly permits an enhanced
adsorption during mixing and the formation of a highly porous and permeable cake
(body feed) supported by the filter aid, similarly to what is done in the brewing
industry where diatomaceous earth (DE) is used to clarify beer (Freeman and
McKechnie, 2003). Several patent applications claim that the body feed filtration
(BFF) avoids membrane fouling and enables lower pressure operation over longer
times at higher flow rates without compromising impurity removal. Recently
published work (Thomassen et al., 2013) refers to the use of diatomaceous earth
for clarification of poliovirus. In particular, Celite (577) filter aid deposited on
stainless steel mesh filter with 75 µm pore size, followed by 0.45 and 0.22 µm,
was used. However, the performance of this method was not disclosed and its
potential remains unexplored.
As an alternative to centrifuges, small-scale decanters, with throughputs up
to 30 ml/min, are commercially available, but the separation efficiency may be
too low for many separation problems in the downstream processing of complex
biopharmaceuticals (Jungbauer, 2013). Overall, the availability of small-scale




Ultrafiltration (UF) is a key operation since large-scale processes produce high
volumes of bulk (up to 2 kL for vaccines and 20 kL for mAbs), (Farid, 2007a)
which should be concentrated 10–100 times prior to being further purified by
chromatography. The volumetric concentration and exchange buffer of the virus
bulk is critical not only to obtain high titer vector stocks in the proper formu-
lation buffer, but also to reduce the handled volume; the latter accelerates the
downstream processing and keeps the scalability of the purification train under
manageable levels (Tatsis and Ertl, 2004).
Ultrafiltration is a pressure-driven separation process that employs anisotropic
membranes with molecular weight cut-offs (MWCO) ranging from 0.5 to 1000 kDa
(van Reis and Zydney, 2007). The MWCO is defined as the minimum molecular
weight at which 90% of the solute is retained by the membrane. Ultrafiltration
membranes are generally composed by two main layers: a thick macroporous
support that provides mechanical strength, and a thin skin layer that is responsible
for membrane selectivity and permeability (Liu et al., 2010). UF membranes can
be manufactured using different polymers, such as regenerated cellulose (RC),
polysulfone (PS), polyethersulfone (PES), and polyvinylidene fluoride (PVDF);
RC and modified RC have often shown the best trade-off between low (unspecific)
protein binding, mechanical strength, and resistance to cleaning procedures
(chemical agents and temperature) (Liu et al., 2010; Zydney, 2009; van Reis and
Zydney, 2006).
Ultrafiltration is frequently used to concentrate the bioproduct of interest.
Consequently, the ultrafiltered concentrated feed suspension is obtained in the
retentate stream and not in the permeate stream. UF membranes are selected in
order to ensure rejection of the product of interest while impurities pass through
the membrane to the permeate side. The medium, in which the product is
suspended, may be exchanged by adding a buffer to the feed reservoir as the
ultrafiltration progresses in a process called diafiltration, which is a technique
that uses ultrafiltration membranes to completely remove, replace, or lower the
concentration of salts or solvents from the original solution.
If the buffer is added at the same rate at which the permeate is removed, in
the absence of membrane rejection, the concentration of a given component in
the medium will decrease exponentially (Castino and Wickramasinghe, 1996).
UF is usually performed in tangential flow mode, wherein the cross flow at the
membrane surface creates a “sweeping action” that avoids or lessens concentration
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polarization and gel layer formation. UF processes are usually operated at
a constant transmembrane pressure; however, operation at constant permeate
flux or constant permeate pressure are also implemented in engineering practice
(Liu et al., 2010). These are normally preferred when unfavorable effects, such
as enhanced fouling or product quality deterioration, are associated with high
concentration of the retained species at the membrane surface (Paulen et al.,
2012). For most downstream processes of viral vectors UF is usually operated at
constant transmembrane pressure.
The transmembrane pressure generally used in the downstream processing of
viruses is between 0.5 and 1.4 bar, while the optimum cross flow rate can vary
greatly due to particular structural stability of the virus: enveloped viruses are
more labile than non-enveloped viruses and, thus, more prone to shear-induced
damage (Rodrigues et al., 2007b; Subramanian et al., 2008). The membrane
modules can be stacked in different geometries, such as, for example, flat-sheet
cassette or hollow fibers (HF).
Although UF cassettes result in greater shear rates, these modules provide
shorter processing times as the hydrodynamics of the flow channel is more effective
than in HF at avoiding concentration polarization and gel layer formation (van
Reis and Zydney, 2007; Wolff and Reichl, 2011). However, the majority of the
published reports refers to the use of hollow fiber (HF) modules for virus processing
(Wolff and Reichl, 2011; Rodrigues et al., 2007a) due to the fact that HF modules
provide wider flow paths resulting in lower shear rates (van Reis and Zydney,
2007; Wolff and Reichl, 2011).
Ultrafiltration has been widely used for concentration as well as for buffer
exchange (diafiltration, DF), and is present in almost every virus DSP described
in the literature (Segura et al., 2013; Bandeira et al., 2012; Kamen and Henry,
2004; Rodrigues et al., 2007b; Segura et al., 2012; Wickramasinghe et al., 2005;
Kalbfuss et al., 2007; Subramanian et al., 2008). The membranes used in virus
UF have MWCOs in the range of 100–750 kDa allowing for reasonably high virus
recovery (70–85 %). Despite increasing efforts in developing robust downstream
processing, most of the research in the field of virus purification has focused on the
chromatographic steps. Nevertheless a few papers have provided an in-depth study
of the concentration/UF step: Negrete et al. (2014) optimized the use of hollow
fibers for VLP concentration, Wickramasinghe et al. (2005) evaluated several PES
membranes (micro and ultrafiltration) for the concentration of influenza virus,
and Grzenia et al. (2008) evaluated four different small cut-off PES membranes
for the purification of parvovirus particles. The rest of the available literature
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is focused on virus removal by ultrafiltration membranes for biopharmaceuticals
purification (Antony et al., 2014; Wickramasinghe et al., 2010; Peinador et al.,
2011).
The ideal UF membrane should yield a very high separation factor, thus high
product retention, but also a very high permeability. As correctly pointed out by
Mehta and Zydney (2005), such membranes are not yet available in the market.
1.5 Density gradient centrifugation
Density gradient centrifugation (DGC), either with sucrose, caesium chloride,
or iododixanol gradients, is a well-known and established, classic purification
technique, generally used to purify limited amounts of bulk for preclinical studies.
Briefly, the principle of the method is the separation of particles according to
differences in density and, thereby, when applied to viruses to separate them from
lighter and heavier cellular material. The main advantage of this technique is
the ability to combine the concentration and purification steps in a single unit
operation. Also, the technique offers a good resolution for separating full virions
from empty capsids, which is very difficult to achieve by chromatography.
Although it is theoretically possible to band approximately 1015 virus particles
in a single run with large-scale continuous ultracentrifugation, from an operational
point of view the technique ends up being very laborious and very expensive
to scale up. At large scale, DGC requires high capital and facility investments
(Altaras et al., 2005). We are not aware of any reported attempts in the open
literature to use DGC for large-scale manufacturing. The only notable exceptions
are the continuous ultracentrifugation processes developed in the early 70’s for
influenza virus (Reimer et al., 1967)., Another issue in gradient ultracentrifugation
is the citotoxicity of CsCl, extensively used for adeno- and adeno-associated
viruses, which requires extensive dialysis to eliminate the residual CsCl from the
final product. Given the drawbacks presented above, it is understandable that
scalable chromatographic separation techniques have been the preferred techniques
for large-scale DSP.
1.6 Chromatography
Chromatography has been widely used in the downstream processing of virus
particles for capture, concentration, and purification of the feedstock. The chro-
matographic separation is driven by the selective physico-chemical interactions
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between the viruses and closest impurities and the stationary phase; the separation
can also be based on molecular sieving. Viruses have been purified using three dif-
ferent arrangements of the stationary phases: bead-based packed beds, membrane
adsorbers, and monoliths. Beads are widely used in all the biopharmaceutical
industry; nevertheless, for the vaccine purification they suffer from two main
disadvantages: (i) limited flow rate imposed the compromise between pressure
drop and mass transfer resistances, (ii) and, in most cases, low dynamic binding
capacity, because the surface available for adsorption is limited to the external
bead area. Viruses have sizes that range from 30 nm to 300 nm or larger and,
as such, they cannot diffuse into the pores of most commercial adsorbent beads.
However, bead-based chromatography is still used for purification of poliovirus
and adeno-associated virus since the size of these viral particles, at around 30 nm,
does not pose limited diffusion issues (Thomassen et al., 2013; Chahal et al.,
2007).
Convective chromatography media, such as membranes and monoliths, offer
substantial improvements in capacity, recovery, and reduction of process time. To
date monoliths have generally offered large capacity and high resolution; they con-
sist of a single block of a material with highly interconnected macropores through
which the; biomolecules are transported by essentially convective flux (D’Souza
et al., 2013); they are thus also known as convective interaction media (CIM).
Monolithic columns are based on polymethacrylate and are manufactured with a
radial geometrical design. Their use for viral purification has been extensively
evaluated in the last years, both for enveloped and non-enveloped viruses. Recent
examples include lentivirus , (Bandeira et al., 2012), baculovirus, (Gerster et al.,
2013), rubella (Forcic et al., 2011), enterovirus 71 (Venkatachalam et al., 2014),
and canine adenovirus purification (Fernandes et al., 2012). However, monoliths
have shown to be prone to clogging, especially when high host cell DNA is present
in the bioreactor bulk, although increasing the monolith pore size up to 6 µm is
expected to solve this issue (Benčina et al., 2007).
Membrane adsorbers have emerged as a cost-effective strategy for processing
large volumes of feed streams; they have been used in the biopharmaceutical
industry almost exclusively in flowthrough mode for mAb purification (Weaver
et al., 2013). They consistently yield low pressure drop and little compression
or channelling, which simplifies the operating conditions. Furthermore, they are
often used as a disposable unit, eliminating the need for lengthy cleaning and




Despite the aforementioned advantages, membranes still have some drawbacks,
such as low capacity and poor resolution. More recently, membrane adsorption
chromatography has been applied to the purification of viral vectors in bind-and-
elute mode, yielding recoveries of 60–80% (McNally et al., 2014; Nestola et al.,
2014b; Peixoto et al., 2008).
Besides the three main adsorbent configurations used in virus purification,
several surface chemistries are employed for the separation of the virus parti-
cles. The most common chromatographic modes are ion-exchange (IEX), affinity
chromatography (AC), hydrophobic interaction (IC), mix-mode chromatography
(MMC), and size exclusion chromatography (SEC).
Size exclusion chromatography can only be achieved with bead-based porous
media and not with membrane adsorbers or monoliths. The separation is based on
the difference in molecular size between the virus particles and the impurities; the
former are excluded from the porous matrix and, hence, elute in the interparticle
volume, whereas the latter elute through the porous matrix at different rates.
The operation conditions of SEC are gentle, allowing to maintain infectivity and
immunogenicity, especially critical for labile viruses. SEC is often used at the later
stage of the downstream train and often employed as a polishing step. However,
purification schemes where SEC is followed by IEX have also been reported in
the literature; two prominent examples are the works of Kalbfuss et al. (2007)
and Eglon et al. (2009) for influenza and adenovirus, respectively. The main
drawbacks of SEC are low capacity, product dilution, and poor pressure resistance
of the matrix. Despite these disadvantages this technique has been used in several
viral purification trains reported in the literature.
Currently, the purification of viruses by using IEX is typically operated in
the positive (bind-elute) mode: most of the impurities are collected in the flow-
through pool, while the virus particles and some of the impurities are retained
in the matrix. Due to the differences in charge of the different biomolecules it is
possible to use this process with high resolution elution gradients, separating the
solutes into fractionated cuts, even though they are closely related. Based on the
isoeletric point of the viruses, anionic or cationic exchangers are used. Among
the anionic-exchange chemistries, diethylaminoethanol (DEAE) and quaternary
ammonium (Q) ligands are the most utilized. However, due to the multipoint
adsorption nature of the viruses to the matrix, ligand densities and chemistry
need to be carefully selected. Nestola et al. (2014b) and Vicente et al. (2011a)
have shown that optimal ligand densities are below 2.2 µmol/cm2 for adenovirus
and baculovirus purification and enveloped and non-enveloped virus, respectively.
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Moreover, not only the ligand density, but also the membrane structure with the
presence of the hydrogel layer, appear to play an important role in the adsorption
process (Nestola et al., 2014b).
One drawback of the Q ligand is that the binding is compromised at high
salt concentration. Therefore, new ligands based on primary amine have been
investigated. STICr chromatography membranes (Sartorius Stedim Biotech) and
ChromaSorb (Merck Millipore) are two examples of commercially available prod-
ucts based on primary amine ligands. Nevertheless, there is still a limited number
of published work on the performance analysis of these novel chromatographic
ligands (Woo et al., 2011) (Kang et al., 2012b). Moreover, no attempts to use
membrane chromatography in flow-through mode for virus purification have been
reported in the open literature. As for the cation exchangers they are mainly
used for viruses with isoelectric points above 6; some influenza strains have been
purified by using sulfonic acid chemistry as reported by Banjac et al. (2014).
Affinity chromatography is based on the specific and reversible adsorption
of a ligand with a component of the virus capsid. This technique has been
extensively used at laboratory scale. Some examples are zinc affinity for adenovirus
(Lee et al., 2009), influenza (Opitz et al., 2009), heparin (Wolff et al., 2010;
de las Mercedes Segura et al., 2007) and specific antibody or antibody fragments
(Cameron-Smith and Harbour, 2001). However, affinity chromatography at a
larger scale requires strong and specific interaction; ideally, the ligand should have
a high binding kinetic constant and mild dissociation conditions. Currently, in
the biopharmaceutical industry the most used affinity chemistry used at a large
scale is Protein A for mAb purification. Recently a recombinant version of F25
monoclonal antibody was used for the purification of a new recombinant factor
VIII. The F25 monoclonal antibody was found to recognize an epitope within the
C-terminal part of the heavy chain from amino acid residue 725 to 740 (Thim
et al., 2010). The current large cost for the purification and immobilization of the
ligand makes affinity chromatography very costly to scale-up for virus purification;
also representing a drive for the search of new cheaper ligands.
HIC chromatography has been rarely used, except for some specific applications
in Vaccinia virus (Wolff et al., 2010). This is mainly due to the fact that high salt
concentration, and sometimes also kosmotropic salts, are needed, which can affect
the integrity of the virus capsid. This is especially critical when viral vectors
are used in gene therapy, where maintaining the infective titers throughout the
purification train is critical.
Multimodal or mixed-mode (MM) chromatography simultaneously employs
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various multimodal binding mechanisms, such as ionic interaction, hydrogen
bonding, and hydrophobic interaction. A typical example of MM media is
hydroxyapatite (HAp). HAp is a very complex crystalline compound that adsorbs
a wide variety of substances; the mechanisms underlying virus adsorption to
HAp are, however, still obscure. Recently, the purification of dengue virus
with 64% recovery was reported (Yae et al., 2012). The same research group
investigated the fundamental mechanism of adsorption and desorption of dengue
virus onto HAp media by scanning electron microscopy (SEM) (Saito et al.,
2013). In this study, dengue viruses were bound to the HAp surface by electronic
interactions, and, subsequently, virus envelope fusion was thought to occur with
temperature dependence. These results suggested that virus-HAp interactions
were substantially similar to virus-cell interactions.
Notwithstanding the use of the well established technologies for virus separation
discussed above, some new concepts have been recently proposed, such as steric
exclusion chromatography (SXC). The principle is based on the capture of the
target biomolecule at a non-reactive hydrophilic surface by its mutual steric
exclusion of polyethylene glycol (PEG) (Lee et al., 2012). No direct chemical
interaction between the target and the solid phase is required. Elution is achieved
by reducing the PEG concentration. The selectivity is generally dominated by
the size of the target biomolecule and the size and concentration of the PEG.
The above mentioned study focused on the purification of IgM and bacteriophage
M13K07, but the authors claim that the principle can be applied to other viruses
or large biopharmaceuticals as a replacement of size-exclusion chromatography
(SEC). There are, however, some fundamental differences between the two size-
exclusion techniques. Whereas in SXC the selectivity correlates with molecular
size, with larger species retained more strongly than smaller species, the reverse
applies in SEC. Also, Lee et al. (2012) successfully implemented SXC in hydroxyl-
substituted polymethacrylate monoliths, which provide a hydrophilic surface and
support convective mass transport that is unaffected by the viscosity of the PEG;
SEC is still limited to the packed-bed configuration.
Most of the applications described in the literature for virus purification
are based on positive mode, where the target product binds to the matrix.
Nevertheless, negative modes are being developed and an interesting review by
Lee et al. (2014) details several applications. In particular, new bead-based resins
have been developed for intermediate virus purification and polishing in flow-
through mode. Iyer et al. (2011) proposed the increase of the mean bead diameter
to maximize the binding capacity for the impurities and reduce the overall column
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surface available for virus binding. GE Healthcare recently launched Capto
Core 700, a resin composed of an active core, functionalized with octylamine
ligand, and an inactive porous shell that excludes larger molecules from entering
the core, thus allowing them to be collected in the flow-through. The core has
multimodal binding ligands that allow operation at various ranges of pH and NaCl
concentrations. Recent work showed that the amount of ovalbumin was greatly
reduced in a influenza A purification process (Blom et al., 2014); and the same
resin was successfully used for the polishing step of canine adenovirus (Fernandes
et al., 2012).
One apparent limitation of negative mode is due to the difficulty to efficiently
remove the impurities as compared to positive-mode chromatography; thus so
far, negative mode has been implemented only as a polishing step. Although
much work is still required to promote negative-mode chromatography as a
purification platform, its potential should not be underestimated, especially for
viral vaccines where different serotypes or strains may influence the binding and
elution behavior, leading to routine optimization for every new viral vaccine
candidate in the pipeline.
1.7 Disposable technologies
Disposable technologies are very appealing for bioprocessing and can definitely
play an important role in many process intensification strategies. Disposable
equipment became popular for upstream production in the 1990s, with the advent
of single-use media bags and bioreactors and the use of disposable capsules for
sterile filtration. Over the next few years, disposable concepts also began to
appear in downstream processing. Initially, there were only buffer bags and
devices for normal flow filtration, including virus filtration and guard filters for
chromatographic columns, but gradually more complex concepts were introduced,
including disposable devices for tangential flow filtration and chromatography
(Gottschalk, 2010).
Most of the DSP unit operations described in the previous section are ready to
be fully disposable, from the clarification and concentration to the chromatography
for both capture and polishing. Furthermore, GE Akta devices have also the
possibility for disposable flow-path.
A disadvantage of current single-use systems is the limitation in the scale of
operation. While disposable bioreactors for cell culture are available up to 2000 L,
the current single-use DSP technologies are struggling to keep up with these
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capacities. For very large-scale DSP applications, it is difficult to find pumps,
piping, and probes that are actually single-use. However, at development and pilot
scales, or for small commercial production, some fully single-use systems (such as
the Sius TFF Skid) already represent good solutions for single-use implementation.
This scale-related limitation can also be partially solved when systems are used
in continuous mode.
1.8 Process intensification
Process intensification is an approach to process development originally pioneered
in the chemical industry by ICI (Imperial Chemical Industries, London, UK) in
the early 90’s. The aim was to reduce plant size while maintaining productivity,
thus decreasing cost of goods by lessening capital investments and overhead costs.
Process intensification requires new concepts to manage plant throughput when
existing technologies are approaching their physical limit, as is the case of DSP in
the biopharmaceutical industry. Indeed, the increasing interest in vaccines and
gene therapy, together with the need to decrease the cost per dose, has led to
the development of new chromatographic tools or their conversion from other
application areas (Barut et al., 2005; Riordan et al., 2009; Vicente et al., 2011a).
A classic viral downstream process consists of discrete sequential unit opera-
tions, such as the ones described in the previous sections. The number of unit
operations can vary greatly depending on the final product specification, thera-
peutic dose, and administration route (i.e., oral, blood, intranasal, etc.). However,
by connecting previously separate unit operations or combining individual steps
into one unit operation, product losses and process economics can be minimized.
Integrated processes are required to reduce the number of processing steps to
simplify handling, and to shorten the time that a sensitive labile product such as
an enveloped virus, has to be in contact with harsh conditions, with the overall
aim to reduce the total processing cost and increasing product quality.
One solution that could streamline the downstream train is the implementation
of technologies such as aqueous two-phase partition (ATPS) and expanded-bed
adsorption (EBA), which could potentially combine two or more unit operations
in a single step (D’Souza et al., 2013) (Table 1.2).
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Table 1.2: Process intensification approaches recently employed in viral downstream
processing. SXC, EBA, and ATPS stand for, respectively, steric-exclusion chromatogra-
phy, expanded-bed adsorption, and aqueous two–phase separation; Rec is a shorthand for
recovery.
Purification tool Virus Rec (%) Ref.
Capto Core 700 Influenza, 69 (Fernandes et al., 2012)
Canine Adenovirus 86 (Blom et al., 2014)
SXC Bacteriophage M13K07 90 (Lee et al., 2012)
EBA Adenovirus (Ad5) 65 (Peixoto et al., 2006)
ATPS Adenovirus 90 (Negrete et al., 2007)
Adeno associate (AVV8) 97 (Guo et al., 2012)
VLP Rotavirus 85 (Benavides et al., 2006)
VLP B19 92 (Luechau et al., 2011)
Aqueous two-phase systems are spontaneously formed by mixing two solutions
of different polymers (PEGs, dextran, polyacrilates) or a polymer and a kos-
motropic salt (phosphate, citrate, sulphate). The partitioning of the biomolecule
can then occur into one of the two phases. ATPS has been employed for a
variety of protein separations, including mAbs (Oelmeier et al., 2010). Recent
work has demonstrated that high product yield and large HCP reduction can be
achieved (Cramer and Holstein, 2011). So far, ATPS has barely been explored
for virus recovery. A few examples include adenovirus recovery from a crude
lysate of HEK293 by using PEG 300-phosphate system yielding 90% of infectious
particles (Negrete et al., 2007), and recovery of adeno-associated serotype 8 virus
(AVV8) (Guo et al., 2012). The latter employed 10%PEG8000-13.2 (NH4)2SO4
at pH 8.0 in HEPES buffer, yielding a purity even higher than conventional CsCl
gradient density centrifugation methods. Lately, ATPS was also investigated
for the purification of VLPs, namely rotavirus (Benavides et al., 2006) and B19
(Luechau et al., 2011) with recoveries of 85% and 92%, respectively. The main
advantage of ATPS is its feasibility to operate in a continuous mode. However,
the incorporation of this technology into an industrial setting is still lagging. This
can be attributed to the fact that the mechanisms governing the partition of
complex biopharmaceuticals are still not well understood, and the development of
the method is rather empirical and laborious. Nevertheless, new advances in high
throughput screening (HTPS) can eliminate these bottlenecks. Indeed promising
preliminary results have been shown by using monoclonal antibody by Oelmeier
et al. (2012). The same research group investigated the partition of avidin protein
in aqueous two phase separation by HTPS (Diederich et al., 2013).
Expanded bed chromatography (EBA) is based on the utilization of a fluidized
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bed whose expansion is controlled by the upward flow of the mobile phase. EBA can
process crude feedstock and can potentially replace the clarification and capture
steps. The first generation of EBA adsorbents (Streamline, GE Healthcare),
which consisted of slightly heavier agarose beads, was successfully applied to the
purification of Adenovirus serotype 5 (Ad5) (Peixoto et al., 2006; Lusky, 2005).
Nevertheless, some of the EBA drawbacks are mainly related to an unfavorable
biomass-adsorbent interaction,and led to the failure of several proposed industrial
processes (D’Souza et al., 2013). However, the development of second-generation
EBA adsorbents (Rhobust, DSM) has led to a significant improvement; these new
EBA beads are high density tungsten carbide-cored beads coated with cross-linked
agarose, and are available with several types of functionalities. Although the new
EBA media presents clear advantages over the first generation of materials, such
as high operational flow rates up to 300–600 cm/h, they have not yet been applied
for processing viral vaccines and vectors.
One process-based way to reduce the overall cost of the downstream chromato-
graphic steps is by changing to continuous processing mode; this, in principle,
yields higher throughput, lower buffer consumption, higher capacity utilization and
reduced column volumes, hence increased productivity. In particular, simulating
moving bed (SMB) chromatography, which is the best practical implementa-
tion of continuous countercurrent solid-fluid chromatography (Seidel-Morgenstern
et al., 2008; Silva et al., 2012), is now widely applied for the binary separation of
small molecules, in particular chiral compounds under isocratic elution conditions
(Francotte and Richert, 1997; Rajendran et al., 2009).
Studies concerning continuous downstream bioprocessing have targeted mostly
proteins and monoclonal antibodies (mAb) (Aumann and Morbidelli, 2007; Silva
et al., 2010b; Bochenek et al., 2013); this is primarily because the biopharmaceu-
tical industry is currently dominated by these bioproducts. The systems currently
employed in biopharmaceutical industry are as: MCSGP, GSSR, 3C-PCC, Bio-SC,
and Capture SMB. All of them have proven their ability to purify complex mul-
ticomponent biological mixtures at laboratory scale with typically two to three
(maximum of four) columns (Nicoud, 2014). Recently, Genzyme and Genentech’s
scientists have developed a continuous process for purification of mAbs and re-
combinant therapeutic enzymes using HIC and affinity chromatography (Warikoo
et al., 2012; Godawat et al., 2012; Mahajan et al., 2012).
In the conventional batch operation the chromatographic matrix is loaded until
product breakthrough is detected at the outlet (i.e., 5–10% of feed concentration).
This means that only a fraction (between 30 and 70%) of the chromatographic
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resin capacity is used, because breakthrough happens before the matrix gets fully
loaded. In 3C-PCC, Bio-SC, and Capture SMB the breakthrough effluent is loaded
onto the next column enabling the loading of the first column until exhaustion
(up to static binding capacity). A similar approach is concurrently employed to
the other steps of the cycle (such as elution, washing, and equilibration). This
strategy enables reduced buffer consumption, shorter processing times and better
matrix usage (with concurrent investment and facility footprint savings) (Godawat
et al., 2012; Warikoo et al., 2012).
To date, the continuous purification of large biomolecules, such as viruses,
has rarely been explored. Kröber et al. (2013) recently implemented a classical
three-zone, open-loop SMB for influenza virus purification. Elution was per-
formed isocratically by employing a size-exclusion medium. These authors have
successfully increased the productivity by switching to simulated countercurrent
operation. The only drawback of the proposed process was the co-elution of DNA
with the virus since the bulk was not pretreated with benzonase. Nevertheless,
this was the first attempt of using SMB in virus purification.
More recently Nestola et al. (2014a) proposed more compact, efficient, simu-
lated countercurrent chromatographic (SCCC) process that was used for aden-
ovirus purification. As used for the earlier cited work on influenza, a SEC medium
was employed but the number of columns used was reduced from three to two.
The performance of the process yielded a 6-fold productivity increase, and boosted
recovery yield to 86% coupled with clearances of 90% and 89% for DNA and HCP,
respectively. These two works are, so far, the state-of-the-art for continuous or
quasi-continuous chromatography for viral vaccine or vectors (Table 1.3).
Table 1.3: (Semi-)continuous chromatography applications in viral processing based on
simulating moving bed (SMB) technology. SFF4 stands for Sepharose 4 Fast Flow (GE
Healthcare).
3-column SMB 2-column SCC
Media Size exclusion (SFF4) Size exclusion (SFF4)
Elution type Isocratic Isocratic
Virus Influenza (H1N1) Adenovirus (Ad5)
Recovery (%) 70 86.3
Productivity 3.8-fold increase 6.1-fold increase
Feed Continuous Quasi-continuous
Cycle design Triangle theory Non-linear optimization
Reference (Kröber et al., 2013) (Nestola et al., 2014)
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Figure 1.2: Classic design steps to undergo for the implementation of an SMB technol-
ogy.
(i) the chromatograms from batch experiments provide the basic information
about the retention factors and broadening of the peaks of interest, (ii) the
packing reproducibility and efficiency of the SMB columns are assessed; (iii) the
batch experiments are frequently modeled to a finer extent to better predict the
propagation of the concentration fronts under conditions of finite column efficiency
and overloaded conditions; (iv) the SMB cycle is designed based on the previously
determined chromatographic data; (v) finally, the cycle is validated experimentally
and the operating parameters are fine-tuned if deemed necessary.
Despite the clear advantages of continuous chromatography, as demonstrated
by the works cited above, the biopharmaceutical industry is still hesitating to
switch to continuous or quasi-continuous, multi-column chromatography. This is,
in part, due to the fact that innovation in this industry has traditionally been
more product- than process-oriented, but also due to the increased complexity
in terms of process design and validation. However, companies like Tarpon
are mitigating these issues by commercializing a fully disposable system called
BioSMB. It is also often argued that the volume processed for viral vector or
vaccines is rather modest, and therefore continuous processing would not have a
large added value. Although this argument can be accepted to some extent, the
pressure for a significant decrease of the cost per dose, thus the cost of goods,
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is a strong driver for switching from batch to continuous chromatography in
line with the trend followed by other industries in the past (Nicoud, 2014). The
current tendency in the biopharmaceutical industry is a decrease of the number
of chromatographic columns used in the downstream train, which makes the
implementation of continuous operation somewhat less relevant. This is not a
strong drawback, provided that the plant is well designed and the simulated
counter-current contact between the fluid phase and the adsorbent media is
maintained.
Overall, chromatography is only a part of the global process including upstream
and downstream, and real improvements are really beneficial when a large part
of the process is switched to continuous. In this respect there is still work to be
done, although some of the examples cited above constitute a promising start.
1.9 Process understanding
Proper understanding and characterization of the process is needed to move
towards a full process intensification. Also, in many ways the Quality by De-
sign (QbD) initiative requires a thorough understanding of the product and
its manufacturing process (McCurdy et al., 2011). For QbD, the product- and
process-knowledge base must include an understanding of the variability in raw
materials, the relationship between the process’s and product’s critical quality
attributes (CQAs), and the association between CQAs and the product’s clinical
properties.
Downstream optimization still relies mainly on empirical-based strategies
because most of the biophysico-chemical properties of complex biomolecules are
not fully understood. Nevertheless, new tools, mainly related to high throughput
screening, are easing the problem. It is appropriate to distinguish two main tools
that are used for process understanding, namely Design of Experiments (DoE)
and mechanistic or semi-empirical model-based knowledge (Fig.1.3).
In this section both methods are briefly explored, although their application
in vaccine process development has been scarcely reported in the literature.
DoE relies on the fitting of multivariate data to an empirical function, usually
linear or quadratic with interaction terms, which can be used to provide informa-
tion about the system (maxima and minima, trends as parameters are changed,
etc.). Statistical theory is used to select values of each factor to generate the
data, and to maximize the information about the function parameters. Random-
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Figure 1.3: Different approaches to increase process knowledge in downstream process-
ing. Mechanistic modeling requires a deep understanding of the physico-chemical property
of the system, whereas a data-driven model requires the use of statistical tools such as
DoE or Monte Carlo simulations. However, the two approaches can complement each
other and provide more robust process knowledge, together with the use of high throughput




any uncontrolled variables (e.g., laboratory temperature), which contribute to the
repeatability variance but do not affect the results in a systematic way (Hibbert,
2012).
Although often considered as an industrial optimization tool, the number of
scientific publications employing DoE has increased in the last years (Hibbert,
2012). Nestola et al. (2014b) implemented a DoE evaluation on a 96-well platform
for assessing the effect of the stationary phase’s ligand density and salt concen-
tration on adenovirus adsorption/desorption. A similar approach was used for
optimization of baculovirus purification (Vicente et al., 2011a). Although the DoE
approach is able to deliver helpful information, mainly for assessing the critical
parameters of the design space, its use is considered as a black box approach, since
it does not provide fundamental information regarding the mechanistic model
that governs the biomolecule–resin interaction.
Mechanistic knowledge had been used, to some extent, in the design and
optimization of virus downstream processing trains. For IEX chromatography of
biomolecules, the most utilized adsorption model is the steric mass action (SMA)
model (Brooks and Cramer, 1992), which can predict the binding and elution
behaviour if good estimations of the characteristic charge, equilibrium constants,
and steric factors are available. Some efforts have been initiated to describe a
VLP elution chromatogram using the SMA model (Vicente et al., 2008). However,
in this preliminary study the contribution of the impurities (many of them with
unknown properties) was not included in the multicomponent model. When the
SMA model is applied to describe the IEX mechanism of large biopharmaceuticals,
it is somewhat difficult to determine the characteristic charge, as shown by
Yamamoto et al. (2007) who studied the retention behavior of oligo-DNA onto an
anionic exchange monolith. Indeed, for a characteristic charge larger than ca. 50
it can be quite challenging to determine this parameter experimentally. However,
even more trickier is to use the SMA model in model-based process design and
optimization due to the difficulties of numerically solving the differential material
balance of an IEX adsorber for large values of the characteristic charge.
Nonlinear mathematical programming was used in another study (Nestola
et al., 2014b) in an attempt to determine adsorption isotherms by an inverse
method based on the fitting of the breakthrough curves of adenovirus particles
and its related impurities (HCP and DNA). Partition coefficients and column
efficiency measurements have also been used for the optimal design of a two-
column SMB cycle for adenovirus purification with excellent agreement between




Despite the recent advances in process understanding by using more or less
complex mathematical modelling tools, most of the works described in the litera-
ture are focused on the design or optimization of a single unit operation, mainly
chromatography, although ultrafiltration has also been the subject of modeling
efforts; e.g., Kanani and Ghosh (2007) described a novel approach for predicting
permeate flux decline in constant pressure mode, while Paulen et al. (2012) re-
ported an optimum feeding strategy for diafiltration. Nonetheless, model-based
global optimization of the whole process by integrating several unit operations
has not been attempted so far.
A common approach in the biopharmaceutical industry is the use of simulation
software for cost of goods estimation intended to model all the aspects of the
process. Well known examples are Intelligen SuperPro Designer, Aspen Batch
Plus, and, more recently, BioSolve. This type of software is best suited to provide
a format for process management, using material and energy balances to answer
scheduling questions, explore equipment change-outs, and calculate cost data.
However, the ability of simulation software to accurately predict unit operation
scale-up and perform bioprocess optimization is limited (Shanklin et al., 2001).
Still, several papers are available describing process economics for different mAbs
(Stonier et al., 2012; Farid, 2007b), but for viral vaccines no data are available in
the literature with the exception of a very recent study of VLP process economics
(Chuan et al., 2014). In this study, Monte Carlo simulation was employed to
identify the variance in the unit production cost (UPC) and, through bioprocess
simulation data, it was shown that a vaccine could be manufactured at 1 cent
(USD) per dose using bioreactor sizes of 500 and 300 L.
Finally, for an ideal process understanding, the combination of a response
model (DoE) with a mechanistic model should be considered. The combination of
the two modeling approaches is often referred to as hydrid modeling. Published
studies in which this modeling strategy was implemented require the use of high
throughput screening (HTS) methods for the determination of physicochemical
and thermodynamic properties (Nfor et al., 2009). By using HTS, Nfor et al.
(2012) estimated the linear IEX isotherm parameters of a crude protein mixture
(effective charge and equilibrium constant) from multiple linear NaCl-gradient
experiments according to the approach of Cramer and co-workers, (Gadam et al.,
1993; Ladiwala et al., 2005), while the steric factor was estimated by inverse
fitting (Osberghaus et al., 2012) using experimental salt-gradient chromatograms
obtained under overloaded conditions. For this purpose, the major protein peaks
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were defined as pseudo components, that is, groups of proteins showing comparable
retention/elution behaviour. To our knowledge, the application of this kind of
approach for viral vaccines and vectors has not been reported to date.
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Abstract
The purification of virus particles and viral vectors for vaccine and gene therapy
applications is gaining increasing importance in order to deliver a fast, efficient,
and reliable production process. Ultrafiltration (UF) is a widely employed unit
operation in bioprocessing and its use is present in several steps of the downstream
purification train of biopharmaceuticals. However, to date few studies have
thoroughly investigated the performance of several membrane materials and cut-
offs for virus concentration/diafiltration. The present study aimed at developing
a novel class of UF cassettes for virus concentration/diafiltration. A detailed
study was conducted to evaluate the effects of (i) membrane materials, namely
polyethersulfone (PES), regenerated cellulose (RC), and highly cross-linked RC
(xRC), (ii) nominal cut-off, and (iii) UF device geometry at different production
scales. The results indicate that the xRC cassettes with a cut-off of approximately
500 kDa are able to achieve a 10-fold concentration factor with 100% recovery of
particles with a process time twice as fast as that of a commercially available hollow
fiber. DNA and host cell protein clearances, as well as hydraulic permeability and
fouling behavior, were also assessed.
Keywords: ultrafiltration, virus concentration, vaccine, cassettes, hy-
draulic permeability.
CHAPTER 2. EVALUATION OF NOVEL LARGE CUT-OFF ULTRAFILTRATION
MEMBRANES FOR ADENOVIRUS SEROTYPE 5 (AD5) CONCENTRATION
2.1 Introduction
Viruses and virus like particles (VLP) are playing an increasingly important role
in the vaccine gene and cell therapy fields. Adenoviruses (Ads), in particular, are
considered one of the most suitable platforms for production of viral vaccines
and gene therapy vectors; they are medium-sized (90–100 nm), nonenveloped,
icosahedral viruses composed of a nucleocapsid and linear, non-segmented double
stranded (ds) DNA genome that is about 36 kb long. The use of recombinant Ads
for vaccination and gene therapy requires fast and highly efficient purification
protocols that yield high recovery of infectious particles, maintain viral infectivity,
and effectively remove contaminating DNA and host cell proteins, while also
concentrating the viral samples for final delivery.
The downstream purification train of biopharmaceuticals has been extensively
developed in the past years by combining different chromatographic steps, namely
ion-exchange (Nestola et al., 2014) and size-exclusion chromatography (and, less
frequently, affinity chromatography), intermingled with concentration and ultra/
diafiltration steps (Eglon et al., 2009; Konz et al., 2005a,b; Burova and Ioffe, 2005;
Peixoto et al., 2008; Goerke et al., 2005).
Ultrafiltration (UF) is a key operation, as large-scale processes produce high
volumes of bulk (up to 2 kL for vaccines or 20 kL for mAbs (Farid, 2007)) that
must be concentrated 10–100 times to be further purified by chromatography.
The volumetric concentration and buffer exchange of virus bulks are critical not
only to obtain high titer vector stocks in the proper formulation buffer, but also
to reduce the handled volume; the latter accelerates the downstream processing
and keeps the scalability of the purification train at a manageable level (Tatsis
and Ertl, 2004).
UF membranes can be synthesized from different polymers, such as regenerated
cellulose (RC), polysulfone (PS), polyethersulfone (PES), or polyvinylidene fluoride
(PVF), although RC and highly cross-linked RC display better trade-off between
low (unspecific) protein binding, mechanical strength, and resistance to cleaning
procedures (chemical agents and temperature).
UF is usually operated in tangential flow mode, where the cross flow at the
membrane surface creates a “sweeping action” that avoids or lessens concentration
polarization and gel layer formation, thus inhibiting membrane clogging. UF







where PF is the feed pressure, PR is the retentate pressure, and PP is the
permeate pressure. However, constant permeate flux or constant permeate pressure
operations are also implemented in practice (Liu et al., 2010). These are normally
preferred when unfavorable effects, such as enhanced fouling or product quality
deterioration, are associated with high concentration of retained species at the
membrane wall (Paulen et al., 2012). The work presented here is, however, focused
on constant-∆PT operation.
In viral downstream processes, ∆PT is usually between 0.5 and 1.4 bar, while
the optimal cross flow rates can vary greatly due to the different structural
stabilities of the various types of viruses; enveloped viruses are more labile than
non-enveloped viruses and, thus, more prone to shear-induced damage (Rodrigues
et al., 2007b; Subramanian et al., 2008).
The membrane modules can also be assembled under different arrangements,
for example flat sheet cassettes (FSCs) or hollow fibers (HFs). The majority of
the published work refers to the use of HF modules for virus processing (Wolff and
Reichl, 2011; Rodrigues et al., 2007a) due to the fact that HF modules provide
wider flow paths with lower shear rates (van Reis and Zydney, 2007; Wolff and
Reichl, 2011).
UF has been widely used both for concentration and for buffer exchange
(diafiltration, DF), and is present in almost every virus DSP described in the
literature (Segura et al., 2013; Bandeira et al., 2012; Kamen and Henry, 2004;
Rodrigues et al., 2007b; Segura et al., 2012; Wickramasinghe et al., 2005; Kalbfuss
et al., 2007; Subramanian et al., 2008) and disclosed patents (Luitjens and van
Herk, 2012; Konz et al., 2008; Weggeman and van Corven, 2005). The membranes
used in virus UF have MWCOs in the range of 100–750 kDa allowing for high
virus recovery (70–85%).
Despite the effort in developing robust downstream processes and platforms,
most of the research in the field of virus purification has been focused on the
chromatographic steps. Indeed, only a few works have investigated thoroughly the
concentration/UF steps: Negrete et al. (2014) optimized the use of a hollow fiber
for concentration of virus like particles (VLP), while Wickramasinghe et al. (2005)
evaluated several PES membranes (micro and ultrafiltration) for the concentration
of influenza virus; also, Grzenia et al. (2008) evaluated four different small cut-off
PES membranes for the purification of parvovirus particles. The rest of the
literature is essentially focused on virus removal by UF membranes (Antony et al.,
2014; Wickramasinghe et al., 2010; Peinador et al., 2011). It should be pointed
out that in the present work the viruses are not a contaminant but the product;
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therefore, the aim here is to concentrate and purify adenoviruses for viral vaccine
or gene therapy applications.
The ideal UF membrane should have a very high separation factor, thus high
product retention, and very high permeability. As correctly pointed out by Mehta
and Zydney (2005) and Cramer and Holstein (2011) such membranes are currently
not available in the market.
The present study aimed to develop a novel class of UF cassettes for adenovirus
type 5 (Ad5) concentration/diafiltration. Typical membranes with cut-offs in the
range of 300 to 1000 kDa were compared, since most of the HF membranes for
viral processes have these cut-off sizes. While PES membranes with pore sizes in
this range are known to have quite open structures, RC membranes are typically
much tighter even when their pore size is not narrowed by adsorptive phenomena
during process operation; thus, current commercially available RC membranes are
not suited for typical viral vaccine processes (virus diameters around 100 nm).
A detailed study was conducted to evaluate the effect of membrane mate-
rial, namely PES, RC, and highly cross-linked RC (xRC), nominal cut-off, and
ultrafiltration device geometry. In the first part of the work, the hydraulic per-
meabilities of a set of membranes, which include eight R&D prototypes were
evaluated. Hydraulic permeabilities were assessed for the clean membranes, after
usage, and after cleaning-in-place (CIP). In the second part of the work, a 10-fold
concentration step followed by 5 diafiltrations was performed under constant-∆PT
conditions. The separation factor (total Ad5 recovery and infectivity) and selec-
tivity towards the major impurities, such as host cell proteins (HCPs) and DNA,
were determined and the throughput of each device was appraised. The outper-
forming membranes were then scaled up and produced in standard manufacturing
equipment. Ultimately, the present study identified a new large cut-off membrane
able to achieve a ten-fold concentration factor with higher throughput and 100%
infective Ad5 recovery.
2.2 Materials and Methods
2.2.1 Adenovirus production
The Ad5 production based on HEK 293 cells cultured in Ex-cell 293 serum-free
media was performed in a 5 L working volume bioreactor (Sartorius Stedim
Biotech, Germany). The dissolved oxygen was controlled at 50% air saturation
by a N2/O2/air mixture delivered by a sparger. The aeration rate was 0.01 vvm
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(vessel volumes per minute). The pH-value was controlled at 7.2 ± 0.05 by
aeration with CO2 in the gas mixture and by base addition (1 M NaHCO3). The
temperature was controlled at 37◦C using an external water-filled jacket. Mixing
was provided by two 6-segment Ruston impellers with the agitation rate controlled
between 60 and 210 rpm. The bioreactor inoculum was 0.5× 106 cells/mL, the
cell concentration at infection (CCI) was 106 cells/mL, and a MOI of 5 was used.
The bioreactor was harvested 48 hours post infection (hpi).
2.2.2 Harvest and clarification
After the Ad5 bioreactor harvest, the cells were lysed by adding Triton X-100
(X100, SIGMA-ALDRICH , Switzerland) to a final concentration of 0.1% (w/w).
Simultaneously, Benzonase (Merck Millipore, Germany) was added to a final
concentration of 50 U/mL. The virus-containing bioreactor bulk was incubated at
37◦C for 2 h.
Clarification of the Ad5 bulk was performed using a Sartopore R© 2 filter with
0.8 + 0.45 µm pore size (Sartorius Stedim Biotech, Germany). Before filtration,
the module was primed with 3 capsule volumes of TRIS buffered saline, pH 8.0
(Sigma-Aldrich, Switzerland). The virus-containing bulk was loaded to the filter at
a constant flow rate equivalent to 150 L/m2/h (LMH) using a Tandem 1082 Pump
(Sartorius Stedim Biotech, Germany). The 5 L clarified bulk was transferred into
450 ml Nalgene bottles and frozen at −80◦C until further use. The performances
of the UF membranes were all assessed with material from this batch with the
same concentration of Triton and Benzonase in order to avoid any batch-to-batch
variability.
2.2.3 Ultrafiltration setup
The ultrafiltration cassettes were kindly provided by Sartorius Stedim Biotech,
Germany, while the 750 kDa hollow fiber module was purchased (GE Healthcare
Life Sciences, Sweden). The membrane modules were set up according to the
manufactures’ instructions. Briefly, a Tandem 1082 Pump (Sartorius Stedim
Biotech, Germany) was used to pump the clarified bulk into the membrane device,
the retentate was recycled to the feed container, and the permeate was collected
separately (Fig. 2.1). The transmembrane pressure, ∆PT, was controlled by
adjusting the retentate flow rate using a flow restriction valve.
Before the experiments, the membranes were thoroughly rinsed with ultrapure
water (Grade 1, as defined in ISO 3696). The membrane permeability was
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Figure 2.1: Set-up of the filtration unit employed in the experiments. The bulk was fed
using a Tandem 1082 Pump and the retentate recirculated to the feed tank. the pressure
was monitored by in-line transducers at the inlet, retentate outlet, and permeate outlet.
∆PT was kept constant at 1–1.2 bar by a flow restriction valve. TRIS saline buffer at
pH 8 was used as diafiltration buffer.
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determined by the normalized water permeability at 20◦C, NWP20◦C, expressed
in units of L m−2 h−1 bar−1 (LMH/bar) .
The NWP20◦C was calculated based on pure water permeate fluxes (Jw)













where the viscosity ratio µ/µ20◦C is a temperature correction factor that adjusts
the value of NWP from the experimental temperature to 20◦C (Kestin et al.,
1978). The NWP20◦C value was measured before and after each experiment, and
after the CIP.
After conditioning the UF system with diafiltration buffer (20 mM TRIS,
pH 8.0, 25 mM NaCl), 450 mL of clarified feedstock containing Ad5 were concen-
trated 10-fold and then diafiltered five times. The UF/DF test was performed at
a constant ∆PT of 1.2 bar and at a constant feed flow rate (cross-flow) equivalent
to a linear velocity u = 0.202 m/s (cf.Table 2.1).
The linear velocity was the same in all experiments to ensure the same
tangential flow/force in the various prototypes in order to properly assess their
performance with respect to MWCO and type of membrane material. As shown
in previous work by our group and others (Segura et al., 2012; Vicente et al.,
2009; Negrete et al., 2014), a ∆PT of 1.2 bar is a suitable pressure value for virus
concentration.
The membrane load was kept constant at 22.5 L/m2 for the membranes with
areas of 200 cm2 and 225 cm2, whereas for the devices with 155 cm2 the membrane
load was 29.0 L/m2. This difference was due to the minimum working volume
of 45 mL allowed by our experimental set-up. Throughout the filtration process,
samples of the retentate (1 mL) were collected and stored at −80◦C for further
analysis.
The shear rate at the wall, γw = τw/µ, where τw is the shear stress and µ is















(cassette, w  h). (2.4)
Here, u and Q are the cross-flow mean fluid velocity and volumetric flow rate,
respectively; n is the number of fibers of the hollow fiber, and d is inner diameter
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2.2. MATERIALS AND METHODS
of the fibers; w and h are the width and height of the cassette channel.
The CIP procedure consisted of washing the UF system with 1 M NaOH at a
flow rate of 500 mL/min and then a 60-min incubation. After this treatment the
system was rinsed with ultrapure water until the outlet stream reached pH 7. For
the Ad5 runs, all procedures were performed at 20–22◦C.
2.2.4 Scanning Electron Microscopy (SEM)
SEM images of membrane cross sections were prepared by rinsing the membrane
samples in AriumTM pure water and soaking them with Sakura Tissue Tek
O.C.T.TMcompound resin prior cutting the membranes with a Leica CM3050 S
cryo microtome. The samples were sputtered with a 5 nm layer of gold under
vacuum in an Emitech K550 Sputter Coater and subsequently transferred to the
FEI Quanta 200F SEM featuring a FEG (Schottky field emission gun) and ETD
(Everhart Thomley Detector) under high vacuum (10×−10 mbar) for imaging.
Version 2.4 of xT Microscope Control software was used for image collection and
instrument control.
2.2.5 Sieving curve
A mixture of technical dextrans (purchased from SERVA Electrophoresis) was
prepared in pure water added with 0,05% sodium azide (NaN3). A sample of this
feed solution was prepared for SEC analysis. Filtration was performed for flat
sheet membranes in Amicon stirred cells (type 8200) under quasi non convective
flow (TMP ¡ 20 mbar) or for hollow fiber modules using a peristaltic pump
under similar conditions. Samples were collected at the permeate outlet after
equilibrating the membrane and discarding twice the dead volume on the permeate
side. Retentate samples were taken after filtration. A subsequent SEC analysis
was performed on an Agilent 1100 integrated SEC system using a PSS Suprema
Linear XL column. Pure water with a content of 0.05% sodium azide (NaN3)
was used as an eluent at a flow rate of 1 mL/min. Detection of the polymer was
performed via RI detection. A dextran standard calibration based on narrowly
distributed PSS polymer standards was used to determine the proper molecular
weight. Molecular weight distribution of feed, permeate and retentate samples as
well as sieve curves and cut-offs were calculated using PSS Unichrom software.
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2.2.6 Gold nanoparticles rejection protocol
Gold nanoparticle solutions with particle sizes of 50 nm and 100 nm were purchased
from BBI, sodiumdoceylsulfate (SDS) was purchased from Sigma-Aldrich, and
pure water was produced using an Arium pro VF Ultrapure Water System. An
amount of 1 g of SDS was dissolved in 1000 g of pure water under vigorous stirring.
Afterwards, 10 mL of each solution of gold nanoparticles (50 nm and 100 nm) were
diluted with 90 mL of SDS solution (1 g/L). The diluted solutions were stored in
the fridge at 3◦C and equilibrated under room temperature prior to filtration.
Filtration was performed in an Amicon 8010 stirred cell. First, 10 mL of SDS
buffer were filtrated by applying a pressure of 1 bar. Subsequently, 10 mL of the
diluted solution were transferred into the Amicon stirred cell and 8 mL were filtered
by applying a pressure of 1 bar while stirring at 1100 rpm. Extinction of feed
solution permeate was determined by UV-/vis-spectroscopy using a PerkinElmer
Spectrophotometer Lambda 16 at a wavelength of 524 nm (50 nm nanoparticles)
and 570 nm (100 nm nanoparticles).
2.2.7 Total virus particle quantification
Total virus particle concentration and size distribution were measured using a
NanoSIGHT NS500 (NanoSIGHT Ltd, UK). The samples were diluted in D-PBS
(Gibco R©, UK) to get a virus concentration in the instrument’s linear range (108–
109 particles/mL). For each sample, three 60-second videos were acquired and
particles between 70 and 130 nm were considered.
2.2.8 Infectious virus particles titration
For Ad5 titration, 293 cells were seeded at 0.25 × 106 cells per well in 24-well
flat bottom plates (Nunc, Denmark). After 24 h, the cells from three wells were
trypsinized and the cell concentration was determined. The cell culture medium
was removed from the remaining wells and replaced with 1 mL of viral suspensions
(10−1–10−6) diluted in fresh medium. After 17 to 20 hours, the cells were collected
in Dulbecco’s phosphate-buffered saline (D-PBS, Gibco R©, UK) with 5% FBS
and immediately analyzed by flow cytometry (CyFlow R©space, Partec GmbH,
Germany). Both the initial feedstock and the samples collected during the 10-
fold concentration steps were analyzed in the same assay, thus using the same
cell culture, to eliminate assay-to-assay variability. The infectious particle (IP)
recovery, IP rec, was calculated as follows:
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IP rec (%) = 100
IP f × Vf
IP i × Vi
, (2.5)
where IP i is the initial infectious particle concentration and IP f is the value
at the end of the 10-fold concentration step; Vi represents the initial volume and
Vf the final volume obtained after the 10-fold concentration step.
2.2.9 DNA quantification
Total DNA was quantified using the fluorescence-based Quant-iTTM PicoGreen R©
assay kit (InvitrogenTM, UK) according to the manufacturer’s protocol. In order
to avoid matrix interference, the samples were diluted between 2–256-fold with
the reaction buffer provided.
2.2.10 Protein analysis
Total protein was quantified using the BCA Protein Assay Kit (Thermo Fisher
Scientific, USA) according to the manufacturer’s protocol. Bovine serum albumin
(BSA) was used for the calibration curve. In order to avoid matrix interference,
the samples were diluted between 2 and 256-fold.
Host cell protein was quantified using the HEK 293 HCP ELISA Kit (Cygnus
Technologies, USA) following the manufacturer’s protocol. The standard curve
was done using the provided 293 HCP standards. Dilutions of 1/103, 1/5×103, and
1/104 were performed in order to avoid dose hook effects and to allow interpolation.
All analytical assays were performed in triplicate.
2.3 Results and discussion
The selection of an appropriate membrane to improve the concentration/diafiltration
step is critical to ease the entire downstream train. With this objective in mind,
three membrane materials—RC (regenerated cellulose), xRC (highly cross-linked
RC), and PES (polyethersulfone)—were evaluated. First, the evaluation of the
R&D prototype is presented; then, the selected best performing membrane is
manufactured and scaled-up in a standard manufacturing casting line. The cut-offs
of the R&D pilot and production prototypes ranked between 300 and 1000 kDa.
Table 2.1 summarizes the membrane characteristics, which are discussed in detail
below.
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Figure 2.2: NWP20◦C (average ± SEM) for the different UF membranes. (A) R&D
prototype devices with different materials, namely RC, xRC, and PES. (C) The pilot
production devices were only made of xRC and compared against commercially available
GE HF 750 kDa (PES UF 7). (B, D) water flux (LMH) at various values of ∆PT
ranging between 0.5 and 2 bar.
2.3.1 Evaluation of R&D membrane prototype
Hydraulic permeability
All eight UF prototypes were characterized by their normalized water permeability,
NWP20◦C; these values are plotted in Figs. 2.2A and 2.2B. As expected, the results
show that increasing the pore size leads to an increase in permeate flux for the
same transmembrane pressure (∆PT). This is in agreement with the findings of
Wickramasinghe et al. (2005) and other authors.
The two PES cassettes (type #2 and type #4) registered the highest NWP20◦C,
ca. 880–925 LMH/bar, and MWCO around 1000 kDa. Although both PES
cassettes are within the same MWCO range, the PES type #4 cassette was
designed to be slightly more open; this is confirmed by its enhanced NWP20◦C.
Both RC cassettes exhibited NWP20◦C values close to 560 LMH/bar, whereas that
of xRC only reached 400 LMH/bar. The HF modules showed lower permeabilities
than the PES and RC-based cassettes. As expected, the lower MWCO of PES
HF 3 (roughly 300 kDa) resulted in lower permeability than PES HF 5 (roughly
500 kDa).
The water flux permeability was measured after membrane usage and after
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Figure 2.3: Flux recoveries (average±SEM) after use and after CIP with 1M NaOH for
different R&D prototypes (Fig.A) and for the pilot production devices (Fig.B). In both
cases the highly cross-linked regenerate cellulose (xRC) was able to achieve higher flux
recovery after use compared to the PES based membranes. After CIP all the membranes
recovered their initial flux with the exception of PES HF 3 and 5 and RC type C.
cleaning in place. This measurement assesses the degree of irreversible/strongly
associated foulants accumulated on the membrane during filtration. On the other
hand, the after-CIP flux recovery gives the loss of permeability after a complete
cycle. This metric is an industrially relevant indicator as it serves as benchmark
of membrane performance, and is used to assess performance decay as well as the
effectiveness of CIP protocols.
The flux recoveries, J/J0, where J and J0 are the fluxes after and before
membrane usage, are given in Fig. 2.3A.
The water flux recovery after use was nearly 3-fold greater for the RC and
xRC than for the PES-based material. A significant water flux permeability decay
indicates the presence of fouling or nonspecific, irreversible adsorption. Since
PES is hydrophobic, this leads to increased fouling compared to the regenerated
cellulose.
However, except for the PES-based HF prototype and RC Type C, after CIP
with NaOH 1M the flux was restored in all cassettes. The type B membrane and
the two xRC cassettes regained their permeability, since their flux loss ranged
between 7% and 11%, indicating that these UF modules withstood a complete
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Figure 2.4: Total virus particle recovery as function (average ±SEM) of the con-
centration/diafiltration volume for different R&D prototypes (Fig.A) and for the pilot
production devices (Fig.B). The plots display the same process first operating in con-
centration mode and then diafiltration. In both cases the highly cross-linked regenerate
cellulose xRC showed the highest recovery yield when compared to PES menbranes.
cycle and might be used as a repeated-use device; the effect of the number of cycles
on the long-term behavior of these membranes was not assessed. The remaining
modules (RC type C and the two PES hollow fibers) showed a decreased of water
permeability after one cycle; these devices are not suited for repeated use.
Virus Recovery
Ultrafiltrated samples were collected at the retentate side upon achieving 3, 5,
and 10 concentration factors (CF) and also after 2 and 5 diafiltrations (DF). The
samples were further analyzed to determine the filtration performance of each UF
device. Fig. 2.4A and Table 2.2 show the total particle and infectious particle
recoveries, respectively.
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All RC-based cassettes achieved total particle recoveries ranging from 69% to
93% after 2 DFs. Contrarily, the PES-based membranes permeated virus particles,
as indicated by the low total particle recoveries (23–58 %). This was partially
anticipated, since the PES cassettes presented the highest MWCO (ca. 1000 kDa).
The infectious particle (IP) data given in Table 2.2 are consistent with the
total particle recoveries except for the PES Type #2 cassette. In particular, all
the RC-based cassettes were able to recover between 79% and 100% of IPs at
the end of the concentration step. Interestingly, of these four modules, the ones
with larger MWCO (RC type B and xRC type E) were those yielding higher IP
recoveries, close to 100%. This result points out the importance of optimizing
the choice of cassette and MWCO for the lowest processing time to avoid loss of
infectivity.
Following the trend observed for total particle recovery, the type #2 PES
cassette recovered more infectious particles than the PES #4 module. Noteworthy,
is the higher recovery of infectious particles than that of total particles; this is more
pronounced for the PES type #2 prototype. The reason for this can be attributed
to the presence of incomplete viral particles or empty capsids that are removed
during the ultrafiltration process by several mechanisms, such as adsorption and
sieving and/or entrapment in the larger pores. Vellekamp et al. (2001) showed that
empty capsids have a slightly different shape than infectious particles, and their
surface appears rounder when observed by electron microscopy. Their stability
might also be compromised and, therefore, they may be are more prone to shear
stress damage. These features, combined with the higher permeability of the PES
Type #2 cassette, may explain the enhanced infectious viral recovery and reduced
total particle recovery. Also, the PES Type #2 cassette performed poorly in
the flux recovery test after usage, suggesting the occurrence of virus entrapment
leading to membrane fouling. The PES cassettes have the same type of membrane
material and the same MWCO; however, it is known that slight differences, such
as a broader (or narrower) pore size distribution, can impact the virus recovery
achieved by the membrane (van Reis and Zydney, 2007). Indeed, the PES#4
prototype was manufactured with a slightly broader pore size distribution; this
is also evident by looking at the superior clean water flux that this membrane
displays.
The HF prototypes yielded low IP recoveries. In particular, the HF 3 module
took seven times longer than the type B or type E prototypes to complete the
same 10-fold concentration step. Still, the HF 3 module showed a moderate IP
recovery (60± 4%). This can be explained by the longer processing time, which
63
CHAPTER 2. EVALUATION OF NOVEL LARGE CUT-OFF ULTRAFILTRATION






















































































































































































































































































































































































































2.3. RESULTS AND DISCUSSION
Figure 2.5: HCP clearance (average ±SEM) as a function of the concentra-
tion/diafiltration volume for different R&D prototypes (Fig.A) and for the pilot production
devices (Fig.B).Both figure display the HCP clearance value after 10 fold concentration.
The HCP clearance does not show important differences among the different cassettes
and or HF. A slight increase in clearance is observed for the PES based cassettes and for
the GE HF 750 kDa (PES HF 7).
may give rise to enhanced adsorptive interactions between the hydrophobic PES
material and the virus particles. The lower flux recovery after usage and after
cleaning in place supports the hypothesis of strong hydrophobic-driven adsorption.
Impurity clearance
The HCP analysis given in Fig. 2.5A shows that the two PES cassettes were
able to remove 86–91 % of the HCP present; this was expected given their high
MWCO and hydrophobic properties. The only exceptions are the HF 3 and HF 5
prototypes as these were in the 300 kDa and 500 kDa ranges, respectively. It is
likely that high molecular weight HCPs can easily pass through the 1000 kDa
pores of the PES membrane cassette.
One of the challenges of Ad purification is host cell DNA removal, not only
because the bioprocess comprises a cell lysis step (Silva et al., 2012) but also
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Figure 2.6: DNA clearance as a function (average ±SEM) of the concentra-
tion/diafiltration volume for different R&D prototypes (Fig.A) and for the pilot production
devices (Fig.B). The plots display the same process first operating in concentration mode
and then diafiltration.
Both for the R&D and pilot production devices the PES-based membranes lead to an
increased DNA removal comparing to their RC and xRC counterparts.
because it has been shown that DNA can associate with the virus particles
resulting in co-purification of both species (Konz et al., 2005a). Both PES-based
cassettes enabled higher DNA clearance, ca. 85%, than the remaining prototypes
(Fig. 2.6).
The types B, C, D, E, and HF 5 prototypes showed intermediate DNA clear-
ances (67–70%) and the HF 3 showed the worst DNA clearance (61 %) (Fig. 2.6
A). Both the HCP and DNA clearance data are in agreement and point out both
PES cassettes as the best modules with respect to impurity removal. However,
when the TP and IP data are also taken into account, these modules were not as
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efficient as the RC-based membranes.
Productivity
The permeate flux over time and membrane throughput (feed processed per
membrane area per unit time, L m−2 h−1, or LMH) were evaluated for all UF
prototypes studied. The membranes with higher cut-off, namely type B and PES
type #4, showed an initial marked flux decrease before a steady state was achieved.
The higher the clean water flux, the lower is the resistance to the permeate side
of the membrane. Low membrane resistance results in initially high permeate
flow for the clean membrane. This will cause rapid convection of particles and
small contaminants towards the membrane surface leading to rapid flux decline
(Wickramasinghe et al., 2005; Belfort et al., 1994).
Fig. 2.7 A shows that all R&D membranes were able to maintain a stable flux
due to the constant-∆PT operation, except for type D which showed a marked
flux decrease between 300 to 405 mL of permeate volume (between 3 to 10 CF).
This indicates the starting point of fouling, which may be due to the low MWCO.
Indeed, this membrane yielded the lowest clean water flux (Fig. 2.2).
2.3.2 Identification of a suitable membrane
Among the R&D prototypes, the PES hollow fiber modules showed the worst
performance under the conditions evaluated. This is supported by the lower IP
recoveries and longer processing times. While the HF 5 module lost nearly all
viruses, the HF 3 prototype was still able to recover 60% of infective particles but
the long processing time is a considerable disadvantage. The results obtained with
the PES R&D prototypes, namely the values of total particle recovery, are below
what has been reported in the literature for this MWCO range. For instance, 300
kDa HFs from GE are able to concentrate 10-fold an Ad5 bulk with 90 % IP yield
(Peixoto et al., 2008). The only exception is the PES Type#,2 which yielded an
IP recovery of 89%. However, the lower flux recovery after use and after CIP
makes this membrane less attractive for processing large volumes of feedstock.
The RC-based R&D prototypes showed better performances, especially with
respect to the IP recovery. In particular, type B and type E membranes registered
superior IP recoveries than what has been reported for Ad5 ultrafiltration (Peixoto
et al., 2008; Segura et al., 2012; Subramanian et al., 2008), indicating that the
shear rates used did not damage the adenovirus virions. These membranes
displayed similar HCP clearance (68% and 71%) and DNA clearance (67% and
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Figure 2.7: Flux decay curves as a function of the filtration time Fig.(A and (B).
Throughput (liter of feed processed in the unit of time (h), given a defined membrane
area (m2)) Fig. C and D. The value reported in Fig. C and D are after to 10-fold
concentration and 2 diafiltration volume.
For the large cut off R&D membranes a strong flux decay is observed at the beginning of
the filtration(Fig A). Pilot production devices and GE HF 750 (PES HF 7) show the
same decay profile (Fig.B). Cassettes with RC Type B and xRC Type E show the highest
throughput (Fig. C). , the throughput for the GE HF 750 is 2 fold less compared to the
pilot production cassette membranes (Fig.D).
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Figure 2.8: Sieving curve for visualization of different pore size by using different
molecular weight dextrans, ranking between 105 and 108 g/mol. RC and xRC exhibit a
narrower rejection range than the other membranes and, therefore, a more homogeneous
pore size distribution. Two commercially available RC cassette are compared against
showing tighter pore sizes even for the membrane rated as 1000 kDa. GE HF 750 kDa
(PES HF 7) exhibits the largest cut-off and wider pore size distribution.
70%, respectively). The throughput capacities of these two modules are rather
high, being able to process up to 77 L of feed in 1 hour using a 1 m2 ultrafiltration
module. It should be pointed out that the throughput analysis was done by taking
into account a 10-fold concentration step and 2 buffer exchanges. Considering
that UF is often employed at an early stage in the downstream processing train,
high recovery yields and high throughput capacities are preferred over enhanced
impurity removal rates, although here there are still remarkable.
Taking into account these features, the type B and type E membranes served
as base for the design and scale-up to the manufacturing casting line. Sieving
curves showed that rejection profile of the selected R%D prototype is comparable
to the profile of the pilot devices, namely type F and type H (Fig. 2.8).
It is also important to point out that the two UF modules that displayed
superior throughputs (Fig. 2.7 B), RC Type B and xRC Type E, were also the ones
that gave the highest virus recoveries (Fig. 2.9). A commercial PES hollow fiber
with 750 kDA MWCO from GE healthcare, hereafter referred to as PES HF 7,
was chosen as benchmark reference. These new pilot production devices were
evaluated by performing the same type of experiments for the R&D prototypes.
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Figure 2.9: Trade-off between throughput, indicated as liter of feed processed in the
unit of time (h), given a defined membrane area (m2), and infective particle recovery
yield. The values referrer at 10 times concentration factor.
The orange area on the right top corner depicts the best membranes. RC and xRC
membranes showed the highest throughput coupled with high recovery yield.
2.3.3 Evaluation of the pilot production devices
The pilot-production cassettes were optimized to increase their water flux perme-
ability. The membranes and cassettes were manufactured on standard production-
scale manufacturing equipment and were designed to be scalable to large-area
devices. xRC was the material chosen for the pilot production due to the goods
values obtained for the various performance metrics discussed in this work. Rele-
vant process performance, such as recovery of infectious particle (IP) and total
particle (TP) recoveries, were the main drivers for this choice.
The xRC type H cassette (ca. 750 kDa) exhibited the highest NWP20◦C of the
pilot devices, 889 LMH/bar, as seen in Fig. 2.2C and D. This is in accordance
with its high MWCO as observed by the sieving curves plotted in Fig. 2.8. The
type F cassette showed a smaller NWP20◦C of 739 LMH/bar, but still larger than
that of HF 7, which was determined to be 630 LMH/bar. The lower permeability
of the GE 750 kDa HF (PES HF 7) is somewhat puzzling. The sieving curve in
Fig.2.8 shows a higher MWCO for HF 7 than for the cassettes, therefore a higher
water flux would be expected. On the other hand, HF 7 has a much broader
sieving curve than the cassettes, which indicates that the HF 7’s permeability is
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controlled by the fraction of smallest pores in its pore size distribution.
Regarding the water flux after cleaning in place, the two xRC cassettes fully
recovered their permeability (96% and 97% flux recovery). This provides a good
indication being reusable. Indeed these membranes were also optimized to sustain
several CIP cycles, as this is an important feature for process robustness. In
particular, when comparing the Type B and E membranes water flux after CIP
with the pilot production devices have an increased flux recovery of 3-4% (Fig. 2.3
A and B).
Contrarily, the HF 7 showed a performance decay after CIP, since its hydraulic
permeability increased by 17 %. This can cause a change in the product and/or
impurities retention rate when the membrane is reused.
Concerning total particle recoveries ranged from 50 % (type H) up to 75 %
(type F) after 10-fold concentration (Fig. 2.4 B); however, after two diafiltration
(DF) volumes the recovery yield decreased to 40 % for all tested membranes. This
effect is essentially membrane independent and most likely due to the formulation
of the diafiltration buffer; in particular increasing ionic strenght and/or adding
polysorbate 80 might overcome this issues, as shown by Konz et al. (2005a)
As for the impurities clearance, xRC type F and type H cassettes removed 67
and 68 % of HCP, respectively, while the PS-based HF 7 was able to achieve 86%
HCP clearance (Fig. 2.5 B). The higher HCP protein clearance registered by the
HF might be due to the different filter material, which is more hydrophobic than
RC, and thus more prone to adsorption.
For the Type F and Type H pilot device cassettes, the DNA clearance after
two DFs was 64 and 60%, respectively, while the HF 7 was able to remove 82% of
DNA present in the Ad5 feed (Fig 2.6 B).
The superior performance in DNA clearance of the GE HF can be attribute to
the higher MWCO as shown in Fig.2.8 allowing DNA to go trough the permeate
side. However, DNA can also adsorb onto the membrane surface due to the
hydrophobic nature of the PES material.
Regarding the removal of impurities, the PES HF gave rise to a slightly
improved DNA and HCP clearance comparing with xRC cassettes. This increased
impurity removal might be due to adsorption phenomenon rather than a size
exclusion mechanism as the filter material’s proprieties are more hydrophobic
(Liu et al., 2010; Zydney, 2009).
Infectivity for the type F and HF 7 membranes was maintained yielding 100%
of IPs, while Type H membrane achieved 94 % IP recovery. Despite being rated
with the same MWCO as the type H cassette, the HF 7 was able to recover
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Figure 2.10: Figure 10. SEM pictures of PES membrane, xRC Type F membrane
and HF 7. Figures A, B and C indicate the cross section structure for the flat sheet
membrane and hollow fiber, while figures D, E and F illustrate the surface structure.
a slightly more infective Ad5. The membranes were also evaluated based on
their rejection of gold nanoparticles (GNP) of 100 nm (approximately the size of
adenovirus) and 50 nm. Almost all the membranes showed a 50% rejection of the
50 nm GNPs and almost completely held back the 100 nm GNPs (Tab.2.3).
The membrane materials, xRC and PES, were also investigated by SEM
analysis (Figs. 2.10). The main morphological difference appears to be related
to the support layer, which shows a more neat and smooth pattern in the xRC.
While one membrane is supported by a non-woven fabric, both filters feature an
asymmetric sponge like structure, which is relevant for membrane stability but
has low to none effect in the filtration process. All retention is performed at the
very top layer of the filters (skin layer). Surface images confirm the asymmetry
structures. (Fig.2.10 D, E and F).
Nevertheless within that structure adsorption of contaminants can occur due
to steric or hydrophobic interaction, the latter of which is more present for PES
based membranes.
The Type F cassette presented the best overall results among the assayed
membranes. This is supported by the complete recovery of infective Ad5, with a
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remarkable improvement compared with the data described in the literature for
500 kDa HF (Peixoto et al., 2008).
Another important feature of the Type F (and H) cassette(s) is their higher
throughput compared with the HF 7. For instance, the Type F module is capable
of processing up to 61 L of Ad5 clarified bulk within 1 h using a 1 m2-membrane
while the GE HF can process only 29 L with the same time and membrane area
(considering a 10-fold concentration and 2 DF).
Although the Type F throughput is 20 % lower compared to those obtained for
the best R&D prototypes previously evaluated, careful comparison of such values
is required since the previous membranes’ MWCO might be slightly different and
the manufacturing process was different.
2.4 Conclusions
This work presented an in-depth characterization of several ultrafiltration mem-
branes. We have identified UF membrane modules alternative to the currently
available HF devices traditionally used for virus purification. A cassette based
on highly cross-linked regenerated Cellulose (xRC, close to 500 kDa and herein
referred to as type E), which showed the best performance among the R&D
prototypes, was successfully scaled up to a pilot production casting line. The
resulting type F module showed better performance than a commercially available
hollow fiber (750 kDa). The key advantage of this UF module is the substantially
shorter processing time coupled with complete infectious particle recovery (100%)
and is, therefore, suggested for Ad5 concentration.
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Abstract
The impacts of quaternary amine ligand density and matrix structure, namely
hydrogel grafted and directly grafted, on state-of-the-art chromatographic mem-
branes operated in bind-and-elute mode were evaluated for the purification of
adenovirus serotype 5. The experiments were performed on a 96-well plate mem-
brane holder, which is a convenient high-throughput screening tool for obtaining
the best operating conditions for a process yield optimization. The results show
that the hydrogel-grafted membranes are more suitable for virus purification
than the directly grafted ones. By reducing the number of grafted ligands to
low (1.7 µmol/cm2) or medium (µmol/cm2) density, it is possible to increase
the recovery of purified virus by 60% compared to a highly charged membrane
(3.3 µmol/cm2) that yielded a recovery rate lower than 30%. In the reported
experiments, Sartobind R©Q, chosen as benchmark comparison, provides a better
compromise between high recovery and large dynamic binding capacity. Overall,
this work contributes to the understanding and development of new membrane
adsorbers specifically designed for virus purification.
Keywords: membrane chromatography; ligand density; hydrogel graft-
ing; adenovirus adsorption; virus purification
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3.1 Introduction
Adenoviruses are considered to be one of the most suitable platforms for producing
viral vaccines and gene therapy vectors. These viruses can be produced using
complementary cell lines in both adherent and suspension culture systems, such
as HEK–293 or PER-C6 cells, or A549 for oncolytic adenovirus (Segura et al.,
2008). Despite the recognized interest in these viral vectors, the development
of an integrated downstream purification platform for adenoviruses is not yet
mature. The complexity of this biopharmaceutical product is partly related to
the large batch-to-batch variability of the bio-reaction bulk, which is a challenge
for the development of reliable and robust purification processes (Morenweiser,
2005). Moreover, it is still a hurdle to achieve a high-purity grade while keeping
host cell protein (HCP) and deoxyribonucleic acid (DNA) within the limits set by
regulatory authorities.
Chromatography is a well-established purification tool of recombinant aden-
ovirus used for vaccine and gene therapy. Indeed, ion exchange (IEX) chromatogra-
phy is the most used technique for the purification of complex biopharmaceuticals.
However, packed-bed chromatography suffers from a number of disadvantages: the
pressure drop across the bed is usually high and may increase during operation
due to media deformation or blockage, and pore diffusion is slow and often leads
to degradation of the protein product. In addition, packed beds display a rela-
tively small dynamic binding capacity for virus particles at common process-scale
linear velocities of 150-450 cm/h, because binding is restricted to the surface of
conventional resin particles (Weaver et al., 2013).
Convective chromatography media, such as membranes and monoliths, offer
substantial improvements in capacity, recovery, and reduction of process time
(Hahn et al., 2007). To date, monoliths have generally offered larger capacity and
higher resolution than membranes (Gerster et al., 2013; Whitfield et al., 2009),
but the latter have proven to be less prone to clogging, and their relatively low
cost has made it practical to discard them after a single use rather than to invest
additional resources on developing and validating regeneration and sanitization
procedures.
Membrane adsorbers are used in the biopharmaceutical industry almost exclu-
sively in flowthrough mode for mAb purification (Boi, 2007; Knudsen et al., 2001;
Zhou and Tressel, 2006). More recently, membrane adsorption chromatography
has been applied to the purification of viral vectors using a bind-and-elute mode,
yielding good overall recovery rates (Lee et al., 2009; Peixoto et al., 2006, 2008).
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However, two major challenges still remain: on one hand, the adequate removal
of contaminants (DNA and HCP) that are closely related with the viral product,
and on the other hand, the low binding capacity for highly concentrated feeds.
There is, therefore, a need for developing membrane chromatography specifically
designed for virus purification (Riordan et al., 2009; Vicente et al., 2011).
The best virus recovery yields reported to date have been obtained with
ligands containing quaternary ammonium ions grafted onto the surface of a
macroporous membrane to produce a strong anion-exchange adsorber; examples
of such membrane adsorbers include Sartobind R©Q (Sartorius Stedim Biotech,
Germany) and Mustang Q R©(PALL, Life Sciences, USA) (Wang et al., 2009;
Weaver et al., 2013). The design of new matrices with appropriate ligand density
and degree of grafting is key for further improving the performance of the bind-
and-elute purification mode for viruses.
This paper studies the effects of ligand density and membrane structure on the
binding and elution of adenovirus serotype 5 (Ad5) feed stock. Ad5 was chosen as
a model virus given its wide utilization and robustness. Two different membrane
platforms manufactured by Sartorius Stedim Biotech (SSB), respectively hydrogel
grafted and directly grafted, were evaluated using a 96-well plate membrane holder.
In the hydrogel-grafted membrane the ligand is immobilized via a hydrogel support
(Zhong et al., 2011), creating a tentacle-like structure; this structure is currently
used in Sartobind R©Q. In the directly grafted membrane the ligand is directly
coupled to the cellulose membrane backbone (Fig.3.1). In the first part of this study
the membrane binding and virus recovery are assessed under various operating
conditions, namely, pH, buffer type, and ionic strength. In the second part of this
work, the dynamic binding capacities of the hydrogel-grafted membranes for the
target product (Ad5) and its related impurities (DNA and HCP) are determined
using a 96-well plate holder with a very small membrane volume. An attempt is
made to elucidate the shapes of the breakthrough curves by matching the frontal
analysis experiments to a simple equilibrium-dispersive adsorption breakthrough
model.
3.2 Materials and methods
3.2.1 Cell line and medium
The 293 cells purchased from ATCC (ATCC-CRL-1573) were adapted to sus-
pension and grown in a commercial serum-free medium, Ex-Cell 293 (SAFC
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(a)
(b)
Figure 3.1: Schematic representation of the two membrane structures: (A) hydrogel-
grafted membrane in which the Q ligand is immobilized onto the tentacle-like structure,
and (B) directly-grafted membrane in which the ligand is directly immobilized onto the
membrane surface. The red dots represent the Q ligands.
Biosciences, USA), supplemented with 4 mM of glutamine (Invitrogen, UK), and
cultured in a humidified atmosphere of 8% CO2 in air at 37 C using shake flasks
(Corning, USA).
3.2.2 Virus production
A replication-defective adenovirus, derived from adenovirus serotype 5 (Ad5)
expressing GFP protein, was used. The virus particles were produced in a 2 L
bioreactor with 1 L working volume (Sartorius Stedim Biotech, Germany). The
agitation rate started at 70 rpm and the dissolved oxygen was controlled at 50%
air saturation by gas mixture and stirred cascade control with an airflow of 0.01
L/min; pH was controlled at 7.2 by aeration with a CO2 gas mixture and 1 M
NaHCO3; all infections were done at a cell concentration (CCI) of 106 cells/mL
using a multiplicity of infection (MOI) of 5; the adenoviruses were harvested at
46 hpi.
3.2.3 Virus clarification and concentration
The bioreactor was harvested and treated with 0.1% Triton X100 (Sigma Aldrich,
MO, USA) and incubated for 2 h at 37◦C with 50 U/mL of Benzonase (Merck Milli-
pore, Germany). Subsequently, the bulk was microfiltrated using 0.8 µm + 0.45 µm
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Sartopore 2 (Sartorius Stedim Biotech, Germany) and concentrated/diafiltered
with Vivaflow 100 (Sartorius Stedim Biotech, Germany) with a cut-off of 100 kDa.
The concentration/diafiltration step was performed with both HEPES 50 mM and
Tris 20 mM to produce two clarified bulks conditioned into two different buffer
types. The bulk was stored in aliquots at 80◦C until further use.
3.2.4 Quantification of total particles
The protocol for the quantification of total particles was a two-step procedure:
DNA extraction according to the instructions on the High Pure Viral Nucleic Acid
Kit (Roche) manual and real-time PCR. The determination of the number of viral
DNA copies was performed by real-time PCR and LightCycler system (Roche
Diagnostic) using Fast Start DNA master SYBR Green I kit to track a specific
adenovirus 5 sequence (Roche Diagnostics). Internal plasmid of 2.07×109copies/µL
was used as reference standard. The total particle concentration was also measured
using Nanosight NS500 (NanoSight Ltd., UK), which also quantifies the particle
size distribution.
3.2.5 Protein analysis
The protein profile analysis was done in 4-12% NuPage gradient pre-cast gels
(Invitrogen). The gels were stained by Coomassie Instant Blue (Expedeon Ltd.,
UK) and the protein concentration was determined using BCA kits (Pierce,
Rockford, USA) taking bovine serum albumin (BSA) as the standard protein.
3.2.6 DNA quantification
The DNA was quantified by QuanT-iT Picogreen kit (Invitrogen). After 5 min of
incubation, the fluorescence was measured by Luminometery (Turner BioSystems).
Purified DNA was used as standard.
3.2.7 Virus titration
The viruses were encoded for a GFP gene, thus infected cells were positive to
GFP, and quantified by flow cytometry analysis with GFP fluorescence signal
monitoring. The flow cytometric data were acquired using a CyFlow Space. The
green fluorescent signal was measured in a photomultiplier tube after passing
through a 525 nm band pass filter. GFP fluorescence of 2×104 single viable
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cells per sample selected on FS versus SS scatter basis was analyzed and high
fluorescent cells were gated.
3.2.8 Chromatography
The devices used for the DBC determination, with a bed volume of 23 µL, were
connected to an kta Explorer 100 Air system or kta Explorer 10 (GE Healthcare)
equipped with UV, conductivity, and pH detectors, and a fraction collector FRAC-
950 (GE Healthcare). Before each experiment, the membranes were sanitized
with 10 membrane volumes (MVs) of 1 M NaOH and then equilibrated with
loading buffer until the pH and conductivity of the outflow reached the values
of the load. After each experimental run all collected fractions were stored at
80◦C for further analysis. High-throughput experiments were performed in a
96-well membrane holder device provided by Sartorius. The small-scale membrane
adsorbers were assembled by mounting a stack of three membrane sheets into each
cell of the 96-well holder to give a differential bed volume of 23 µL. Each cell was
loaded with 500 µL of bioreaction bulk, corresponding to approximately 22 MVs;
subsequently a vacuum of 0.35 bar was applied to force the whole liquid to flow
through the membrane bed into the low-pressure side of the cell. The first elution
step consisted of flowing 500 µL of 1 M NaCl through the membrane as running
buffer; this step was then followed by a second elution step with 500 µL of 2 M
NaCl. All the experiments were duplicated to ensure statistical significance.
3.3 Result and discussion
3.3.1 Hydrogel-grafted membranes
Protein binding
The results obtained with the hydrogel-grafted membranes are presented first.
These membranes were functionalized by Sartorius Stedim Biotech with quaternary
amine at three different ligand densities, namely 1.7, 2.4, and 3.3 µmol/cm2; these
ligand densities are hereafter referred to as low, medium, and high ligand densities,
respectively (Table 3.1 ). The ligand densities were determined by acid/base
titration by monitoring the corresponding conductivity curve. Besides the ligand
density, the impacts of buffer type, namely 20 mM Tris and 50 mM HEPES, and
pH (Table 3.2) were also evaluated.
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Table 3.1: Characteristics of the prototype hydrogel-grafted and directly-grafted
membranes manufactured by Sartorius Stedim Biotech.
Hydrogel-grafted membrane Directly-grafted membrane
Ligand density Static BSA Ligand density Static BSA
(µmol/cm2) binding capacity (µmol/cm2) binding capacity
(mg/cm2) (mg/cm2)
1.7 0.51 0.5 N/A
2.4* 1.05 2.5 N/A
3.3 1.51 4.5 N/A
*Sartobind Q R©membrane used as benchmark reference.
Table 3.2: Experimental conditions for the runs with the hydrogel-grafted membranes:
buffer type, ionic strength, and pH.
Buffer NaCl concentration (mM) Load volume per well (µL)
20mM Tris pH 8 0; 50; 100; 150; 200 500
20mM Tris pH 7.5 0; 50; 100; 150; 200 500
50mm HEPES pH 8 0; 50; 100; 150; 200 500
50mm HEPES pH 7.5 0; 50; 100; 150; 200 500
In a first instance, protein binding was assessed by analyzing the flow-through
with BCA kits (see Section 3.2.5 ). The total protein concentration obtained in the
flow-through, coutp i.e., the concentration of total unbound protein in the 500 µL
of bioreaction bulk flown through the membrane, showed an approximately linear
correlation with increasing ionic strength. No significant differences were observed
between the medium- and high-ligand densities. Given that all experiments used
the same amount of bioreaction bulk, the amount of bound protein bound per unit
membrane volume unit is qp = (Vbulk/Vm)(C
in
p − Coutp ), where Vbulk/Vm = 21.7
is the number of membrane volumes of injected bulk and cinp = 600 µg/mL is the
initial protein concentration in the bioreaction bulk. Hence, the dependence of qp
on the ionic strength is that the opposite of coutp .
On the other hand, the membrane with the lowest ligand density (1.7 µmol/cm2)
behaved differently, since it bound larger amounts of total protein (cf. two topmost
plots of Fig. 3.2). This might seem contradictory, since a lower degree of grafting
is expected to result in lower protein binding; however, previous studies (Wang
et al., 2009; Wei et al., 2013; Wickramasinghe et al., 2006) suggest that this can
be due to a decrease of the effective pore size with increasing grafting density for
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grafting levels above a given threshold. Under these conditions, proteins with low
binding charge might be excluded from the larger pores at high ligand densities.
Indeed, the SDS–PAGE gel analyses shown in the bottom picture of Fig. 3.2 show
increased bands of low and medium molecular weights for the hydrogel–grafted
membrane, confirming that small proteins are excluded or displaced by other
species of the bioreactor bulk. The SDS–PAGE was performed for the samples in
HEPES buffer since they exhibited a pattern similar to those in Tris buffer.
The results obtained at a pH of 8.0 were very close to those reported above
and are not described here for the sake of brevity.
DNA clearance
To assess the effect of ligand density on DNA removal, the membranes loaded with
the same amount of adenovirus bulk were eluted with 500 µL of 1 M NaCl. No
significant differences were observed for the medium- and high-charge densities,
in contrast to the low-ligand density for which the amount of DNA eluted from
the membrane showed a 2–fold decrease (top plots in Fig. 3.3). Noteworthy was
the significant decrease of the eluted DNA with the increasing ionic strength of
the load; the total desorbed protein as a function of the ionic strength of the
load followed the same trend (data not shown). This is a well–know effect in
IEX adsorption: at the solid–liquid interface the charged surface attracts counter–
ions from the solution to form a “double layer” whose thickness is reduced with
increasing ionic strength. When a protein or other biological components adsorb
on an ion-exchange support, only a small fraction of their total surface area
contacts the double layer (Wei et al., 2013). A thin double layer therefore limits
the molecular contact area and thereby weakens the electrostatic interactions
between the ion exchanger and the biological adsorbateprotein or DNA in the
present caseresulting in a reduced adsorption capacity (Hunter and Carta, 2001a).
In other words, increasing the ionic strength of the load reduces the available
contact surface area, and thus the binding of a biological molecule, such as DNA.
After elution with 1 M NaCl, each well was eluted with 500 µL of 2 M NaCl
solution to completely desorb the remaining DNA. In contrast to the elution with
1 M NaCl, the amount of DNA desorbed by subsequently eluting the membrane
with 2 M NaCl increased only slightly with salt concentration for the loaded bulk
in HEPES buffer; moreover, the corresponding results obtained for the Tris buffer
were mostly independent of the ionic strength (bottom plots in Fig. 3.3). This is an
expected result, given that the DNA desorbed in the second elution at 2 M NaCl
is the residual amount that was more strongly bound to the membrane through
88
3.3. RESULT AND DISCUSSION







































































































































0 50 100 150 200
NaCl Concentration in the load (mM)
0 50 100 150 200
NaCl Concentration in the load (mM)
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Figure 3.2: (Top) Total protein concentration in the flow–through for the experiments
with the hydrogel–grafted membranes at different ionic strengths in the loaded bulk
(experiments performed in duplicated). (Bottom) SDS–PAGE analysis of the flow–through
experiments. The ligand density is indicated at the top of each lane (1.7, 2.4, and 3.3
µmol/cm2); the NaCl concentration in the loaded bulk is given in parentheses. The
arrows point to the lower molecular weight limit of unbound protein due to the increased
ligand density.
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Figure 3.3: DNA concentration in the 1 M NaCl eluted volume (top) and DNA recovery
in the subsequent 2 M NaCl eluted volume for different ionic strengths in the loaded bulk.
The buffer types in the loaded bulks were HEPES 50 mM and Tris 20 mM both at pH
7.5. Experiments were performed in duplicate and analyzed by PicoGreen kit. The lines
in the top plots are a guide to the eye.
unspecific mechanisms that are essentially independent of the ionic strength of
the loading conditions.
Also, for an initial DNA concentration of 1.74 µg/mL in the loaded bioreaction
bulk, no clear differences were observed between the 1 M NaCl elutions for the
three ligand densities; on the other hand, when the membranes were eluted with
2 M NaCl, it is clear that the membrane with highest ligand density has a larger
residual amount of bound DNA (25-40%) that is only desorbed at a strong ionic
strength than the other two membranes (3-10%).
Given that the elution step with 2 M NaCl removed practically all the DNA
still bound to the membranes, the amount of DNA bound in the loading step
should then be equal to the cumulative amount of DNA recovered in the two
elution steps. The bound DNA concentrations calculated this way were found to
be proportional to the DNA concentrations recovered in the first elution step (1
M NaCl). The data plotted in the top-left graph of Fig. 3.3 can be converted to
bound DNA concentration, expressed as g per mL of membrane volume, using a
scale factor of 25 for the low- and medium-density membranes and a scale factor
of 35 for the high-density membrane. Likewise, the conversion factors for the
data obtained with Tris buffer (top-right plot of Fig. 3.3) are 22-25 for all ligand
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Table 3.3: Percentage of virus particles detected in the flow-through (FT) for ionic
strengths of the load in the 0-200 mM NaCl range.




densities. These results are in line with the data shown in the bottom plots of
Fig. 3.3.
The results given above suggest that with increasing ligand density the DNA
interacts with a higher number of charge sites in the surface of the tentacle-like
hydrogel layer and, hence, that its displacement requires higher ionic strength.
The results obtained at a pH of 8.0 were very close to those reported above and
are not described here for the sake of brevity.
Virus recovery yield
The percentage of virus in the flow-through and the virus recovered in the 1
M NaCl elution step were determined for the conditions described above (cf.
Table 3.2). It was not possible to measure the amount of virus recovered in the
2 M NaCl elution due to the damage of the particles that occurs at this ionic
strength. As expected, the low-ligand density membrane gives the highest amount
of virus in the flow-through, attaining levels of ca. 1.5×109 vp/mL for a salt
concentration in the loaded bulk of 200 mM NaCl. The virus concentration in
the flow-through for the high and medium ligand density is less influenced by
the ionic strength over the range of measured concentrations (0-200 mM NaCl)
(Table 3.3). This may be due to the increase of the electrostatic double layer
and multipoint attachment resulting from the tentacle structure, which induces
a more salt tolerant profile. The use of 50 mM HEPES, at either pH 7.5 or pH
8, gives virus recoveries between 50% and 90% on the membrane with medium
ligand density (2.4 µmol/cm2) (Fig. 3.4). The use of Tris buffer, on the other
hand, does not give recovery yields higher than 20% under the best conditions;
such low recovery yields were not expected, and there is no clear explanation
for this. However, pragmatic evidence from the literature confirms that the 50
mM HEPES buffer is widely used for adenovirus purification, achieving fairly
good recovery yields (Konz et al., 2005). It is worth noting that for the highest
ligand density of 3.3 µmol/cm2, not only did the total particle titer decrease but
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Figure 3.4: Impact of ligand density of hydrogel-grafted membranes and buffer type of
the bioreaction bulk on the virus recovery yield at 1 M NaCl elution. HEPES and Tris
buffer were evaluated at two different pH values: 7.5 and 8. The virus concentration was
assessed by RT-PCR and Nanosight.
Table 3.4: Concentration of infectious virus particles obtained at the best recovery
conditions for each hydrogel-grafted membrane. Salt concentration refers to NaCl (mM)
in 50 mM HEPES buffer at pH 7.0.
Ligand density Infectious virus particle Salt Concentration




also the infectivity was dramatically compromised (Table 3.4). This can be due
to a damage of the virus’s capside or fibers during the binding or, most likely,
during the desorption step. Vicente et al. (2011) observed the occurrence of a
similar behavior while purifying baculoviruses. Also, the virus entrapment into
the hydrogel structure is likely to be enhanced at high ligand density (Tatárová
et al., 2009), which explains the low recovery yield.
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3.3.2 Directly-grafted membranes
Protein binding
The directly grafted membrane prototypes produced by Sartorius Stedim Biotech
had the following three different ligand densities: 0.5, 2.5, and 4.5 µmol/cm2
(Table 3.1); these values are comparable to those of the hydrogel-grafted mem-
branes, especially those of the medium and high ligand densities. The structure of
the directly-grafted membrane is different from that of the hydrogel-grafted one
because the quaternary amine is directly immobilized onto the membrane’s surface.
The buffer used in the experiments was 50 mM HEPES at pH 7.5 because of its
good performance with the hydrogel-grafted membranes. The NaCl concentrations
evaluated were kept below 100 mM, since the binding to these membranes is
seriously compromised at higher ionic strengths.
The analysis of the total protein concentration in the flow-through did not
show any major differences between the 0.5 and 2.5 µmol/cm2 ligand densities
(Fig. 3.5, top graphic). However, as opposed to what was previously observed for
the hydrogel-grafted membranes, the directly grafted membrane with the highest
ligand density yielded a marked reduction on the protein content down to 250
µg/mL. This is corroborated by the SDS-PAGE analysis shown in the bottom
picture of Fig. 3.5. This result supports our previous claim whereby increasing
the grafting degree excludes some proteins from binding, as certain ligand sites
will be shielded from the proteins.
Virus recovery yield
Fig. 3.6 presents the virus recovery yields obtained with the directly-grafted
membranes. Although the ligand densities of these membranes are comparable
to those of the hydrogel-grafted ones, the virus binding is compromised. The
percentage of viruses in the flow-through for the membranes with 2.5 and 0.5
µmol/cm2 ligand densities is ca. 60-70%, and even larger values are obtained if
the ionic strength is increased. Only the membrane with 4.5 µmol/cm2 ligand
density yielded 25% of viruses in the flow-through. It is also worth mentioning
that it was not possible to close the virus material balance for the hydrogel-grafted
membranes, most likely due to irreversible binding or entrapment. On the other
hand, in the experiments with the directly grafted membranes there was a fairly
good agreement between the viruses in the flow-through and in the subsequently
elution volume. This can be due to the inexistence of the tentacle structure and its
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Figure 3.5: (Top) Protein concentration in the flow-through for the experiments with
the directly grafted membranes at different ionic strengths in the loaded bulk ranging
from 0 to 100 mM NaCl (experiments performed in duplicated). All experiments were
performed with 50 mM HEPES buffer at pH 7.5. (Bottom) SDS-PAGE analysis of the
flow-through experiments. The ligand density is indicated at the top of each lane (0.5, 2.5,
and 4.5 µmol/cm2); the NaCl concentration in the loaded bulk is given in parentheses.
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Figure 3.6: The top panel gives the virus recovery yield and percentage of viruses in
the flow through (FT) for the direct grafted membrane. The bottom panel shows the
DNA both in FT and at 1 M NaCl elution. The fittings illustrate, respectively, the DNA
increase in the FT at higher ionic strengths and the consequently exponential decay at 1
M elution.
associated multipoint attachment. Furthermore, entrapment and steric hindrance
are reduced because of the absence of the hydrogel support.
DNA clearance
The DNA clearance in bind-and-elute mode was evaluated and compared with the
results obtained for the hydrogel-grafted membranes. In line with the results of
proteins content, the amount of DNA captured with the highest ligand density is
close to 60% of the initial DNA concentration presented in the load. The elution
with 1 M NaCl has a substantially reduced amount of DNA when compared
to a similar elution of the hydrogel-grafted membrane. Only the 4.5 µmol/cm2
membrane shows a binding capacity comparable to the grafted membrane. Again,
if the ionic strength is increased even slightly, the binding is reduced (Fig. 3.6).
The amount of DNA detected upon further elution with 2 M NaCl is under the
sensitivity limit of the assay, showing that DNA is already almost completely
desorbed with 1 M NaCl.
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3.3.3 Dynamic binding capacity of the hydrogel-grafted mem-
branes
The results discussed above indicate that the hydrogel-grafted membrane is more
suitable than the directly grafted membrane for a bind-and-elute purification,
although there is still some room for improving the results obtained with the
directly grafted membranes. Therefore, the dynamic binding capacities (DBCs) of
the three hydrogel-grafted membranes for the virus and for the two contaminants
were measured for a 50 mM HEPES buffer at pH 7.5.
The breakthrough curves shown in the left-hand-side plots of Fig. 3.7 were
obtained by collecting and analyzing samples every 0.25 mL. The breakthrough
curves illustrate the different shapes and quasi-horizontal plateaus obtained with
the low-, medium- and high-ligand density, hydrogel-grafted membranes. In
particular, it is interesting to observe that although the breakthrough curves
exhibit the characteristic sigmoidal shape expected for a favorable isotherm, the
titers in the flow-through do not reach the values in the feed bulk, but instead
nearly stabilize at lower values, which is indicative of a pronounced tailing behavior;
the only noteworthy exception is the breakthrough curve for DNA on the low-
density membrane, which exhibits the expected Langmuir-type behavior with the
correct horizontal plateau. In general, the experimental breakthrough curves are
quite sharp, except those obtained with the high ligand density membrane. The
sharpness of the breakthrough curve (i.e., smaller mass transfer zone) is one of
the advantages of membrane chromatography over packed-bed chromatography
(unless the binding kinetics is the limiting rate step): membrane adsorbers are
usually not limited by pore diffusion because they operate under nearly convective
flow conditions.
The apparent stabilization of the exit titer at a value below the value in the
feed bulk over the duration of the experiment indicates that the membrane is
retaining increasingly larger amounts of biological when the concentration in the
liquid phase surpasses the concentration defined by the plateauthis follows from
an overall material balance to the membrane adsorber by noting that the position
in the adsorber that exhibits the most retarded dynamics during the binding step
is precisely the one at the downstream end of the adsorber.
It is worth noting that the membranes under study are convective-flow media
with pore sizes of around 3 µm, which are significantly larger than those of
conventional resin beads used in packed-bed chromatography. For this reason,
the porous structure of the membrane matrix is expected to significantly reduce
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Figure 3.7: Breakthrough curves (left) of the main components of the adenovirus biore-
actor bulk for the low-, medium-, and high-ligand densities, hydrogel-grafted membranes
with 50 mM HEPES buffer at pH 7.5; total protein, DNA, and virus contents were ana-
lyzed for each collected fraction. The right-hand-side plots show the apparent adsorption
isotherms obtained by fitting the equilibrium-dispersed model given by Eqs. (3.1)–(3.6)
to the experimental breakthrough data; the gray areas depict the regions where the fitting
uncertainty is highest.
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the diffusional mass transfer resistances. Thus, the dynamics of the membrane
adsorber should be essentially governed by the thermodynamics of adsorption
rather than by mass transfer or kinetic resistances. Assuming that the adsorption
process is equilibrium-controlled, the influence of the adsorption isotherm on the
different shapes of the breakthrough curves can be put into evidence using a
































where i is the solute index, c is the solute concentration in the fluid phase
(amount per unit volume), q is the solute concentration in the adsorbed phase
(amount per unit adsorber volume), x = z/L is a dimensionless coordinate along
the axial length L of the membrane adsorber, and θ = Qt/V is a dimensionless time
coordinate that gives the number of eluted column volumes (t is the dimensional
time coordinate, Q is the volumetric flow rate, and V is the volume of the
membrane adsorber); cin is the concentration in the feed mixture.
The Pclet number, Pe, which is a simple measure of finite membrane efficiency,
is used here to account for the combined effect of axial dispersion due to the
convective transport through the membrane and the presumably small contribution
from diffusional resistances; it also helps to stabilize the numerical solution. In
the numerical fitting procedure Pe was fixed at 500. It is worth noting that the
obtained breakthrough curves are not very sensitive to the selected value of Pe,
unless it is set to a very small value or to a very high value. For example, doubling
the value of Pe to 1000 or reducing it to 250 does not significantly change the
simulated breakthrough profiles.
The equilibrium-dispersed model assumes that the adsorbed phase is in local
equilibrium with the contacting bulk fluid, i.e., qi = q
∗
i (ci, ..., cn), where q
∗
i
represents the adsorption isotherm for component i in the presence of the other
n-1 solutes (i.e., under multicomponent conditions). Given that the experiments
were performed for a single overall feed concentration of the bioreaction bulk
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mixture, it is not possible to determine q∗i . Instead, we shall concentrate on
the apparent single-component adsorption isotherm, qi = q
∗
i (ci), which is the
adsorption isotherm that gives the same breakthrough curve for component i
under multicomponent conditions if the component was injected isolated at the
same concentration as in the bioreaction bulk. Obviously, q∗i (ci) can only be
estimated up to the value of the feed concentration, cini .
To determine the function q∗i = (ci), we discretize it over the concentration
range ci ε [0, c
in
i ] using third-order orthogonal collocation on finite elements (we
have used three equal-sized elements)the left-most collocation point of the first
element is set to 0 and the right-most collocation point of the last element is set
to cini . By definition q
∗
i (0) = 0, so this value is fixed. To ensure continuity of the
function value and its first derivative across elements, each boundary collocation
point shared by two consecutive elements, say point c
(m)

















The remaining unknown values of q∗i (c
(k)
i ) at the interior collocation points c
(k)
i
(and also at the right-most collocation point cini ) are determined by minimizing the
sum of the squares of the deviations between the Ni experimental measurements
of the breakthrough curve, couti,exp(tj), j = 1, ..., Ni, and the simulated values,
couti,exp(tj), i.e.,







[couti,exp(tj)− couti (tj)]2 (3.5)
To guarantee that the estimated shape of q∗i (ci) is physically meaningful, the
values of q∗i (c
(k)
i ) are further constrained by the following conditions that yield a
monotonically increasing function of ci:
q∗i (c
k+1













The equilibrium-dispersed adsorption is discretized in both space and time
(Araújo et al., 2008; Mota et al., 2007) ; to generate a sparse system of nonlinear
algebraic that forms the set of equality constraints of the objective function
given by Eq. (1). This nonlinear optimization problem was formulated in AMPL
(R. Fourer, 2003)and solved with the interior-point solver Ipopt 3.10 (Wächter
and Biegler, 2006) For each of the analyzed componentsvirus, total protein,
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and DNAthe initial estimate of q∗i (ci) was the linear adsorption isotherm that
reproduces the experimental breakthrough time at half height (c/2)
The numerical results are summarized in Fig. 3.7, which on the left-hand-side
plots compares the experimental breakthrough measurements against the simula-
tion curves and on the right-hand-side plots shows the apparent single-component
adsorption isotherms that best reproduce the experimental breakthrough curves.
The first conclusion that can be drawn from Fig. 3.7 is that the observed break-
through curves can be perfectly fit by adsorption-equilibrium relations satisfying
the monotonic constraint. Note, however, that despite the excellent description
of the breakthrough experiments, we are quite aware of the limitations of our
modeling effort, namely the somewhat fuzzy physical meaning of q∗i (ci) curves.
Below a given threshold concentration value each adsorption isotherm is
approximately linear. We note that under these conditions the effects of axial
dispersion, external mass transfer resistance, and diffusion are approximately
additive (see, e.g., (Haynes and Sarma, 1973)). This means that in the modeling
of chromatographic columns under linear equilibrium conditions it is seldom worth
modeling the band broadening using a more complex descriptor than an overall
Pclet number (or, alternatively, and overall effective rate coefficient) incorporating
both effects of axial dispersion and the various mass transfer resistances (Ruthven,
1984).
Above a threshold concentration value, the amount adsorbed increases drasti-
cally with the solute concentrationsimilar to the behavior observed for a type III
isotherm according to the IUPAC classification for vapor-solid equilibria (Rou-
querol et al., 1994)-as if consequence of an “apparent stronger binding mechanism.”
One could argue that a plausible explanation is the entrapment or molecular
sieving of the large biological particles due to the reduction of the unobstructed
channel width created by the already bound particles at the outer edges of the
tentacle structure of the membrane. Moreover, the thickness of the double layer
has been shown to be direct proportional to the charge density (Kopaciewicz et al.,
1983; St̊ahlberg, 1999). Thus, the increase in charge density leads to an extended
electrostatic double layer and consequently, also increases the interaction forces
with the biological particles. Our membranes have pore size around 3 m, the
virus particlesthe largest component in the bulkare approximately 100 nm (0.1
µm). Assuming cylindrical pore geometry, one monolayer of virus particles would
reduce the unobstructed cross section of the pore by only 13%. Thus, it seems
unlikely that the dense adsorbed phase can effectively block the passage of the
large biological particles, even at the highest ligand density.
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It is likely that aggregation effects may have taken place in our experiments:
(i) virus aggregation at high concentrations, such as that of our breakthrough
experimentsfor example, several studies (Altaras et al., 2005; Croyle MA, 2003;
Konz et al., 2005) have demonstrated that Ad5 has an aggregation concentration
dependent behavior; (ii) DNA can form complexes with the virus particles, since it
may bind to positive local patches on the capside (Goerke et al., 2005; Konz et al.,
2005); (iii) proteins can precipitate or aggregate due to the local high concentration
on the membrane at the concentration conditions of the plateau phase (Whitley
et al., 1991). It is worth noting that various explanations and theories have
been advanced in the literature for the pronounced tailing behavior, including
extra-column contributions, hindered diffusion, and steric hindrance (Weinbrenner
and Etzel, 1994; Jin et al., 1994; Talbot et al., 2000). However, as Hunter and
Carta (2001b) correctly point out, it is not trivial to elucidate the mechanisms of
adsorption equilibrium and kinetics by matching breakthrough curves to theoretical
models unless highly pure single-component feeds are employed. Nevertheless,
although the modeling procedure employed above is embodied of some empiricism,
it is still a useful tool for process design.
Despite the effects mentioned above, the shapes of the breakthrough curves
suggest that if the membrane adsorber were operated with a more diluted feed,
the gap between the breakthrough plateau and the initial feed stock concentration
would be reduced. In the following discussion the breakthrough point at 10%
height was taken as a reference measurement for comparison.
Table 3.5 summarizes the DBC at 10% and breakthrough points (BT) at 10%
height for the virus, proteins, and DNA. Whereas for DNA the DBC10% increases
5-fold when the ligand density is increased from 1.7 to 3.3 µmol/cm2 (low to high
level), such a substantial increase is less visible for the virus and not observed at
all for the proteins. For the low-ligand density membrane the 10%-DBCs follow
the sequence: virus ≈ proteins > DNA, whereas for the medium ligand density
membrane the sequence is DNA > virus ≈ proteins, and for the high ligand density
the sequence changes to DNA > virus > proteins. The 10%-DBCs obtained with
the low ligand density membrane are nearly similar, yielding poor selectivity, but
get progressively separated with increasing ligand density. However, the spreading
of the breakthrough curve also increases with increasing ligand density, which
is undesirable. Thus, although a highly decorated tentacle structure is desirable
from a thermodynamic perspective it hinders the fast access of large particles to
the whole tentacle structure.
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Table 3.5: Dynamic binding capacity of total protein, DNA, and virus for the three
hydrogel-grafted membranes. Breakthrough point at 10% height BTP10% is expressed in
column volumes (CV).








CV (mg/cm2) CV (mg/cm2) CV (mg/cm2)
Protein 57 0.98 57 0.98 63 1.90
DNA 50 0.023 103 0.0055 227 0.10
Virus 58 3.02 58 3.02 106 4.70
aDBC10% for viruses is expressed in 10
10 virus particle per squared centimeter (1010
vp/cm2).
3.4 Conclusions
In this study the effect of membrane ligand density on the binding and elution of
adenovirus (Ad5) and its associated impurities, such as DNA and total protein
content, was evaluated. A complex bioreactor feed stock was used to obtain a
more realistic approach compared to other studies where model proteins or pure
product were used (Lu et al., 2013; Wang et al., 2006; Wrzosek and Polakovič,
2011; Wrzosek et al., 2009). The use a novel 96-well plate system coupled with
the small-scale device significantly decreased the time needed for assessing the
performance of the two membrane platforms.
The following conclusions can be drawn: (i) the hydrogel-grafted membranes
yield higher virus recoveries than the directly grafted membranes; (ii) moving
toward hydrogel-grafted membranes with ligand densities lower than 2.4 µmol/cm2
led to virus recovery higher than 70%; (iii) the directly grafted membranes showed
low binding for the virus and give rise to significant percentages of viruses in the
flow-through, up to 60-70%.
The estimation of the design space for the two types of membranes points
to the optimal conditions with respect to recovery, and clearly illustrates the
different characteristics of the two membrane structures evaluated in this study
(Fig. 8). A decreased ligand density and increased ionic strength to a value of
150-200 mM NaCl are suitable conditions for hydrogel-grafted membranes; on
the other hand, increasing the ligand density and lowering the ionic strength to a
maximum of 25 mM NaCl is more suitable for directly grafted membranes.
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Figure 3.8: Space design for the hydrogel and the directly grafted membranes. The
top-right panel shows the best recovery yield conditions. The top-left panel shows the
selectivity, where the red area gives the DNA clearance in the elution at 1 M NaCl. The
bottom panel shows the predicted performance of the directly grafted membranes where
increasing the ligand density and lowering the ionic strength yields higher recoveries.
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Abstract
Adenovirus serotype 5 (Ad5) was successfully separated by size-exclusion chro-
matography (SEC) using a simple, yet efficient, two-column, quasi-continuous,
simulated moving-bed process operated in an open-loop configuration. The oper-
ating cycle is divided into two identical half-cycles, each of them consisting of the
following sequence of sub-steps: (i) elution of the upstream column and direction
of the effluent of the downstream column to waste; (ii) elution of the upstream
column and redirection of its effluent to waste while the downstream column is fed
with the clarified bioreaction bulk and its effluent collected as purified product;
(iii) operation of the system as in step (i) but collecting the effluent of the down-
stream column as product; (iv) elution of the upstream column and direction of
its effluent to waste while the flow through the downstream column is temporarily
halted. Clearance of impurities, namely DNA and host cell protein (HCP), were
experimentally assessed. The pilot-scale run yielded a virus recovery of 86%, and
a clearance of 90% and 89% for DNA and HCP, respectively, without any fine
tunning of the predetermined operating parameters. These figures compare very
favorably against single-column batch chromatography for the same volume of
size-exclusion resin. However, and most importantly, the virus yield was increased
from 57% for the batch system to 86% for the two-column SEC process because
of internal recycling of the mixed fractions of contaminated Ad5, even though
the two-column process was operated strictly in an open-loop configuration. And
last, but not least, the productivity was increased by 6-fold with the two-column
process. In conclusion, the main drawbacks of size-exclusion chromatography,
namely low productivity and low product titer, were overcome to a considerable
extent by an innovative two-column configuration that keeps the mixed fractions
inside the system at all times.
Keywords: simulating moving bed; two-column chromatography; virus
purification; size exclusion chromatography; downstream processing;
adenovirus.
CHAPTER 4. ADENOVIRUS PURIFICATION BY TWO-COLUMN,
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4.1 Introduction
Viral vectors are playing an increasingly important role in the vaccine and gene
therapy fields. Adenoviruses (Ads), in particular, are considered one of the most
suitable platforms for production of viral vaccines and gene therapy vectors. They
are medium-sized (90–100 nm), nonenveloped, icosahedral viruses composed of
a nucleocapsid and linear, non-segmented double stranded DNA genome that
is about 36 kb long. Their broad tissue tropism and large transgene packing
capacity make them attractive candidates for innovative virotherapies (Eglon
et al., 2009). Adenoviruses can be produced in a complementary cell line in both
adherent and suspension culture systems, such as HEK-293 or PER-C6 cells, or
A549 for oncolytic therapies (Segura et al., 2008; Kamen and Henry, 2004).
The use of recombinant adenoviruses for vaccination and gene therapy requires
fast and highly efficient purification protocols that yield high recoveries of infectious
particles, maintain viral infectivity, and effectively remove contaminating DNA
and host cell proteins (HCPs), while also concentrating the viral samples for final
delivery. The concentration of adenoviruses is critical not only to obtain high
titer vector stocks, but also to reduce the handled volume; the latter accelerates
the downstream processing and keeps the scalability of the purification train at a
manageable level (Tatsis and Ertl, 2004).
The downstream biopurification train has been extensively developed in the
past years by combining different chromatography steps, namely ion-exchange
(IEX)) and size-exclusion chromatography (SEC), and, less frequently, affinity chro-
matography, intermingled with concentration and ultra/diafiltration steps (Eglon
et al., 2009; Konz et al., 2005a,b; Burova and Ioffe, 2005; Peixoto et al., 2006;
Goerke et al., 2005).
To be more specific, the classical approach for adenovirus purification consists
of three major steps—clarification, concentration/purification, and polishing—
applied sequentially: (i) clarification of the harvested bioreaction bulk to re-
move cell and cell debris; (ii) ultra/diafiltration; (iii) anion exchange; (iv) ultra/
diafiltration to concentrate the product; and (v) SEC as a final polishing step.
The SEC step is usually carried out last, mainly because of its low productivity
and low product titer. Usually in this final step the amount processed is reduced
by 50 to 100 fold.
The purpose of the clarification step is to efficiently remove cell debris and
large product- or process-related aggregates, while maintaining and protecting
the product quality in the flow-through stream. The concentration step reduces
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the volume of clarified bulk by effectively removing low molecular weight HCP,
fragmented HC DNA, and possibly fragmented, product-related impurities, e.g.,
viral proteins. This step is a key factor for decreasing the upfront investment in
downstream equipment and materials. If detergent was used to disrupt the cells,
the diafiltration removes the detergent and associated lipids from the cells (Peixoto
et al., 2007).
As with many bioactive therapies, there is a clear trend towards liquid chro-
matography as the core technique for vector purification, and its use is often
integrated vertically within the DSP strategy, as it easily fits into the early capture
stage as well as into the final purification phase. The use of high-performance
liquid chromatography (HPLC) for large-scale adenoviral purification was first
described by Huyghe et al. (1995) and several approaches have been applied since
then, including IEX, SEC, hydrophobic interaction, and immobilized metal affinity
chromatography (Blanche et al., 2000; Kalbfuss et al., 2008; Lee et al., 2009).
Unlike traditional processes based on CsCl-gradient purification, HPLC offers a
straightforward linear scale-up path, and procedures for purifying up to around
1014 input particles have been reported.
IEX chromatography of virus particles is typically operated in positive (bind-
and-elute) mode: most of the impurities are collected in the flow-through pool,
while the virus particles and some of the impurities are retained in the resin. Due
to the differences in charge of the different components, it is possible to use this
process with high-resolution elution gradients, separating the adsorbed materials
into fractionated cuts, even though they are closely related.
SEC and ultra/diafiltration (usually by tangential flow filtration) are two
other widely used processes at the very latest stage for formulating the product
(Dormond et al., 2010; Peixoto et al., 2007; Rodrigues et al., 2007). However,
purification schemes where SEC is followed by IEX have also been reported in
the literature; two prominent examples are the works of Kalbfuss et al. (2007)
and Eglon et al. (2009) for influenza and adenovirus, respectively. These schemes,
when operated in batch mode, do not appear to be very cost efficient because they
apply a low-productivity unit operation (SEC) at an early stage of the downstream
train.
The increasing interest in vaccines and gene therapy, together with the need
to decrease the cost per dose, has led to the development of new chromatographic
tools or their conversion from other application areas (Barut et al., 2005; Lee
et al., 2009; Riordan et al., 2009; Vicente et al., 2011). One process-based
way to reduce the overall cost of the downstream chromatographic steps is by
115
CHAPTER 4. ADENOVIRUS PURIFICATION BY TWO-COLUMN,
SIZE-EXCLUSION, SIMULATED COUNTERCURRENT CHROMATOGRAPHY
changing to a continuous processing mode, which, in principle, yields higher
throughput, lower buffer consumption, higher capacity utilization and reduced
column volume, hence increased productivity. In particular, simulating moving bed
(SMB) chromatography, which is the best practical implementation of continuous
countercurrent solid-fluid chromatography (Seidel-Morgenstern et al., 2008; Silva
et al., 2012), is now widely applied for the binary separation of small molecules,
in particular chiral compounds under isocratic elution conditions (Francotte and
Richert, 1997; Gomes et al., 2006; Rajendran et al., 2009).
Studies concerning continuous downstream bioprocessing have targeted mostly
proteins and monoclonal antibodies (mAb) (Aumann and Morbidelli, 2007; Silva
et al., 2010; Godawat et al., 2012; Warikoo et al., 2012; Krättli et al., 2013); this
is primarily because the biopharmaceutical industry is currently dominated by
these bioproducts. To date, the continuous purification of large biomolecules,
such as viruses, has rarely been explored. Kröber et al. (2013) have recently
implemented a classical three-zone, open-loop SMB for influenza virus purifica-
tion. These authors have successfully increased the productivity by switching
to simulated countercurrent operation, although the DNA and HCP clearances
were not properly evaluated. In particular, since the bulk was not pretreated
with benzonase, DNA co-eluted with the virus; also, HCP contaminants were not
properly assessed due to the lack of an adequate ELISA kit for the utilized cell
line (MDCK).
Despite the clear advantages of continuous chromatography, as demonstrated
by the works cited above and others, the biopharmaceutical industry is somewhat
skeptical about switching to continuous or quasi-continuous, multi-column chro-
matography. This is, in part, due to the fact that innovation in this industry has
traditionally been more product- than process-oriented (Godawat et al., 2012),
but also due to the increased complexity in terms of process design and validation.
However, the implementation of single-use and ready-to-process technologies are
mitigating these issues. Therefore, there seems to be room for exploring compact
and efficient, simulated countercurrent, multi-column chromatographic processes
for biopurification.
The present work reports on the design and experimental validation of a simple
quasi-continuous, open-loop, two-column countercurrent chromatographic process
for size-exclusion purification of adenovirus serotype 5 (Ad5). As mentioned above,
SEC has been used in the past for both polishing and intermediate purification
of adenoviruses (Eglon et al., 2009; Burova and Ioffe, 2005; Kalbfuss et al., 2008;














Figure 4.1: (a) Standard downstream processing train for adenovirus purification and
(b) the adopted streamlined Ad5 purification train for assessing the effectiveness of the
two-column SMB-SEC step; in the streamlined train, the SMB-SEC step replaces the last
three steps of the standard purification train.
of SEC, namely low productivity and high product dilution, make it a costly
purification step. Here, it is shown that these drawbacks can be eliminated to
a large extent by switching from single-column batch operation to two-column
SMB-type operation.
Because of the anticipated boost in performance obtained by switching to
multi-column (quasi-)continuous operation, the Ad5 purification train employed
for assessing the effectiveness of the enhanced SEC step was streamlined. Figure 4.1
shows schematics of the standard and streamlined purification trains; in the latter
case, the SMB-SEC step is applied after the first ultra/diafiltration step and
replaces the last three steps of the standard purification train.
The main reason for working with the streamlined purification train was to
challenge the SMB-SEC step with a less purified bulk in order to prove that,
once the classical limitations of SEC are alleviated, the standard purification
train can be changed to meet specific needs in terms of cost reduction or purity
requirements. Moreover, running the process with a less clean bulk gives more
confidence on the performance assessment of the SMB-SEC step.
The paper is organized as follows. The materials and methods, including the
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physical realization of the two-column SMB, are first described. Then, the design
of the SEC step and the numerical tools employed to predict and optimize its
operation are discussed. We then proceed with the experimental validation of
the two-column process, demonstrating the stability of its cyclic steady behavior
and operating robustness. Impurity clearance, namely DNA and HCP, were
experimentally assessed on a cycle-to-cycle basis. Finally, the performance of
the streamlined purification train, evaluated with respect to impurity clearance,
productivity, and yield, is compared to that of a similar train but operated with
a standard single-column batch SEC step to highlight the gains obtained by
switching to the SMB-SEC design.
4.2 Materials and Methods
4.2.1 Cell line and medium
Two hundred and ninety-three cells of Human Embryonic kidney (HEK-293) pur-
chased from ATCC (ATCC-CRL-1573) were adapted to suspension and grown in
a commercial serum-free medium, Ex-Cell 293 (SAFC Biosciences, USA), supple-
mented with 4 mM of glutamine (Invitrogen, UK), in a humidified atmosphere of
8% CO2 in air at 37
◦C using shake flasks (Corning, USA). The cells were routinely
propagated twice a week using an inoculum of 0.5× 106 cells/mL. Cell concen-
tration and viability were determined by counting cells on a Fuchs-Rosenthal
haemocytometer (Brand, Germany) using the trypan blue (Invitrogen, UK) dye
exclusion method.
4.2.2 Virus production
We used a replication-defective adenovirus derived from serotype 5 adenovirus
(Ad5) encoding for GFP protein. The viruses were produced in a 2 L bioreactor
with 1 L working volume (Sartorius-Stedim Biotech, Germany). The agitation rate
was set at 70 rpm and the dissolved oxygen was controlled at 50% air saturation
by gas mixing and stirred cascade control with an airflow of 0.01 L/min; the pH
was controlled at 7.2 by aeration with a gaseous CO2 mixture and 1 M NaHCO3;
all infections were done at a cell concentration of 106 cells/mL using a multiplicity
of infection of 5; the adenoviruses were harvested at 48 hours post-infection. The
amount of infective particles (IP) in the bulk (before purification) was in the
range 109–1010 IP/mL.
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4.2.3 Clarification and concentration
Upon harvesting, the bioreaction bulk was supplemented with 0.1% Triton X100
(Sigma Aldrich, MO, USA) and incubated for 2 hours at 37◦C with 50 U/mL
of Benzonase (Merck Millipore, Germany) to digest the DNA and to release the
adenoviral vectors from the intracellular material by cell lysis.
Subsequently, the bulk was microfiltrated using a Sartopore 2 membrane
capsule (Sartorius Stedim Biotech, Germany) comprising a 0.8 µm prefilter and
a 0.45 µm filter, and concentrated up to 10 times and diafiltered up to 5 times
with 20 mM Tris & 150 mM NaCl at pH 8 on a Sartorius Stedim Biotech cassette
prototype with an average cut-off of 750 kDa. Before use, the capsules were
washed with one capsule volume of Milli Q water and two capsule volumes of
buffer. The bulk was stored in aliquots at −80◦C until further use.
4.2.4 Analytics
The protocol for the quantification of total viral particles was a two-step procedure:
DNA extraction according to the instructions on the “High Pure Viral Nucleic Acid
Kit” (Roche) manual and real-time PCR. The number of viral DNA copies was
determined by real-time PCR and LightCycler system (Roche Diagnostics) using a
Fast Start DNA master SYBR Green I kit to track a specific Ad5 sequence (Roche
Diagnostics). Internal plasmid of 2.07× 109 copies/µL was chosen as reference
standard. The total particle concentrations were confirmed using Nanosight
NS500 (NanoSight Ltd, UK), and the size distribution was determined. The
average of the two measures was the value chosen for assessing the virus recovery
yield. Protein profile analysis was performed in 4–12% NuPage gradient pre-cast
gels (Invitrogen). The gels were stained by Coomassie Instant Blue (Expedeon
Ltd, UK) and the protein concentration was determined using BCA kits (Pierce,
Rockford, USA) and bovine serum albumin (BSA) as the standard protein. The
protein were precipitated using 99% ethanol and incubated overnight at −20◦C.
The amount of HCP was determined using a commercially available ELISA kit
for HEK293 cell line (Cygnus Technologies, Inc.). The sample was diluted in PBS
and the assay was performed according to the manufacture protocol, the 96 well
plate was read by an absorbance microplate reader at 450/650 nm (SpectraMax
340). DNA was quantified by Quant-iT Picogreen DNA assay kit (Invitrogen).
After 5 minutes of incubation, the fluorescence was measured by Luminometery
(Turner BioSystems). Purified DNA was used as standard.
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4.2.5 SEC medium and columns
The selected size-exclusion medium was Sepharose 4 Fast Flow (S4FF, GE Health-
care), which was supplied by the manufacturer with an average particle size of
90 µm (range of 45–165 µm). S4FF is based on a highly cross-linked 4% agarose
matrix, which gives good physical stability and chromatographic qualities; its
exclusion limit for globular proteins is ca. 3× 107. This size-exclusion medium is
suitable for use in our application, since, as shown next, it completely excludes the
Ad5 particles from its porous matrix and, hence, they elute in the interparticle
volume, whereas the impurities present in the clarified bioreaction bulk elute
through the porous matrix at different rates.
The first preliminary data employed to design the process was the chro-
matogram for a small injection of the clarified bioreaction bulk in a XK 26/40
column (GE Healthcare; 2.6 cm i.d., maximum bed height of 40 cm) at a flow
rate of 3 mL/min (data not shown because they are qualitatively similar to those
discussed in § 4.3).
Before carrying out this experiment the fractionation properties of the column
were assessed using a high molecular weight (HMW) gel filtration calibration
kit (GE Healthcare, Buckinghamshire, UK) containing 5 globular proteins with
molecular weights in the range 44,000 to 669,000 and Blue Dextran (BD) 2000.
This kit was complemented with a small amount of CsCl-purified Ad5. The
obtained results are summarized in Fig. 4.2.
BD 2000 is expected to be completely excluded from the S4FF’s intraparticle
porosity and, thus, its elution volume should be equal to the interparticle column
volume, Vo = εoVc, where Vc is the geometric column volume and εo is the
interparticle porosity of the S4FF medium. As expected, the elution volume for
a short pulse of CsCl-purified Ad5 gave a value of Vo similiar to that obtained
for BD (Fig. 4.2), which proves that the Ad5 particles are excluded from the
S4FF matrix. The total porosity, ε = εo + (1− εo)εp, where εp is the intraparticle
porosity, was estimated from the elution peak for a small injection of 2% acetone
as tracer.
By noting that the resolution in SEC varies with the square root of bed height
(E.G. Malawer, 2004) it was estimated that the total bed height could be reduced
to around 20–25 cm while keeping a reasonable separation between the virus peak
and its closest impurity. We thus aimed at packing two columns with a bed height
of ca. 10–12 cm.
Two XK 26/20 chromatographic columns (2.6 cm i.d., maximum bed height of
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Figure 4.2: Analysis of the pore size distribution of S4FF medium using a high
molecular weight (HMW) gel filtration calibration kit (GE Healthcare, Buckinghamshire,
UK) containing several protein standards complemented with the CsCl-purified Ad5. The
Ad5 particles, like BD 2000, are excluded from the S4FF’s porous matrix and elute in
the void volume of the column.
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Table 4.1: Characterization of the two XK 26/20 columns packed with S4FF. Vc and L
are the volume and length of the column, N is the number of theoretical plates, Af is the
peak asymmetry factor, and N/L is the number of theoretical plates of meter of column
length.
Column 1 Column 2
Vc (cm
3) 55.2 57.3
L (cm) 10.4 10.8
Vo (cm
3) 16.8 15.2
N (–) 281 220
Af (–) 1.25 1.0
N/L (m−1) 2702 2037
20 cm) were slurry packed with S4FF according to the manufacturer’s specifications.
The excess ethanol supplied with SF44 was decanted and replaced with working
buffer (20 mM Tris, 150 mM NaCl, pH 8) before packing into the columns. The
columns were initially filled with 70% slurry of S4FF and allowed to settle by
gravity overnight. The flow rate was then increased in stepwise fashion up to
4 mL/min (ca. 45 cm/h). The final, stabilized column lengths were 10.4 cm and
10.8 cm. No measures were taken to improve the balancing of the bed heights.
Before each experiment the columns were sanitized with 1 M NaOH, washed with
Milli Q water, and equilibrated with 5 bed volumes of running buffer (20 mM
Tris, 150 mM NaCl, pH 8).
After packing the two columns, their efficiency was tested, as described above,
to check the quality of the packing. The total porosity, ε, was estimated from
the acetone elution peak; for completeness, the number of theoretical plates (N)
measured with this tracer was also calculated (Table 4.1).
For a well-packed column of gel-filtration media the void volume Vo should be
equivalent to approximately 30% of the total column volume Vc (GE-Healthcare).
Table 4.1 shows that this is indeed the case of our two columns.
4.2.6 Experimental two-column SEC setup
Fig. 4.3 shows a schematic of the set of feasible flow diagrams for designing the
operating cycle for the class of two-column, open-loop SEC processes considered
in the present work; they represent the alternative configurations that can be
considered for the implementation of any given step of the cycle.
The set includes the following configurations: (a) directing the flow to the next
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Figure 4.3: Set of admissible flow-line configurations for designing a two-column,
open-loop SEC purification step without outlet split flow: (a) complete direction of flow
to the next column, (b) flow addition to the circulating stream, (c) frozen bed, and (d)
complete withdrawal and flow injection at the same node. Each schematic represents a
valid configuration for a given step of the two-column SEC cycle. For simplicity of design
and robustness of operation, schematic e (outlet split flow) and schematic f (closed-loop
recirculation) are excluded from the design, since configuration e cannot be implemented
with simple two-way valves and configuration f requires an extra pump.
column; (b) adding an external stream to the circulating flow; (c) freezing one
column (temporarily stopping the flow through the column); and (d) withdrawing
the effluent from one column while injecting an external stream into the other
column. In this class of two-column, open-loop SEC processes the flow through a
column is always in one of three states: (i) frozen, (ii) completely directed to the
next column, or (iii) entirely diverted to either the product line or the waste line.
We have purposively excluded from the set of feasible configurations those in
which the flow exiting one column is split into two or more streams — schematic e
illustrates what is meant by split flow — or in which the flow is recirculated in
closed loop (schematic f ). The reason for discarding these configurations is to
avoid the use of flow controllers or an extra pump; the objective is to design a
SEC process that is physically realizable with simple two- or three-way valves to
control the flow paths in the system and requires a minimum number of pumps —
one for injecting the feed and another for injecting the mobile phase.
Figure 4.4 shows a schematic of the experimental two-column set-up. The
distributed valve design is based on two-way valves, since they allow independent
port switching and are quite versatile. Two-way valves allow the flow either to go
through or not to go through.
A two-way valve is placed immediately downstream of the two outlet ports
of each column, but preceding the two inlet ports, to control the flow rate of
liquid from the column that is circulated to the other column. This valve is closed
when the effluent from the upstream column is totally withdrawn as product
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Figure 4.4: Schematic of the preparative unit for the two-column, open-loop SEC
purification step. Each column has five two-way valves associated to it; an UV detector
is placed at the outlet of each column. E denotes the eluent inlet; F , the feed inlet; and
P and W , the product and waste outlets, respectively
or the fluid in the column needs to be temporarily frozen. Overall, the set-up
employs 10 two-way valves to control the port switching. The two-way valves are
model SFVO from Valco International (Schenkon, Switzerland) with pneumatic
actuation. Each valve is automated by means of a single computer-controlled
three-way solenoid: application of 50 psi opens the valve; venting the air allows
the spring to return the valve to the closed position.
The two HPLC pumps—one for injecting feed and the other for injecting
fresh mobile phase—are model K-501 from Knauer (Berlin, Germany) with 10
mL heads, and controlled via RS232 communication protocol. The experimental
set-up is fully automated and driven by an in-house developed automation system
using LabView software (National Instruments).
The UV absorbance of the effluent from each column was automatically
monitored in real-time at 12 distinct wavelengths ranging from 230 nm to 300 nm
using two USB4000 multiwavelength UV detectors (Ocean Optics, USA) with
attenuator, sharing the same DH-2000-S-DUV light source (Micropack, Ostfildern,
Germany) by means of a bifurcated optical fiber assembly.
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4.2.7 SEC column breakthrough model
A simple equilibrium-dispersive adsorption column breakthrough model was
adopted for computer-aided design of the SEC step. In this model the column
efficiency is measured by the dimensionless plate height, hi = L/Ni, where L is
the column length and Ni is the number of theoretical plates for component i. The
approximate additivity of the effects of axial dispersion, external mass transfer
resistance, and diffusion for linear systems was demonstrated long ago by various
authors (e.g., (Glueckauf, 1955; Glueckauf and Coates, 1947); also Haynes and
Sarma (1973) using moments analysis). This means that in the modeling of
chromatographic columns under inert or linear equilibrium conditions it is seldom
worth modeling the band broadening using a more complex descriptor than an
overall effective dispersion coefficient (or, alternatively, and overall effective rate
coefficient) incorporating both effects of axial dispersion and the various mass
transfer resistances (Ruthven, 1984).















= 0 ∀x : 0 < x < 1, (4.1)
where t is the time coordinate, x = z/L is the dimensionless axial coordinate
along the packed bed, L and Vc are the length and volume of the column, i is
the solute index, c is the solute concentration in the mobile phase, and Q is the
volumetric flow rate of mobile phase.
The symbol εi denotes the volumetric fraction of the SEC column that is
accessible to component i (i.e., the overall porosity of the packed bed that is
probed by component i); εi can be expressed as




where ψ(·) is the pore size distribution of the size exclusion medium,1 i.e., ψ(σ) dσ
is the fraction of the S4FF’s porous volume with pore diameters between σ and
σ + dσ, and dm,i is the size of the biomolecule (including any existing hydration
layer).
1The function ψ(·) is a normalized distribution,
∫∞
0 ψ(σ) dσ = 1, and
∫∞
dm,i
ψ(σ) dσ can be
regarded as the exclusion factor for a biomolecule of size dm,i.
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= cini for x = 0, (4.3)
∂ci
∂x
= 0 for x = 1, (4.4)
where cini (t) is the inlet concentration of component i; c
out
i (t) shall denote the
temporal concentration profile of component i in the outlet effluent of the column.
4.3 Design of the SEC step
Figure 4.5 shows the chromatograms for the elution of dilute pulse injections of
the bioreaction bulk through each XK 26/20 column and through the two columns
arranged in series. The solid, black lines plotted in Figs. 4.5A and 4.5B represent
the experimental chromatograms obtained with each column separately, whereas
the solid, black line in Fig. 4.5C is the chromatogram obtained with the serial
arrangement of the two columns.
The rising fraction of the first peak in the chromatogram of Fig. 4.5C was
collected separately and analyzed for its particle size distribution (PSD) and
concentration in a Nanosight NS500 (Nanosight Ltd, UK); this peak is the one
that elutes in the void volume of the columns. Figure 4.6 shows that the PSD
profile is centered around 85–96 nm, which is the average size of an Ad5 particle,
and drops sharply for smaller particle sizes, indicating that the fraction eluting
in the void volume of the S4FF columns is practically free of impurities. The
very mild tailing of the PSD over sizes larger than 96 nm indicates the absence of
relevant amounts of aggregates. These results ensure that this first eluting peak
consists essentially of purified Ad5 particles.
Unlike IEX or affinity chromatography, the solutes do not bind to the SEC
medium, because of lack of reactivity and strong adsorptive interactions, so they
elute through the SEC medium at a rate that depends on their molecular size and
shape but not on the presence of the other solutes. Therefore, for the purposes of
process design the complex multicomponent mixture in the clarified bioreaction
bulk can be modeled as a simpler mixture of three key components: (1) the virus,
which is the largest species and, hence, the fastest eluting component; (2) the
group of impurities that elute nearest to the virus; and (3) the group of small
impurities that elute at the slowest rate. The difference in the selectivity factor
between the first two key components will essentially define the difficulty of the
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Figure 4.5: Dilute pulse experiments of the clarified bioreaction bulk on the two
XK 26/20 columns packed with S4FF medium. Plots A and B show the experimental
chromatogram (black line, UV signal 230 nm) obtained with the individual columns,
(column 1 and 2, respectively); the colored lines represent the deconvolution of the
experimental chromatogram into the superimposition of fours noninteracting peaks. Plot C
shows the experimental chromatogram (black line, UV signal 230 nm) obtained with the
two columns placed in series and the best fit of the chromatogram to the superimposition
of four noninteracting peaks (red line); the latter are represented individually in plot D
(colored lines)
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Particle size (100 nm
 per division)
Figure 4.6: Particle size distribution (PSD) and concentration of the rising fraction
of the first elution peak shown in Fig. 4.5C; this peak is the one fitted by the solid blue
line in Fig. 4.5D. The analysis was carried out in a Nanosight NS500 (NanoSight Ltd,
UK). The PSD profile is centered around 85–96 nm, which is the average size of an Ad5
particle, and drops sharply at smaller particle sizes, indicating that the fraction eluting
in the void volume of the S4FF columns is practically free of impurities. The very mild
tailing of the PSD over sizes larger than 96 nm indicates the absence of relevant amounts
of aggregates.
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Table 4.2: Model parameters derived from analysis of pulse experiments performed on
the two columns placed in series, L = L1 + L2 = 21.2 cm. i is the component index, c
F
is the feed concentration, which is assumed to be proportional to the area under the UV




i = 1), ε is the accessible porosity, and N is
the number of theoretical plates per column.
i 1 2 3 4
cFi 0.140 0.165 0.154 0.541
εi 0.306 0.564 0.750 0.945
Ni 61 18 51 69
separation, whereas the difference in the selectivity factor between the first and
last key components will define the cycle time. Since all the other molecules in
the bioreaction bulk necessarily elute at intermediate rates between those of the
second and third key components, they are withdrawn from the system in one of
the waste fractions if the SEC process is well designed.
To design the SEC process it is necessary to measure the retention volume
of each key component, from which the value of εi can be determined, and the
extent of band broadening at the working flow rate to determine the value of hi.
We used PeakFit (Systat Software Inc., San Jose, CA) to quickly estimate the
location, area, and broadening of the key chromatographic peaks for injections of
the clarified bioreaction bulk in each column and in the two columns arranged in
series. These data were then used as initial guess in a more accurate deconvolution
procedure, which fits the superposition of multiple solutions of eq. 4.1 (one for
each component) without neglecting the non-infinitesimal size of the injected
sample.
The fitted chromatographic peaks for the three key components are shown in
Fig. 4.5 as blue (virus), dashed yellow (large impurities), and dotted orange (small
impurities) lines. Figure 4.5 also shows a fourth modeled component, plotted
as a dash-dot green line, corresponding to the group of intermediate impurities
that elute between the two groups of key impurities. This fourth component was
not considered in the design of the SEC process, it was only used to get a better
description of the simulated elution profiles for comparison with the experiments.
Table 4.2 lists the model parameters derived from the analysis of the pulse ex-
periments performed on the two columns placed in series. The feed concentrations




i = 1, and were determined assum-
ing that the concentration is proportional to the area under the corresponding
UV absorbance peak.
129
CHAPTER 4. ADENOVIRUS PURIFICATION BY TWO-COLUMN,
SIZE-EXCLUSION, SIMULATED COUNTERCURRENT CHROMATOGRAPHY
In a two-column SEC process the cycle is divided into two equal-length time
intervals, which we shall henceforth refer to as switching intervals. To design the
cycle it suffices to define the sequence of flow-line configurations for one of the
switching intervals; the sequence for the other twin switching interval is similar,
but the positions of the two columns are exchanged. In practice, it is easier to
keep the columns fixed in space and to move the positions of the inlet and outlet
lines by means of an automated arrangement of two- or three-way valves. Over a
full cycle, each column undergoes the same sequence of steps but phased out in
time by one switching interval.
The sequence for a switching interval is defined as a serial arrangement of
flow-line configurations taken from the set shown in Fig. 4.3. To each flow-path
configuration one has to assign (i) the positions of columns 1 and 2, (ii) the
nature of each inlet (feed or eluent), and (iii) the nature of each outlet (product
or waste). Although this picture may look too theoretical to the downstream
process engineer, we advocate that this process-systems-engineering view of the
downstream process, and of the SEC step in particular, is very helpful, as it
clearly establishes the elementary steps that the columns should undergo and the
number and type of design variables associated to each step.
In previous work (Silva et al., 2010; Araújo et al., 2010) we have demonstrated
that a half-cycle consisting of steps a-b-a gives rise to a very efficient process
for binary separation. This scheme supplies the feed mixture into the middle of
the system where the composition of the circulating fluid is closest to that of the
feedstock fluid, and recovers the purified product and waste fraction alternately
at the downstream end of the unit, while desorbent is continuously supplied into
the upstream end of the system. Moreover, we have shown that the injection of
feed, step b, can be replaced by steps c or d without loss of performance and in
some instances increased productivity (Rodrigues et al., 2008; Silva et al., 2012).
These steps are mandatory when the duration of product collection is larger than
the time taken to inject the feed (Silva et al., 2010), which is the case when there
is large band broadening in the system as is the case in SEC.
Using these guidelines we developed the cycle shown in Fig. 4.7, whose half-
cycle (or switching interval) is divided into the sequence of steps a-d -a-c:
Step 1. The upstream column is eluted while the effluent of the downstream
column is diverted to the waste line.
Step 2. The upstream column is eluted but its effluent is diverted to the waste
line instead of being directed to the downstream column. The downstream
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1st half cycle 2nd half cycle
Figure 4.7: schematic of the operating cycle for the two-column, open-loop SEC
purification step; E denotes the eluent inlet; F , the feed inlet; and P and W , the product
and waste outlets, respectively
column is fed with the clarified bioreaction bulk while its effluent is collected
as purified product.
Step 3. The system is operated as in step 1 but the effluent of the downstream
column is collected as product.
Step 4.
The upstream column is eluted but its effluent is again diverted to the waste
line instead of being directed to the downstream column. The downstream
column is kept frozen, that is, the flow through that column is temporarily
halted.
The feed and eluent flow rates, QF and QE, were both fixed at 3 mL/min
because of the constraint imposed by the pressure drop through the SEC medium
in steps 1 and 3 of the cycle.
After defining the step sequence, a rigorous model-based optimization approach
was employed to determine the optimum duration of each step, τk, k = 1, . . . , 4,
for the fixed values of the process flow rates. The purpose of the nonlinear
programming problem is to guarantee the fulfilment of product and process
specifications, such as minimal purity and recovery, while optimizing process
performance in terms of productivity.
Let
ci,j(x, t) = f(ci,j(x, 0); τ1, . . . , τ4) for 0 < t ≤ τ (4.5)
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represent the dynamic model for the first half (0 < t ≤ τ) of the cycle depicted
in the schematic of Fig. 4.7 for given initial conditions ci,1(x, 0) and ci,2(x, 0) in
columns 1 and 2, respectively; here, i is the index that runs over the set of solutes
and j runs over the set of columns. For example, if we wanted to simulate the
startup of the process when the two columns are initially clean, we would set
ci,1(x, 0) = 0, ci,2(x, 0) = 0. (4.6)
For process design, however, the initial transient behavior is of little interest
but only the fully established steady, periodic state. Thus, we are interested in
the solution of eq. 4.5 subject to the constraint




which simultaneously imposes the condition of simulated counter-current operation
(the two columns exchange roles every switching interval) and time periodic
behavior.
For the cycle depicted in Fig. 4.7 the amount of feed injected per switching
interval, which is a direct measure of productivity, is given by
QF = (τ2/τ)QF, (4.8)
and the purity and recovery of purified Ad5 under cyclic steady-state conditions,






















































i,j is the total concentration in the outlet stream of column j;
the flow rates drop out of the expressions because they happen to be equal. If
PAd5 is high, say above 90%, the impurities in the collected product fraction will
necessarily be the key components 2 and/or 3, the former because of its proximity
to the product and the latter because of circulation around the system from the
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Table 4.3: Optimum duration of each step, τk (k = 1, . . . , 4) of the cycle shown
in Fig. 4.7 for the chromatographic parameters given in Table. 4.2; the values of τk
are reported in minutes. The duration of the switching interval, or half-cycle, is τ =
17.76 min. The elution (QE) and feed flow (QF) rates are both fixed at 3 mL/min;
PAd5,min = 0.98, RAd5,min = 0.95.





previous switching interval. This is why it is unnecessary to include more key
impurities in the design procedure, although considering more components would,
of course, make no harm but increase the computational overhead.





s.t. eq. 4.5 and eq. 5.8,
PAd5 ≥ PAd5,min,
RAd5 ≥ RAd5,min.
4.4 Results and Discussion
4.4.1 Simulation results
The solution of the design problem for the set of parameters listed in Table 4.2,
column lengths L1 = L2 = (10.8+10.4)/2 = 10.6 cm, PAd5,min = 0.98, RAd5,min =
0.95, and QE = QF = 3 mL/min is given in Table 5.3.
One practical consideration in size exclusion chromatography is the volume of
injected sample. For high-resolution fractionation, a sample volume from 0.5% to
4% of the total column volume (CV) is recommended, depending on the type of
medium used; for most applications the sample volume should not exceed 2% to
achieve maximum resolution. For group separations, however, volumes up to 30%
of the total CV can be used (GE-Healthcare).
An advantage of the proposed two-column SMB-SEC process is the relaxation
of the requirement of high resolution for achieving high purity. Therefore, the
purification of the Ad5 bioreaction bulk using our two-column SEC system can
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be classified as a group separation problem, for which sample volumes up to 30%
of the total CV are admissible.
From Table 5.3 it is seen that the sample volume injected per switching interval
is 11.8 cm3, which is 20.9% of the total volume of one of the twin columns; this
is the same as 2× 11.84 cm3 of feed injected per cycle, corresponding to 20.9%
of the summed volumes of the two twin columns of SMB-SEC system. This is
within the operating range recommend by the manufacturer of the gel filtration
medium (GE-Healthcare).
For the optimized SEC process, Fig. 4.8 shows the simulated temporal concen-
tration profiles at the outlet of the two columns for the first switching interval
of the cycle under cyclic steady-state conditions. The temporal profiles for the
second switching interval of the cycle are identical to those of the first but the
two column indices are exchanged.
Fig. 5.9 provides more simulation results about the cyclic steady-state behavior
of the process; it shows the simulated axial concentration profiles of the key
components in the two columns at the start of each sub-step of the switching
interval.
The simulation data plotted in Figs. 4.8 and 5.9 predict that the optimized
SEC process can effectively purify the Ad5 bioreaction bulk to a high purity
specification; as expected, the simulation profiles show that the group of impurities
that most adversely affect the purity of the product fraction is the group of slowest
eluting impurities—those whose profile is plotted as a dashed orange line.
Fresh feed is injected while the Ad5 product from the previous switching
interval is being displaced from column 1 to column 2. A purified band will then
slowly detach from the group of nearest eluting impurities. As soon as the product
is confined into column 2, the impurities trapped in column 1 can be directed to
the waste line and then the steps are repeated but with the two column positions
exchanged. At the start of each cycle the concentration bands are nearly all
confined to column 1, whereas column 2 is clean except for a small region at its
downstream end that contains the trailing band of the group of more retained
impurities. If required, at this instant of the cycle column 2 can be replaced
by a clean one and subject to a cleaning-in-place (CIP) procedure to be readily
available for use at a later cycle. This is a convenient way to implement a periodic
CIP procedure in our process without changing the step sequence and durations.
An alternative CIP procedure, which could potentially decrease the process
time, stems from the observation that, at the end of step 3, column 1 is loaded
with impurities while the product is confined to column 2. Hence, this optional
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Figure 4.8: Simulated temporal concentration profiles at the outlet of column 1 (top)
and column 2 (bottom) for the first switching interval of the cycle under cyclic steady
state conditions. The temporal profiles for the second switching interval of the cycle
are identical to those of the first but the two column indexes are exchanged. The cycle
parameters are given in Table 5.3. Color coding: solid blue line, virus; dashed yellow
line, first group of eluting impurities; dash-dot green line, intermediate group of eluting
impurities; dotted orange line, last group of eluting impurities; solid red line, total
concentration.
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Figure 4.9: Simulated axial concentration profiles at the start of each step of the first
switching interval of the cycle under cyclic steady state conditions. For completeness,
the concentration profiles at the end of the cycle, immediately after switching the ports
to start the first step of the second switching interval of the cycle, are shown in the
bottom. The y-axis in each column ranges from 0 to the total feed concentration. The
cycle parameters are given in Table 5.3. Color coding: solid blue line, virus; dashed
yellow line, first group of eluting impurities; dash-dot green line, intermediate group of
eluting impurities; dotted orange line, last group of eluting impurities; solid red line, total
concentration.
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Figure 4.10: Experimental UV signal (230 nm) measured at the outlet of column 1
over the first five cycles of operation. The blue strips show the time intervals for product
collection from column 1. Note that the time scale for t/τ < 7 has been compressed to
improve the visualization of the UV signal for t/τ > 7
CIP procedure replaces column 1 by a clean one at the end of step 3 and moves
directly to the beginning of the next half-cycle, thus bypassing step 4. However,
since this CIP strategy shortens the duration of that particular half-cycle, it would
have to be applied less frequently than the other CIP procedure.
4.4.2 Experimental validation
The optimized SEC process was implemented experimentally in the preparative
prototype unit described in section 4.4. The unit was operated for five full cycles,
which were more than enough to attain cyclic steady state conditions. Figure 4.10
shows the temporal profile of the UV signal measured at the outlet of column 1 over
the duration of the experiment, which corroborates our observation about the fast
attainment of the steady, periodic behavior, but also the excellent cycle-to-cycle
reproducibility of the profile exhibited by the process.
Also noteworthy is the fairly good agreement between the periodic shape of
the UV profile and the predicted total concentration profile plotted in Fig 4.8 as
a solid red line, which is the information extracted from the simulation that is
closest to being proportional to the UV signal. The similarity between these two
profiles is a strong indication that the process is behaving as expected. Note that
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to visually compare Fig. 4.8 and Fig. 4.10, the bottom graphic of Fig. 4.8 must
be horizontally aligned at the right of the top graphic to generate the temporal
profile for column 1 over a complete cycle.
The product fraction collected at each switching interval was analyzed sepa-
rately to determine the Ad5, HCP, and DNA contents. These measurements are
plotted in Fig. 4.11 as a function of the number of elapsed switching intervals.
It is worth noting that a full cycle is completed every two switching intervals,
and that even tics on the horizontal axis correspond to fractions collected from
column 1 and odd tics to fractions collected from column 2. Given that the values
plotted in Fig. 4.11 correspond to measurements of each product fraction collected
into a perfectly mixed cup, the system’s periodic behavior gives rise to steady
values of those measurements upon attainment of the cyclic steady state.
The 4% difference between the two column heights does not visually manifest
itself as an odd-even periodicity in the quality of the collected fractions, although
one may argue the contrary about the DNA content.
A qualitative evaluation of the total protein profile in the product fractions
collected during the fourth and fifth cycles of operation of the two-column SMB-
SEC process was performed by SDS-PAGE (Fig. 4.12). For each lane 15 µg of
protein were loaded. The proteins related to the adenovirus capside, namely
hexon, penton, and core, are marked within the red boxes. Although the visual
information provided by the SDS-PAGE analysis is only qualitative, it is seen
that bands related to the adenovirus pattern in the purified product are more
visible compare to the feed, where a smear is observed due to the presence of
several indistinguishable contaminant proteins.
Using the data of Fig. 4.11 it is straightforward to compute the product
recovery and impurity clearance. Table 4.4 summarizes the evaluated performance
of the two-column SEC system. The virus recovery yield was determined by
both RT-PCR and Nanosight quantification. The two-column process was also
compared against the standard single-column batch process with the same amount
of SEC medium. In the later case, the two columns were arranged in series to
mimic the operation of a single column.
The optimization procedure for the batch SEC step is the same as that
employed by Rodrigues et al. (2010) and Silva et al. (2010). In particular, the
optimized cycle time is such that for every injection it minimizes the lag between
the leading edge of the product fraction of Ad5 particles, which are the fastest
migrating component, and the trailing band of the slowest migrating components
of the previous injection. The performance metrics for the standard single-column
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Figure 4.11: Experimental concentrations of total virus particles, host cell protein
(HCP), and DNA in the product fraction collected every switching interval during the
first five cycles of operation.
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Figure 4.12: SDS-PAGE protein profile analysis of the product fractions, P1 and P2,
collected in cycles 4 and 5; P1 and P2 are the product fractions collected during the
second and third steps of the switching interval, respectively (see Figs. 4.7 and 5.9). For
each line 15 µg of protein were loaded. The protein related to the adenovirus capside,
namely hexon, penton, and core, are marked by the red boxes. Labels: Pk-n-j, product
fraction Pk collected from column j during cycle n; Feed, clarified bioreaction bulk; CsCl,
CsCl-purified Ad5.
Table 4.4: Comparison of experimental performance between the two-column SEC
system and a single-column SEC batch process for the same amount of stationary phase.
The virus recovery yield was determined by RT-PCR and Nanosight quantification.
Productivity Virus Yield DNA Clearance HCP Clearance
(L/min) (%) (%) (%)
Two-column, open-loop SCC-SEC
0.67 86.3 90 89
Single-column batch SEC
0.11 57.4 94 94
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batch SEC process are listed in Table 4.4 alongside the results for the two-column
process.
It worth pointing out that the purity level required by the authorities is
usually expressed as amounts of DNA and HCP per dose, which implies that an
application where the therapeutic dose is very high (e.g., gene therapy) can require
several purification steps, whereas for VLP or mucose vaccine fewer purification
steps can be sufficient to reach the desired purity level. For this reason, in the
present work the process performance is always quantified in terms of percentage
of clearance.
Table 4.4 shows that the two-column SEC process achieves about the same
DNA and HCP clearances as the standard batch process. However, and most
importantly, the virus yield is increased from 57% for the batch process to 86%
for the two-column process, an improvement of 51%, because of internal recycling
of the mixed fractions of contaminated Ad5 even though the process is operated
strictly in an open-loop configuration. And last, but not least, the productivity
is increase by 6-fold with the two-column process. This is a clear demonstration
that with this increased productivity, size exclusion can go beyond the classical
purposes of final polishing and buffer exchange in the downstream train of a
biopurification.
The level of product dilution, as measured by the product-to-feed concentration
ratio, (cP/cF)Ad5, is given by the volume ratio of collected product and injected
feed per cycle, adjusted for the product recovery yield, RAd5. This is valid for
both the two-column SMB-SEC process and the standard batch SEC process. For
example, for the former process the concentration ratio is given by τ2RAd5/(τ2+τ3).
The experimental value of (cP/cF)Ad5 for the two-column SMB-SEC process
is 1/1.5 and for the batch SEC process is 1/3, which is considerably smaller.
Therefore, it is seen that the product fraction obtained with the two-column
SMB-SEC process is significantly less diluted than the product fraction obtained
with the standard batch SEC process.
Before concluding and summarizing the work, the problem of tackling process
uncertainty, that is, of how to adjust the operating parameters to compensate for
modeling uncertainty and process variability, is briefly discussed. When the model
mismatch is significant, there is no other option than recalibration of the model
and calculation of new operating parameters. But when the mismatch is small or
moderate, there are two straightforward approaches to correct a purity that is out
of specification. One option entails directing the outlet stream of column 2 to the
waste line during a final fraction of step 3 of the switching interval (cf. Fig. 4.7),
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but at the cost of reducing the product recovery, since it was shown in Fig. 5.9
that the last part of the collected product fraction is the more amenable to
contamination. The other option, which sacrifices productivity instead of recovery,
entails reducing the length of step 2—the feed step—and increasing by the same
amount the duration of step 3. In any case, any measure to bring the purity to
within specification has necessarily a cost in process performance with respect to
the optimum conditions derived from the computer-aided process design.
4.5 Conclusions
This work reported on the design and experimental implementation of a simple,
yet efficient, two-column, quasi-continuous, simulated moving-bed process for
the separation of Ad5 by SEC. The process is strictly operated in an open-loop
configuration to dispense the use of an internal recirculation pump; it uses two
HPLC pumps only: one for injecting the clarified bioreaction bulk and another
for injecting fresh eluent. At any instant of the operating cycle, the flow through
a column is either temporarily stopped or completely directed to one of three
destinations: the other column, the waste line, or the product line. This class of
flow-path configurations is easily implemented with simple two-way valves and
gives rise to very robust operating cycles.
Care was taken to experimentally monitor the process performance on a cycle-
to-cycle basis. For example, clearance of impurities, namely DNA and HCP, and
virus concentration, were experimentally assessed at each cycle. The experimental
results show a virus recovery of 86%, and a clearance of 90% and 89% for DNA and
HCP, respectively. These figures compare very favorably against single-column
batch chromatography for the same volume of size-exclusion resin. The 6-fold
productivity boost and 51% increase in Ad5 recovery, without compromising the
impurity clearance, are strong arguments in favor of implementing the type of
process presented here in a real production DSP train.
The adopted process-systems-engineering view of the downstream process,
coupled with state-of-the-art process optimization and process automation, can
pave the way to ready-to-process technologies where the complexity is hidden
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Abstract
A simple, yet efficient, two-column simulated moving-bed (2CSMB) process for
purifying adenovirus serotype 5 (Ad5) by size-exclusion chromatography (SEC) is
presented and validated experimentally, and a general procedure for its robust
design under parameter uncertainty is described. The pilot-scale run yielded a
virus recovery of 86% and DNA and HCP clearances of 90% and 89%, respectively,
without any fine tunning of the operating parameters. This performance compares
very favorably against that of single-column batch chromatography for the same
volume of size-exclusion resin. To improve the robustness of the 2CSMB-SEC
process the best set of operating parameters is selected only among candidate
solutions that are robust feasible, that is, remain feasible for all parameter
perturbations within their uncertainty intervals. This robust approach to optimal
design replaces the nominal problem by a worst case problem. Computational
tractability is ensured by formulating the robust design problem with only the
vertexes of the uncertainty region that have the worst effect on the product purity
and recovery. The robust design is exemplified on the case where the column
volume and interparticle porosity are subject to uncertainty. As expected, to
increase the robustness of the 2CSMB-SEC process it is necessary to reduce
its productivity and increase its solvent consumption. Nevertheless, the design
solution given by the proposed robust approach is the least detrimental of all
possible feasible candidate solutions.
Keywords: virus purification; size-exclusion chromatography; simulat-
ing moving bed; two-column chromatography; robust design.
CHAPTER 5. ROBUST DESIGN OF ADENOVIRUS PURIFICATION BY
TWO-COLUMN, SIMULATED COUNTERCURRENT CHROMATOGRAPHY
5.1 Introduction
Viral vectors are playing an increasingly important role in the vaccine and gene
therapy fields. Adenoviruses (Ads), in particular, are considered one of the most
suitable platforms for production of viral vaccines and gene therapy vectors. They
are medium-sized (90–100 nm), nonenveloped, icosahedral viruses composed of
a nucleocapsid and linear, non-segmented double stranded DNA genome that
is about 36 kb long. Their broad tissue tropism and large transgene packing
capacity make them attractive candidates for innovative virotherapies (Eglon
et al., 2009). Adenoviruses can be produced in a complementary cell line in both
adherent and suspension culture systems, such as HEK-293 or PER-C6 cells, or
A549 for oncolytic therapies (Segura et al., 2008; Kamen and Henry, 2004).
Liquid chromatography is currently the core technique for vector purification,
and its use is often integrated vertically within the downstream processing (DSP)
strategy, as it easily fits into the early capture stage as well as into the final
purification phase. The use of high-performance liquid chromatography (HPLC)
for large-scale adenoviral purification was first described by Huyghe et al. (1995),
and several approaches have been applied since then, including ion-exchange
(IEX), size-exclusion (SEC), hydrophobic interaction, and immobilized metal
affinity chromatography (Blanche et al., 2000; Kalbfuss et al., 2008; Lee et al.,
2009). Unlike traditional processes based on CsCl-gradient purification, HPLC
offers a straightforward linear scale-up path, and procedures for purifying up to
around 1014 input particles have been reported.
SEC and ultra/diafiltration (usually by tangential flow filtration) are two
other widely used processes at the very latest stage for formulating the product
(Dormond et al., 2010; Peixoto et al., 2007; Rodrigues et al., 2007). However,
purification schemes where SEC is followed by IEX have also been reported in
the literature; two prominent examples are the works of Kalbfuss et al. (2007)
and Eglon et al. (2009) for influenza and adenovirus, respectively.
One process-based way to improve the performance of the DSP chromato-
graphic steps is by changing to a (quasi-)continuous processing mode, which, in
principle, yields higher throughput, lower buffer consumption, higher capacity
utilization of the stationary phase and reduced column volume, hence increased
productivity.
Studies concerning continuous or quasi-continuous downstream bioprocessing
have targeted mostly proteins and monoclonal antibodies (mAb) (Aumann and
Morbidelli, 2007; Silva et al., 2010; Godawat et al., 2012; Warikoo et al., 2012;
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Krättli et al., 2013); this is primarily because the biopharmaceutical industry is
currently dominated by these bioproducts. To date, the continuous purification of
large biomolecules, such as viruses, has rarely been explored. A notable exception
is the recent work of Kröber et al. (2013), who implemented a classical three-zone,
open-loop simulated moving bed (SMB) for influenza virus purification. These
authors have successfully increased the productivity by switching to simulated
countercurrent operation.
Uncertainties in isotherm parameters, band broadening, pump stability and cal-
ibration, extra-column volumes, and packing reproducibility are inevitable in every
multicolumn chromatographic process. This is particularly true in bioproduction-
scale operation. Robust analysis of single-column batch biochromatography has
been extensively studied by Nilsson’s group at Lund University (Jakobsson et al.,
2005, 2007; Degerman et al., 2008, 2009; Westerberg et al., 2012, 2013; Borg
et al., 2013) and Gétaz et al. (2013). On the other hand, very few studies have
addressed the problems of handling parameter uncertainty and robustness of
operation of SMB processes (Mun et al., 2003; Mota et al., 2007) and none has
studied configurations with few columns.
Robust design of DSP chromatography increased of importance since the
US Food and Drug Administration’s PAT initiative (FDA, 2004), followed by
ICH guidelines (ICH, 2005, 2009, 2007), opened up the possibility for a risk-
based approach to pharmaceutical production. Provided that sufficient process
knowledge is available, the process can be run within a design space instead
of at one fixed operating point. The design space is the space in which all
possible process parameter values are represented, every degree parameter of
the process being represented as an axis of a multidimensional space; the design
space boundaries are selected so that the process, when operated under conditions
within the design space, fulfills the quality specifications, i.e., the design space in
the parameter space has a projection in the quality attribute space that is inside
the specification ranges (Westerberg et al., 2012)
In the present work, a simple, yet efficient, two-column simulated moving-bed
(2CSMB) process for purifying adenovirus serotype 5 (Ad5) by size-exclusion
chromatography (SEC) is presented and validated experimentally. It is shown
that the main drawbacks of SEC, namely low productivity and high product
dilution, can be eliminated to a large extent by switching from single-column
batch operation to two-column SMB-type operation.
In line with the framework proposed by FDA and ICH, a general procedure
for robust design of the 2CSMB-SEC process under parameter uncertainty is
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proposed wherein the best set of operating parameters is selected only among
candidates that are robust feasible, that is, remain feasible for all parameter
perturbations within their uncertainty intervals. This robust approach to optimal
design replaces the nominal problem by a worst case problem (Grossmann and
Sargent, 1978; Halemane and Grossmann, 1983; L.T. Biegler, 1997; Ben-Tal and
Nemirovski, 2002). The proposed procedure was successfully employed to find the
optimal robust values of the step durations when both the interparticle porosity
and column volume are subject to two types of uncertainties.
The paper is organized as follows. After describing the 2CSMB-SEC process,
the methodology and numerical tools for model-based optimal design of the
operating conditions in the absence of parameter uncertainty are discussed. This
discussion is followed by the experimental validation of the 2CSMB-SEC process,
where the stability of its cyclic steady behavior and its good performance are
demonstrated. Finally, the model-based nominal design procedure is generalized
to the case of optimal design under parameter uncertainty. The proposed method
is further enhanced to cope with the more general problem of robust design under
probabilistic uncertainty.
5.2 Two-column, open-loop, simulated moving-
bed, size-exclusion chromatography
In a two-column (2C) SMB process the cycle is divided in half into two intervals,
or half cycles, which hereafter are referred to as switching intervals. To design
the cycle it suffices to define the sequence of flow-line configurations for one of
the switching intervals; the sequence for the other interval is similar, but the
positions of the two columns are exchanged. In practice, it is easier to keep the
columns fixed in space and to move the positions of the inlet and outlet lines by
means of an automated arrangement of two- or three-way valves. Over a full cycle
each column undergoes the same sequence of steps but phased out in time by one
switching interval.
The 2CSMB-SEC scheme developed for Ad5 purification is shown in Fig. 5.1b
(Nestola et al., 2014). It is an open-loop process that is physically realizable with
simple two-way or three-way valves to control the flow paths in the system and
requires a minimum number of pumps—one for injecting feed and another for
injecting eluent. The half-cycle (or switching interval) is divided into the following
sequence of steps:
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Figure 5.1: (a) Schematic of the (b) Schematic of the 2CSMB-SEC operating cycle for
Ad5 purification; E denotes the eluent inlet; F , the feed inlet; and P and W , the product
and waste outlets, respectively
Step 1. The upstream column is eluted while the effluent of the downstream
column is diverted to the waste line.
Step 2. The upstream column is eluted but its effluent is diverted to the waste
line instead of being directed to the downstream column. The downstream
column is fed with the clarified bioreaction bulk while its effluent is collected
as purified product.
Step 3. The system is operated as in step 1 but the effluent of the downstream
column is collected as product.
Step 4. The upstream column is eluted but its effluent is again diverted to
the waste line instead of being directed to the downstream column. The
downstream column is kept frozen, that is, the flow through that column is
temporarily halted.
This process is based on our group’s previous work on the development
of efficient multicolumn chromatographic processes for binary and center-cut
separations (Silva et al., 2012; Rodrigues et al., 2008; Araújo et al., 2010; Rodrigues
et al., 2010; R.J.S., 2013). The feed mixture is suppled into the middle of the
system where the composition of the circulating fluid is closest to that of the
feedstock fluid, and recovers the purified product and waste fraction alternately
155
CHAPTER 5. ROBUST DESIGN OF ADENOVIRUS PURIFICATION BY
TWO-COLUMN, SIMULATED COUNTERCURRENT CHROMATOGRAPHY
at the downstream end of the unit, while desorbent is continuously supplied into
the upstream end of the system. We have also shown that the feed step, in which
the feed is usually admixed with the effluent from the upstream column, can be
replaced by step 2 of Fig. 5.1 without loss of performance and in some instances
increased productivity (Silva et al., 2012; R.J.S., 2013). Actually, it is advisable
to use steps 2 and 3 of Fig. 5.1 when the duration of the product collection is
larger than the time taken to inject the feed, which is the case when there is large
band broadening in the system as is the case in SEC.
The 2CSMB-SEC process is quasi-continuous because the clarified bioreaction
bulk is not continuously fed into the system but periodically injected as a series of
rectangular pulses. The two HPLC pumps are operated under steady conditions
at their prescribed flow rates to minimize disturbances in their operation. To
interrupt the feed flow, the control software redirects it back to the feed tank by
switching the three-way valve placed in front of the feed pump to the position
shown in the left schematic of Fig. 5.1a. Since for all purposes the valve switching
is instantaneous, the net effect is a very good approximation of the sharp edge of
the step change in the flow rate. To redirect the feed flow to one of the column
inlets, the three-way valve is switched to the position shown in the right schematic
of Fig. 5.1a; the sharp edge of the step change in the flow rate is well reproduced
again.
The selected size-exclusion medium employed in our process was Sepharose 4
Fast Flow (S4FF, GE Healthcare) supplied by the manufacturer with an average
particle size of 90 µm. S4FF is suitable for Ad5 purification because it completely
excludes the Ad5 particles from its porous matrix and, hence, they elute in the
interparticle volume, whereas the impurities present in the clarified bioreaction
bulk elute through the porous matrix at different rates. The S4FF medium and
slurry packed into two XK 26/20 chromatographic columns (2.6 cm i.d., maximum
bed height of 20 cm); the final, stabilized column lengths were 10.4 cm and
10.8 cm. No measures were taken to improve the balancing of the bed heights.
Before each experiment the columns were sanitized with 1 M NaOH, washed with
Milli Q water, and equilibrated with 5 bed volumes of running buffer (20 mM
Tris, 150 mM NaCl, pH 8).
5.3 SEC column breakthrough model
A simple equilibrium, dispersed plug flow model is adopted for computer-aided
design of the SEC step. In this model the column efficiency is measured by the
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dimensionless plate height, hi = L/Ni, where L is the column length and Ni is














= 0, 0 < x < 1, t > 0, (5.1)
where i is the solute index, t is the time coordinate, x = z/L is the dimensionless
axial coordinate along the packed bed, L and Vc are the length and volume of the
column, c is the solute concentration in the mobile phase, and Q is the volumetric
flow rate of mobile phase.
The symbol εi denotes the volumetric fraction of the SEC column that is
accessible to component i (i.e., the overall porosity of the packed bed that is
probed by component i); εi is given by




where ψ(·) is the pore size distribution of the size exclusion medium, i.e., ψ(σ) dσ
is the fraction of the S4FF’s porous volume with pore diameters between σ and
σ + dσ, and dm,i is the size of the biomolecule.






= cini for x = 0, t > 0, (5.3)
∂ci
∂x
= 0 for x = 1, t > 0, (5.4)
where cini (t) is the inlet concentration of component i. Hereafter, c
out
i (t) ≡ ci(t)|x=1
denotes the temporal concentration profile of component i in the outlet effluent
of the column.
5.4 Model-based optimal process design
Unlike IEX or affinity chromatography, the components of the bioreaction bulk do
not bind to the SEC medium, because of lack of reactivity and strong adsorptive
interactions, so they elute through the SEC medium at a rate that depends
on their molecular size and shape but not on the presence of the other solutes.
Therefore, for the purposes of process design the complex multicomponent mixture
in the clarified bioreaction bulk can be modeled as a simpler mixture of three key
components: (1) the virus, which is the largest species and, hence, the fastest
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Table 5.1: Model parameters derived from the analysis of pulse experiments performed
with the two XK 26/20 columns placed in series, L = L1 + L2 = 21.2 cm. i is the
component index, cF is the feed concentration, which is assumed to be proportional to the




i = 1), ε is the accessible
porosity, and N is the number of theoretical plates per column.
i 1 2 3 4
cFi 0.140 0.165 0.541 0.154
εi 0.306 0.564 0.945 0.750
Ni 61 18 69 51
eluting component; (2) the group of impurities that elute nearest to the virus;
and (3) the group of small impurities that elute at the slowest rate. All the
other components in the bioreaction bulk necessarily elute at intermediate rates
between those of the second and third key components; if the SEC process is
properly designed, these components will be withdrawn from the system in one of
the waste fractions.
To design the SEC process it is necessary to measure the retention volume
of each key component, from which the value of εi can be determined, and the
extent of band broadening at the working flow rate to determine the value of hi.
These parameters were determined from the position, area, and broadening of the
key chromatographic peaks of the samples of clarified bioreaction bulk injected
into the two columns arranged in series.
Table 5.1 lists the model parameters derived from the analysis of the pulse
experiments performed with the two columns arranged in series. The feed concen-




i = 1, and were determined
assuming that the concentration is proportional to the area under the correspond-
ing UV absorbance peak. Table 5.1 includes a fourth component (component 4)
corresponding to the group of intermediate impurities that elute between the
two groups of key impurities. This fourth component was not considered in the
design of the SEC process, but only to obtain a better description of the simulated
elution profiles for comparison with the experiments.
The optimal durations of the cycle steps, τk (k = 1, . . . , 4), were determined
using a rigorous model-based design procedure. The feed and eluent flow rates,
QF and QE, were both fixed at 3 mL/min because of the constraint imposed by
the pressure drop through the SEC medium in steps 1 and 3 of the cycle, but they
could have easily been included in the set of decision variables. The purpose of
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Table 5.2: Flow rates and boundary conditions for the first half (0 < t ≤ τ) of the
2CSMB-SEC cycle (cf. Fig. 5.1). The boundary condition cini,2 = ci,2|x=0 for column 2
during step 4 is equivalent to (∂ci,2/∂x)x=0 = 0.
Step Column 1 Column 2
Q cini Q c
in
i
1 QE 0 QE c
out
i,1
2 QE 0 QF c
F
i
3 QE 0 QE c
out
i,1
4 QE 0 0 ci|x=0
the optimization procedure is to guarantee the fulfillment of product and process
specifications, namely minimal product purity and recovery, while maximizing
the productivity of the 2CSMB-SEC process.
Let
ci,j(x, t) = g(ci,j(x, 0); τ1, . . . , τ4), 0 < t ≤ τ, (5.5)
represent the desired solution for the set of decision variables parameters {τ1, . . . , τ4}
and initial conditions ci,j(x, 0); here, i is the index that runs over the set of solutes
and j the index that runs over the set of columns. For example, to simulate
the startup of the process when the two columns are initially clean, the initial
conditions would be
ci,j(x, 0) = 0. (5.6)
The dynamic response of the 2CSMB-SEC process for the first-half of the cycle
(0 < t ≤ τ) is given by the solution of 6 instances (2 columns × 3 key components)
of the equilibrium, dispersed plug flow model (eq. 5.1), subject to the boundary
conditions given by eqs. 5.3 and 5.4, together with the coupling conditions listed in
Table 5.2 For process design, however, only the fully established steady, periodic
state, also known as cyclic steady state (CSS), is of interest. The CSS for a
two-column SMB process is the solution ci,j(x, t) that satisfies
For process design, however, only the fully established steady, periodic state,
also known as cyclic steady state (CSS), is of interest. The CSS for a two-column
SMB process is the solution ci,j(x, t) that satisfies
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This constraint imposes the conditions of simulated counter-current operation
(the two columns exchange roles at the end of every switching interval) and time
periodic behavior. Let ci,j(x, t) = g
css(τ1, . . . , τ4) represent the CSS solution for
the first half of the cycle; the solution for the second half of the cycle is simply
ci,1(x, t) = ci,2(x, t− τ), ci,2(x, t) = ci,1(x, t− τ), τ < t ≤ 2τ. (5.8)
For the 2CSMB-SEC cycle shown in Fig. 5.1 the amount of feed injected per
switching interval, which is a direct measure of productivity, is given by
QF = (τ2/τ)QF, (5.9)






















































i,j is the total concentration in the outlet effluent of column j;
the flow rates drop out of the expressions because they happened to be equal in
the experimental run.
If PAd5 is high, say above 90%, the impurities in the collected product fraction
are necessarily the key component 2, because of its proximity to the Ad5 product,
and/or key component 3 from the previous switching interval because of its
circulation around the system. Given that the components elute through the
SEC medium at rates that depend on their molecular sizes and shapes but not
on the presence of other solutes, in the design procedure it is unnecessary to





s.t. ci,j(x, t) = g
css(τ1, . . . , τ4), (5.12)
PAd5 ≥ PAd5,min, RAd5 ≥ RAd5,min.
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This problem was formulated numerically in AMPL (R. Fourer, 2003) (http://
ampl.com) using a full discretization approach (Mota and Araújo, 2005; Araújo
et al., 2006). The column length was discretized using third-order orthogonal
collocation on 50 finite elements and the time domain (half cycle) was discretized
using third-order Radau collocation on 15 finite elements per sub-step of the
switching interval. The resulting nonlinear programming problem was solved using
Ipopt (Wächter and Biegler, 2006), version 3.11.2 (https://projects.coin-or.org/
Ipopt), coupled to the Watson Sparse Matrix Package (WSMP) (Gupta, 2000),
version 13.6.10 (http://www.research.ibm.com/projects/wsmp). Ipopt implements
a primal-dual interior-point method and uses line searches based on filter methods;
it directly exploits first and second derivative (Hessians) information provided by
AMPL via automatic differentiation.
5.5 Experimental validation
The optimal step durations for the set of parameters listed in Table 5.1, column
lengths L1 = L2 = (10.8 + 10.4)/2 = 10.6 cm, PAd5,min = 0.95, RAd5,min = 0.95,
and QE = QF = 3 mL/min are given in Table 5.3 in the column labeled ‘Nominal’.
Figure 5.2 shows a surface plot of the simulated concentrations of the four
key components in the fluid phase as a function of time (vertical axis) and
axial distance in each column (horizontal axis) for a full cycle of the optimized
2CSMB-SEC process under CSS conditions.
At the start of the cycle the concentration bands are nearly all confined to
column 1, whereas column 2 is practically clean. Fresh feed is injected while the
Ad5 product from the previous switching interval is displaced from column 1 to
column 2. A purified band will then slowly detach from the group of nearest
eluting impurities. As soon as the product is confined into column 2, the impurities
trapped in column 1 can be directed to the waste line and then the steps are
repeated but with the two column positions exchanged. Notice that the trailing
edge of the slowest impurity (key component 3) is displaced from the upstream
end to the downstream end of a column over the duration of a switching interval
(half-cycle). As expected, the intermediate group of impurities is always confined
between the key components (impurities) 2 and 3.
The surface plot embeds all the information about the movement of the
concentration fronts inside the two columns: slicing the surface plot horizontally
generates a snapshot of the axial concentration profiles at a given instant of
the cycle; slicing the plot vertically gives the time history over the cycle of the
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Figure 5.2: Surface plot of the simulated concentrations of the four key components in
the fluid phase as a function of time (vertical axis) and axial position in each column




Table 5.3: Optimal step durations, τk (k = 1, . . . , 4), of the 2CSMB-SEC cycle for the
chromatographic parameters given in Table. 5.1; the τk are reported in minutes. The
elution (QE) and feed (QF) flow rates are both fixed at 3 mL/min; PAd5,min = 0.95,
RAd5,min = 0.95. QF is the average feed flow rate (mL/min), which is a direct measure
of productivity; QE/QF is a measure of solvent consumption. Robust 1: robust solution
for the case in which ε′o and V
′
c are uncorrelated, uniformly distributed, random variables
in the interval [−2.5%,+2.5%]. Robust 2: robust solution with 95% success rate for the
case in which ε′o and V
′
c are uncorrelated, normally distributed, random variables with
zero mean and standard deviations σε/δεo = σV /δVc = 1.96.
Nominal Robust 1 Robust 2
Step index, k τk τk/τ τk τk/τ τk τk/τ
1 4.868 0.273 4.965 0.291 4.938 0.289
2 3.958 0.222 3.161 0.185 3.371 0.197
3 1.275 0.072 1.629 0.095 1.522 0.089
4 7.704 0.433 7.305 0.428 7.273 0.425
τ =
∑
k τk 17.81 1 17.06 1 17.10 1
QF 0.667 0.556 0.591
QE/QF 4.50 5.40 5.07
concentration profiles at a fixed position in the column. For example, to get the
temporal concentration profiles in the outlet effluent of, say, column 1, it suffices
to march in time over the surface plot along the right edge of column 1 (x = 1);
the obtained profiles are plotted in Fig. 5.3a.
The optimized 2CSMB-SEC process was implemented experimentally in a
preparative prototype unit (Nestola et al., 2014). The unit was operated for five
full cycles, which were more than enough to attain cyclic steady state conditions.
Figure 5.3b shows the temporal profile of the UV signal measured at the outlet of
column 1 over the duration of the experiment, which shows a fast attainment of
the steady, periodic behavior, and also an excellent cycle-to-cycle reproducibility
of the profile exhibited by the process. There is also fairly good agreement
between the periodic shape of the UV profile and the predicted total concentration
profile (
∑
i ci) plotted in Fig 5.3a as a solid brown line, which is the information
extracted from the simulation that is closest to being proportional to the UV
signal. The similarity between these two profiles is a strong indication that the
process behaved as expected.
The product fraction collected at each switching interval was analyzed sepa-
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Figure 5.3: Temporal concentration profiles in the outlet effluent of column 1. (a)
Simulated profiles for a full cycle under cyclic steady state conditions; color coding:
blue solid line, Ad5 product; green dashed line, group of fastest eluting impurities; dark
yellow dash-dotted line, group of intermediate eluting impurities; red dotted line, group
of slowest eluting impurities; brown solid line, total concentration. (b) Experimental UV
signal (239 nm) measured over the first five cycles of operation; the gray strips show
the time intervals for product collection from column 1; the time scale for t/τ < 7 is
compressed to improve the visualization of the UV signal for t/τ > 7.
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rately to determine the Ad5, HCP, and DNA contents. The virus recovery yield
was determined by both RT-PCR and Nanosight quantification. The following
data summarize the evaluated performance of the 2CSMB-SEC process: produc-
tivity, 0.67 L/min; virus yield, 86.3%; DNA clearance, 90%; HCP clearance, 89%.
It worth pointing out that the purity level required by the authorities is usually ex-
pressed as amounts of DNA and HCP per dose, which implies that an application
where the therapeutic dose is very high (e.g., gene therapy) can require several
purification steps, whereas for VLP or mucose vaccine fewer purification steps
can be sufficient to reach the desired purity level. For this reason, in the present
work the process performance is quantified in terms of clearance percentage. The
performance of the 2CSMB-SEC process compares very favorably against that of
the standard single-column batch SEC process with the same amount of stationary
phase (Nestola et al., 2014) (productivity, 0.11 L/min, 6 times lower; virus yield,
57.4%, 34% lower; DNA clearance, 94%; HCP clearance, 94%).
5.6 Optimal robust design under parameter un-
certainty
The ability of a process to handle normal process variations and parameter
uncertainty is known as process robustness and it can be achieved by making
the allowed range of variations in process parameters small and/or the process
operating point insensitive to variations or uncertainties (Degerman et al., 2008).
The procedure described below is a method to enlarge the design space in an
optimal way, so that the process, when operated under conditions within the
design space, fulfills the quality specifications with the least impact on productivity
and solvent consumption.
It is assumed that the major process uncertainty is due to variability of the
packing procedure, which influences the interparticle porosity, εo, and column
volume, Vc. It is further assumed in a first instance that although these two
parameters are unknown, their uncertainties are bounded by known maximum
deviations, δεo and δVc, from their nominal (or average) values, ε̄o and V̄c. Thus,
εo and Vc can be split as follows:




o ∈ [−δεo,+δεo], (5.13)




c ∈ [−δVc,+δVc]. (5.14)
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Figure 5.4: Product purity (top) and recovery (center) for 1000 random values of ε′o
and V ′c (bottom) uniformly distributed in the [−2.5%,+2.5%] interval for the optimal
nominal values of the step durations. The blue symbols below the horizontal dashed
line in each of the two top graphs represent the perturbations that do not satisfy the
corresponding product quality constraint, whereas those above it meet the target. The
arrows identify the points on the (ε′o, V
′
c ) plane where the purity and recovery attain their
lowest values
where ε′o and V
′
c are the deviations from the nominal values, which as a first
approximation are assumed to be uncorrelated, uniformly distributed random
variables in the intervals given above.
The parameters εo and Vc influence the process dynamics through the products
Vi ≡ εiVc in eq. 5.1, which take a different value for each key component in the
system; using eqs. 5.13 and 5.14, the Vi’s can be rewritten as
Vi = [ε̄o + ε
′
o + (1− ε̄o − ε′o)Hi](V̄c + V ′c ). (5.15)
Figure 5.4 shows the result of randomly perturbing the values of εo and Vc
over a ±2.5%-uncertainty interval around ε̄o and V̄c for the design values of the
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step durations given in Table 5.3. As expected, when the 2CSMB-SEC process is
operated with the nominal design values of the step durations, many perturbations
fail to satisfy the purity or recovery constraints, or both. Figure 5.4 also shows
that the lowest purity is obtained for (ε′o, V
′
c ) = (−δεo,−δVc) whereas the lowest
recovery is obtained for (ε′o, V
′
c ) = (+δεo,+δVc). Moreover, it is clear that if a set
of τk’s satisfies the purity and recovery constraints for the two worst cases, it will
































Ad5 are shorthand notations for PAd5(−δεo,−δVc) andRAd5(+δεo,+δVc),
respectively, and it is assumed that ε′o and V
′
c are indeed perturbations, |ε′o|  εo
and |V ′c |  Vc, and not significant changes of the nominal values. The reason why
the worst cases occur at vertexes of the boundary of the uncertainty region is the
monotonic dependence of the Vi’s on εo and Vc:
∂Vi
∂εo
= (1−Hi)Vc > 0 and
∂Vi
∂Vc
= [εo + (1− εo)Hi]Vc > 0 ∀i. (5.17)
Equation 5.16 is the basis for the robust design procedure, which can be formulated




s.t. c−i,j(x, t) = g
css(ε̄o − δεo, V̄c − δVc; τ1, . . . , τ4),
P−Ad5 ≥ PAd5,min, R
−
Ad5 ≥ RAd5,min.
c+i,j(x, t) = g
css(ε̄o + δεo, V̄c + δVc; τ1, . . . , τ4),
P+Ad5 ≥ PAd5,min, R
+
Ad5 ≥ RAd5,min.
Note that whereas the nominal design procedure requires the optimization of
a single instance of the CSS model of the 2CSMB-SEC unit, the robust design
procedure requires the simultaneous optimization of two instances of the CSS
model of the 2CSMB-SEC unit with the same step durations but different values of
εo and Vc. There is thus an increase in complexity while moving from the nominal
problem to its robust counterpart, because the latter works simultaneously with
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Figure 5.5: Product purity (top) and recovery (center) for 1000 random values of ε′o
and V ′c (bottom) uniformly distributed in the [−2.5%,+2.5%] interval for the optimal
robust values of the step durations. In the two top graphs all symbols are above the
horizontal dashed lines and thus satisfy both product quality constraints.
more than one instance of the chromatographic model. However, the robust
problem remains computationally tractable if the right solution approach and
optimization solver are employed. It is also worth noting that in the above
equation the two worst cases are forced to satisfy both quality constraints and
not just the critical one as implied by eq. 5.16; this increases the robustness of
the numerical procedure without introducing any computational overhead.
The solution of the robust design problem for δεo = δVc = 2.5% are the optimal
step durations given in Table 5.3 in the column labeled ‘Robust 1’. Figure 5.5
shows the result of randomly perturbing the values of εo and Vc over a ±2.5%-
uncertainty interval around ε̄o and V̄c for the robust values of the step durations.
It is seen that when the 2CSMB-SEC process is operated with the robust values of
the step durations, all perturbations of εo and Vc satisfy the purity and recovery
constraints. The robust solution is thus fully immunized against variability in
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the values of εo and Vc, as long as they stay confined to the specified confidence
intervals.
The bottom rows of Table 5.3 show that, as expected, robust operation is
achieved at the expense of reducing the feed throughput and increasing the solvent
consumption. This is further detailed in Fig. 5.6, which shows the influence of
the size of the εo and Vc uncertainty intervals on the productivity and solvent
consumption of the 2CSMB-SEC process. It is seen that the isolines of constant
productivity and those of constant solvent consumtion are straight lines on the
δεo × δVc plane. Moreover, the ratio of QF to its nominal value drops to 0.83, a
16.6% reduction, when the uncertainty intervals of εo and Vc increase to ±2.5%,
and that of QE/QF goes up to 1.2, a 20% increase.
This loss in separation performance, 16.6% reduction in QF and 20.0% increase
in QE/QF, is larger than what might be anticipated for an uncertainty interval of
only ±2.5%. This shows that the optimal step durations for nominal operation
are not robust at all, and that the process must be operated rather conservatively
to withstand even slight uncertainties in the packing quality of the columns.
Nevertheless, it is worth pointing out that the robust set of step durations
provided by our approach is optimal, since it is the one that yields the best
performance for the specified uncertainties.
Figure 5.7 shows how the sizes of the εo and Vc uncertainty intervals influence
the durations of the cycle steps. Changes in δεo have only a slightly impact on
the step durations and nearly none on those of steps 1 and 4: for δεo = ±2.5%,
the size of step 2 is reduced by 7.2%, i.e., less feed is injected into the system per
cycle, and the size of step 3 is increased by 11.1% to compensate for the reduction
of step 2 and thus maintain the same amount of collected product. Changes in
δVc have a larger effect on the step durations but still nearly none on step 1; for
δVc = ±2.5%, the size of step 2 is reduced by 12.2% and that of step 3 is increased
by 14.8%; moreover, the size of step 4 is slightly decreased (−5.2%). Overall, δVc
has a larger effect on the cycle time than δεo.
5.6.1 Optimal process design under probabilistic uncertainty
A more realistic and less stringent way of tackling the problem of parameter
uncertainty is to work with probability distributions instead of well defined
uncertainty intervals. We thus assume that εo and Vc are uncorrelated, normally
distributed, random variables with means ε̄o and V̄c and standard deviations σε




c have zero means and standard
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Figure 5.6: Surface plots of relative productivity, QF/(QF)δ=0%, and relative solvent
consumption, (QE/QF)/(QE/QF)δ=0%, as a function of the size of the εo and Vc uncer-
tainty intervals; both plotted variables are scaled by the their values for δ = 0%. The
lines represent paths of constant productivity or solvent consumption on the δεo × δVc
plane.
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Figure 5.7: Step durations of the 2CSMB-SEC cycle as a function of the sizes of the
(a) εo and (b) Vc uncertainty intervals. The that is not varied along the horizontal axis
of each plot is kept fixed at 0%.
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deviations σε and σV .
To generate results that can be more or less compared to those obtained by the
previous approach, we first determine the values of σε and σV for which the 95%
confidence intervals of ε′o and V
′
c are [−δεo,+δεo] and [−δVc,+δVc], respectively.
The values sought are
σε/δεo = σV /δVc = Φ(1− 0.95/2) = 1.9600, (5.19)
where Φ(x) is the cumulative distribution function (CDF) of the standard normal
distribution.
The problem now is to determine the optimal values of the step durations that
maximize the productivity of the 2CSMB-SEC process while satisfying both the
purity and recovery specifications with a given probability of success, say 95%,
i.e., such that on average at most only 5 out of 100 attempts to pack the two
columns at the nominal values of εo and Vc make the 2CSMB-SEC process violate
one or both product specifications.
At first glance this robust design problem appears to be much more difficult
to solve than the previous approach, but in fact it is not. It suffices to find the
two worst cases of process performance that lie on the boundary that delimits
the set of all (εo, Vc) pairs that have a probability of occurring of at least 95%.
One of the cases is the one that yields the worst product purity whereas the other
case is the one that yields the worst product recovery. These two cases are then
plugged into eq. 5.16 to solve an optimization problem similar to that employed
in the previous robust design procedure.
A way to determine the two worst conditions that lie on the 95%-probability
boundary is described next. Suppose that many normally distributed, random
values of ε′o and V
′
c with zero mean and standard deviations σε and σV are
generated. Let N be the number of randomly generated (ε′o, V
′
c ) pairs. Now, 5%
of those pairs are randomly discarded to generate a 95%-confidence set. For each
of the remaining pairs, say the nth one, the value of parameter Vi for each key
component, say V
(n)
i , is calculated. Then, the two worst cases are given by the
smallest and largest values of the V
(n)
i : the former, Vi,min, is an estimate of Vi for
the conditions that yield the worst product purity, whereas the latter, Vi,max, is
an estimate of Vi for the conditions that yield the worst product purity.
An alternative and more efficient procedure is to sort the array of V
(n)
i values
in ascending order without discarding any (ε′o, V
′
c ) pairs. Then, V
(0.025N)
i is an
estimate of Vi,min because it is the largest value of the 2.5% smallest Vi’s and
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Table 5.4: Minimal and maximal values of the parameters Vi for δεo = δVc = 2.5%
(worst case interval) and those for which the 95%-confidence intervals of ε′o and V
′
c are
[−2.5%,+2.5%]; V i denotes the nominal value.
1 2 3
V i 17.55 32.36 55.31
Worst case interval
Vi,min 16.68 31.28 53.91
Vi,max 18.43 33.45 56.72
95%-confidence interval
Vi,min 16.93 31.50 53.93
Vi,max 18.17 33.21 56.69
V
(0.975N)
i is an estimate of Vi,max because it is the smallest value of the 2.5%
largest Vi’s. Both procedures yield improved estimates of Vi,min and Vi,max by
increasing the number of points, N .
The second procedure was coded in a small python script, which took less than
a second to run for N = 104. The obtained values of Vi,min and Vi,max are listed
and compared in Table 5.4 to the nominal values, V i, and to the values for the two
worst cases of the previous robust design procedure, (ε′o, V
′
c ) = (−2.5%,−2.5%)
and (ε′o, V
′
c ) = (+2.5%,+2.5%).
From the array of V
(n)
i values it is also straightforward to derive the corre-
sponding probability density functions. They are plotted in Fig. 5.8 for the three
key components; the shaded areas bounded by Vi,min and Vi,max represent the
95%-confidence intervals.
It is clear that if a set of τk’s satisfies the purity and recovery constraints
for the case in which Vi = Vi,min and for the case in which Vi = Vi,max, it
will satisfy the two constraints for any normally distributed values of εo and
Vc with a probability of success of at least 95%. If the nonlinear programming
problem defined by eq. 5.18 is solved with c−i,j(x, t) = g
css(Vi,min; τ1, . . . , τ4) and
c+i,j(x, t) = g
css(Vi,max; τ1, . . . , τ4), the optimal set of τk’s will satisfy the two
constraints for any normally distributed values of εo and Vc with a probability of
success of exactly 95% while maximizing the feed throughput.
Figure 5.9 shows the result of randomly perturbing 1000 times the values of εo
and Vc according to the normal distributions (bottom graph); the top two graphs
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Figure 5.8: Probability distribution function of Vi = [εo + (1− εo)Hi]Vc for each of the
three key components when εo and Vc are uncorrelated, normally distributed, random
variables with means ε̄o and V̄c and standard variations σε = 1.96δεo and σV = 1.96δVc,
where δεo is 2.5% of ε̄o and δVc is 2.5% of V̄c. The shaded areas represent the 95%-
confidence intervals.
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Figure 5.9: Product purity and recovery for 1000 normally distributed random values of
εo and Vc with means ε̄o and V̄c and standard variations σε = 1.96δεo and σV = 1.96δVc,
where δεo is 2.5% of ε̄o and δVc is 2.5% of V̄c. Results obtained for the (a) nominal and
(b) robust design values of the step durations.
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show the purity and recovery values obtained for the nominal design values of
the step durations, whereas the other two graphs were obtained for the robust
design values of the step durations. As expected, when the 2CSMB-SEC process is
operated with the nominal design values of the step durations, many perturbations
fail to satisfy the purity or recovery constraints, or both. However, when the unit
is operated with the robust values of the step durations, most of the perturbations
of εo and Vc satisfy the purity and recovery constraints; in fact, only 5% of the
perturbations fail to satisfy both quality constraints, which is exactly what was
intended.
5.7 Conclusions
A general procedure for robust design of the 2CSMB-SEC process under parameter
uncertainty was proposed under the framework of rigorous optimization theory.
The optimal values of the operating variables are chosen only among candidates
that are robust feasible, that is, that remain feasible for all possible variations
of the uncertain parameters within their uncertainty intervals. Computational
tractability is ensured by formulating the robust optimization problem with only
the vertexes of the uncertainty domain that most adversely affect the product
purity and recovery. In practice the nominal design problem is replaced by a
worst-case design problem. The procedure was successfully employed to find the
optimal robust values of the step durations when both the interparticle porosity
and column volume are subject to two types of uncertainties. In one case εo
and Vc are uncorrelated, uniformly distributed random variables, whereas in the
other case εo and Vc are normally distributed random variables. Moreover, in
the second case the 2CSMB-SEC operating conditions were optimized to yield a
given probability of success of satisfying both product quality specifications, say
95%, so that on average at least 95 out of 100 attempts to pack the two columns
yield purified batches in which the product is within the specifications—this is
achieved while maximizing the feed throughput.
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Araújo, J. M., Rodrigues, R. C., and Mota, J. P. (2006). Use of single-column models
for efficient computation of the periodic state of a simulated moving-bed process. Ind
Eng Chem Res, 45 , 5314–5325.
Aumann, L., and Morbidelli, M. (2007). A continuous multicolumn countercurrent
solvent gradient purification (MCSGP) process. Biotechnol Bioeng , 98 , 1043–1055.
Ben-Tal, A., and Nemirovski, A. (2002). Robust optimization–methodology and applica-
tions. Math Program, 92 , 453–480.
Blanche, F., Cameron, B., Barbot, A., Ferrero, L., Guillemin, T., Guyot, S., Somarriba,
S., and Bisch, D. (2000). An improved anion-exchange HPLC method for the detection
and purification of adenoviral particles. Gene Ther , 7 , 1055–1062.
Borg, N., Westerberg, K., Andersson, N., von Lieres, E., and Nilsson, B. (2013). Effects
of uncertainties in experimental conditions on the estimation of adsorption model
parameters in preparative chromatography. Comput Chem Eng , 55 , 148–157.
Degerman, M., Jakobsson, N., and Nilsson, B. (2008). Designing robust preparative
purification processes with high performance. Chem Eng Technol , 31 , 875–882.
Degerman, M., Westerberg, K., and Nilsson, B. (2009). A model-based approach to
determine the design space of preparative chromatography. Chem Eng Sci , 32 ,
1195–1202.
Dormond, E., Chahal, P., Bernier, A., Tran, R., Perrier, M., and Kamen, A. (2010).
An efficient process for the purification of helper-dependent adenoviral vector and
removal of helper virus by iodixanol ultracentrifugation. J Virol Methods, 165 , 83–89.
Eglon, M. N., Duffy, A. M., O’Brien, T., and Strappe, P. M. (2009). Purification of
adenoviral vectors by combined anion exchange and gel filtration chromatography. J
Gene Med , 11 , 978–989.
177
REFERENCES
FDA (2004). Guidance for Industry PAT – A Framework for Innovative Pharmaceutical
Manufacturing and Quality Insurance,. Technical Report US Departmenet of Health
and Human Services, Rockville, MA,.
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Purification of complex biopharmaceuticals, such as recombinant proteins, antibod-
ies or vaccines, is gaining increasing importance in order to fulfill the requirements
for a reliable production process with high purity and yield, and, also importantly,
cost efficiency. The downstream train of biopharmaceuticals has been extensively
developed in the past years by combining different chromatography steps, namely
ion-exchange and size-exclusion chromatography (and less frequently affinity
chromatography), intermingled with concentration and ultra/diafiltration steps.
Currently,purification of viruses and VLP by using IEX is typically operated in
positive (bind-elute) mode: most of the impurities are collected in the flow-through
pool, while the virus particles and some of the impurities are retained in the
matrix. Nevertheless, recently new bead based resin has been developed by for
intermediate and polishing in flow-through mode. In the present work a rational
design of a flowthrough process was implemented by employing SPR as scale down
tool to evaluate the ligands of two recently launched chromatography matrices:
STIC membrane and Capto Core. The full process development showed that the
DNA clearance achieved is roughly 4 logs reduction. Also, adenovirus recovery is
boosted, especially in the first chromatographic unit operation (STIC membranes)
where summing up the virus in FT and the virus eluted the recovery is close to
100%. As for HCP reduction is 5 logs, however while most of the DNA clearance is
achieved in the STIC membrane, the HCP reduction is mainly achieved by using
the Capto Core 700. Overall the flowthrough process designed is suitable for a
platform concept and was implemented for adenovirus and retro-VLP purification
with minimal amount of optimization required.
Keywords:flow-through purification, Surface plasmon resonance, lig-
and screening, adenovirus, virus-like-particle.
CHAPTER 6. RATIONAL DEVELOPMENT OF FLOWTHROUGH
PURIFICATION STRATEGIES FOR VIRUSES AND VLP
6.1 Introduction
Viral vectors are playing an increasingly important role in the vaccine and gene
therapy fields. Adenoviruses (Ads), in particular, are considered one of the most
suitable platforms for production of viral vaccines and gene therapy vectors; they
are medium-sized (90–100 nm), nonenveloped, icosahedral viruses composed of a
nucleocapsid and linear, non-segmented double stranded (ds) DNA genome that is
about 36 kb long. Their broad tissue tropism and large transgene packing capacity
make them attractive candidates for innovative virotherapies (Eglon et al., 2009).
Adenoviruses can be produced in a complementary cell line in both adherent
and suspension culture systems, such as HEK-293 or PER-C6 cells, or A549
for oncolytic therapies (Segura et al., 2008; Kamen and Henry, 2004). Recently
the development of virus-like particle (VLP) for vaccine applications is gaining
attention (Kushnir et al., 2012; Roldão et al., 2010). VLPs are non-infective and
non-replicating, since they are essentially devoid of infectious genetic material.
VLPs display antigenic epitopes in the correct conformation and in a highly
repetitive manner, leading to cross-linking of B cell immunoglobulin receptors and
B cell activation. The lack of DNA makes this biopharmaceutical safer compared
to Adenovirus. Currently, both adenovirus and VLP are very important platforms
fo vaccine development in several applications (Lua et al., 2013; Tatsis and Ertl,
2004) .
Purification of complex biopharmaceuticals, such as recombinant proteins,
antibodies or vaccines, is gaining increasing importance in order to fulfill the
requirements for a reliable production process with high purity and yield, and,
also importantly, cost efficiency (Wang et al., 2009). The downstream train of
biopharmaceuticals has been extensively developed in the past years by com-
bining different chromatography steps, namely ion-exchange and size-exclusion
chromatography (and less frequently affinity chromatography), intermingled with
concentration and ultra/diafiltration steps (Eglon et al., 2009; Konz et al., 2005a,b;
Burova and Ioffe, 2005; Peixoto et al., 2006; Goerke et al., 2005). Chromatography
is a well-established purification tool of recombinant adenovirus used for vaccine
and gene therapy. Indeed, ion exchange (IEX) is the most used technique for
purication of complex biopharmaceuticals. However, packed-bed chromatography
suffers from a number of disadvantages: the pressure drop across the bed is usually
high and may increase during operation due to media deformation or blockage;
pore diffusion is slow and often leads to degradation of the protein product;
also, the scale up of packed beds is difficult. In addition, packed beds display a
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low dynamic binding capacity for virus particles at common process-scale linear
velocities of 150–450 cm/h, because binding is restricted to the surface of resin
particles.
Convective chromatography media, such as membranes and monoliths, offer
substantial improvements in capacity, recovery, and reduction of process time
(Hahn et al., 2007). To date, monoliths have generally offered higher capacity and
higher resolution (Gerster et al., 2013; Whitfield et al., 2009), but membranes have
proven less prone to clogging, and their relatively low cost has made it practical to
discard them after a single use rather than invest additional resources developing
and validating regeneration and sanitization procedures.
Currently,purification of viruses and VLP by using IEX is typically operated
in positive (bind-elute) mode: most of the impurities are collected in the flow-
through pool, while the virus particles and some of the impurities are retained
in the matrix. Due to the differences in charge of the different components, it is
possible to use this process with high resolution elution gradients, separating the
adsorbed materials into fractionated cuts, even though they are closely related.
Nevertheless, recently new bead based resin has been developed by for intermediate
and polishing in flow-through mode. Iyer et al. (2011) proposed the increased
of the beads mean diameter maximizing the binding capacity for the impurities
and reducing the surface available for virus binding. GE healthcare recently
launched Capto Core 700, a resin composed by an activated core functionalized
with octylamine ligand, and an inactivated ligand shell excluding larger molecules
entering the core thus collecting them in the flow-through. Each core of the beads
present a multimodal biding allowing to operate at various range of pH and NaCl
concentrations.
Negative mode purification, with membrane chromatography is used almost
exclusively in mAb industry (Zhou and Tressel, 2006; Knudsen et al., 2001; Boi,
2007). Anionic exchange membranes are utilized to bind impurities such as viruses,
host cell proteins, and DNA, while allowing the mAb to flow through. Usually the
feed pH is greater than 7.0 and the ionic strength is low, as high ionic strength
can disrupt the electrostatic interactions and reduce the removal of contaminants.
However, new chromatography membranes are being developed mainly to over-
come to drawabacks of the Q ligand where the binding is compromised to high
salt concentrations. Therefore new ligands based on primary amine have been
investigated. STICr chromatography membrane (Sartorius Stedim Biotech) and
CromaSorb ( Merck Millipore) are two examples commercially available products
based on primary amine ligands. Nevertheless a limited number of works are
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Figure 6.1: Design strategy employed in the optimization of a platform flowthrough
process. PAA and Octylamine were evaluated in respect their ability to bind DNA by
using SPR technique. The results were confirmed and the operation conditions were
evaluated by using STIC membrane and Capto Core 700 beads. With the constrains
indentified, the FT process was designed and experimental validated by using adenovirus
and retro VLP.
present in the literature investigating the performances of these novel chromato-
graphic membranes (Woo et al., 2011; Kang et al., 2012). Yet, no attempts are
reported using membrane chromatography in flow-through mode for virus purifi-
cation. Also it is known that multivalent ions (e.g phosphate, citrate) strongly
bind onto polyallylamin (HOLMES-FARLEY et al., 1999), therefore one goal of
this study is to evaluate how far such buffers can modulate the binding of both
contaminants and target virus on the membrane, thus achieving high selectivity
in FT mode.
In the present work a rational design of a flowthrough process was implemented
as shown in figure 6.1. SPR was employed to evaluated the ligands of the STIC
membrane and Capto Core.
Surface Plasmon Resonance (SPR) is a powerful technique to measure biomolec-
ular interactions in real-time in a label free environment(Majka and Speck, 2007;
Jason-Moller et al., 2006). While one of the interactants is immobilized to the
sensor surface, the other are free in solution and passed over the surface. Associ-
ation and dissociation is measured in arbitrary units and displayed in a graph
called the sensorgram. As described by Vicente et al (Vicente et al., 2010) SPR
techniques can be used for downstream bioprocess development as scale down
tool of chromatography column. Although some physical characteristics of the
purification bed cannot be mimic by SPR chip some early screening, for instance,
immobilization chemistries, buffer properties and washing procedure might be
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rapidly evaluated by using a small sample volumes (Thillaivinayagalingam et al.,
2010). The design space predicted by SPR experiments were then confirmed
by using a small scale device for the STIC membrane and packed column for
Captocore resin under various buffer type and concentration.Virus recovery yield,
DNA and Host cell protein clearance were assessed. Furthermore, dinamic binding
capacity for DNA under various NaCl concentrations were determined for both
system. Lastly, the data from the batch experiments were used in order to design
a platform flowthrough process for adenovirus and retro-VLP.
6.2 Material and Methods
6.2.1 Cell line and medium
For adenovirus production two hundred and ninety-three (293) cells purchased from
ATCC (ATCC-CRL-1573) were adapted to suspension and grown in a commercial
serum-free medium, Ex-Cell 293 (SAFC Biosciences, USA), supplemented with
4 mM of glutamine (Invitrogen, UK), in a humidified atmosphere of 8% CO2 in air
at 37◦C using shake flasks (Corning, USA). The cells were routinely propagated
twice a week using an inoculum of 0.5 × 106 cells/mL. Cell concentration and
viability were determined by counting cells on a Fuchs-Rosenthal haemocytometer
(Brand, Germany) using the trypan blue (Invitrogen, UK) dye exclusion method.
For retro-VLP production 293 Ceb25 cells were cultured in Dulbeccos modied
Eagle medium (Gibco, Life Technologies, Paisley, UK) supplemented with 10%
(v/v) fetal bovine serum (FBS) (Gibco), maintained at 37◦C in a humied atmo-
sphere containing 7% CO2. Cells were amplified to twenty 175 cm
2 flasks with a
split ratio dilution of 1:5.
6.2.2 Virus production
We used a replication-defective adenovirus derived from serotype 5 adenovirus
(Ad5) expressing GFP protein. The viruses were produced in a 2 L bioreactor with
1 L working volume (Sartorius-Stedim Biotech, Germany). The agitation rate
was set at 70 rpm and the dissolved oxygen was controlled at 50% air saturation
by gas mixing and stirred cascade control with an airflow of 0.01 L/min; the pH
was controlled at 7.2 by aeration with a gaseous CO2 mixture and 1 M NaHCO3;
all infections were done at a cell concentration (CCI) of 106 cells/mL using a
multiplicity of infection (MOI) of 5; the adenoviruses were harvested at 48 hpi
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(hours post-infection). The amount of infections particples (IP) in the bulk (before
clarification) was in the range 109–1010 IP/mL.
VLP are constitutively expressed and contrarily with the adenovirus no lytic
infection is required. After 3 days with cells 80% confluent, 10 hyperflasks
were inoculated with a dilution split ratio of 1:5 (2 T175 flasks, 20 mL of cell
suspension + 540 mL DMEM per Hyperflask). DMEM without phenol red (Gibco,
Life Technologies, Paisley, UK), supplemented with 10% (v/v) FBS and 4 mM
L-glutamine (Gibco) was used as culture media. When the cells reached 90%
confluence a media exchange was performed with DMEM without phenol red
(Gibco, Life Technologies, Paisley, UK) and FBS. The T-flasks were harvested 3
days later. Since the production of retro-VLP is not trivial at all, sucrose cushion
was performed and TEM analysis carried out to ensure the presence of VLP
(Figure 6.2). The production titer was 5x109 VLP particle/ml.
6.2.3 Transmission Electron microscopy (TEM)- Negative
staining
The sample suspensions have been shaken gently, approx. 10 µL drops retrieved
and placed on clean parafilm sheets. Formvar- and carbon-coated positively glow-
discharge treated grids were incubated on the top of the suspension droplets for 10
minutes and subsequently blotted dry with a filter paper. After this, each sample
was negative stained with 2% aqueous phosphotungstic acid (pH 7.2) for 1 minute
using the droplet technique and air-dried for at least 30 minutes. The samples
were examined in a LEO912AB electron microscope (Zeiss, Oberkochen/Germany)
operating at 100 kV, equipped with a side-mounted CCD-camera capable to record
images with 2kx2k pixels. The documentation and calibrated measurements of
the observed structures were done with the iTEM-software, Ver. 5.2 (Olympus
Soft Imaging Solutions GmbH, Muenster/Germany).
6.2.4 Clarification and concentration
Upon harvesting, the adenovirus bioreaction bulk was supplemented with 0.1% Tri-
ton X100 (Sigma Aldrich,USA) and incubated for 2 hours at 37◦C with 50 U/ml
of Benzonase (Merck Millipore, Germany) to digest the DNA and to release the
adenoviral vectors from the intracellular material by cell lysis.
Subsequently, the bulk was microfiltrated using a Sartopore 2 membrane
capsule (Sartorius Stedim Biotech, Germany) comprising a 0.8 µm prefilter and a
0.45 µm filter, and concentrated up to 10 times and diafiltered up to 5 times with
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(A)
(B)
Figure 6.2: TEM analysis of retro-VLPs at two different magnifications 5µm (Figure
A) and 500 nm (Figure B.) An omogeneuous population of VLP can be observed with
irregular shapes originated by the budding process.
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20 mM Tris saline buffer (Tris Buffered Saline, Sigma Aldrich, USA) at pH 8 on
a Sartorius Stedim Biotech cassette prototype with cut-off of 500 kDa selected
after an accurate evaluation and published by Nestola P (2014) Before use, the
capsules were thoroughly washed with one capsule volume of Milli Q water and
two capsule volumes of buffer.
VLP bulk contrarily of the adenovirus bulk was not treated with Triton X100 as
the release of VLP occurs by budding. The bulk was microfiltrated with a 0.45µm
Stericup filter (Merck Millipore, Germany). Ultrafiltration and diafiltration were
performed with Viva flow 100kDa (Sartorius Stedim Biotech). Both adenovirus
and VLP bulks, were stored in aliquots at −80◦C until further use.
6.2.5 Chromatography
One XK 16/20 chromatographic columns (i.d. of 1.6 cm, maximum bed height
of 20 cm) were slurry packed with Capto Core 700 (Ge) resin according to the
manufacturer’s specifications. The excess ethanol supplied with Capto Core 700
(CC700) was decanted and replaced with working buffer (20 mM Tris, 150 mM
NaCl, pH 8) before packing into the column. The column was initially filled
with 70% slurry of CC700 and allowed to settle by gravity overnight. Flow
rate was increased step wise up to packing velocity of 300 cm/h. The final bed
volume resulting of the packing was 7mL. After each experiments the column was
thoroughly regenerate with 1M NaOH.
Membrane volume for the STIC r device (VivaPure) was of 0.023 mL allowing
fast processing time, and cost efficiency screening at various conditions. The
device was connected to an Akta 10 system. Loading was performed at a constant
linear velocity of 212 cm/h. Linear gradient of 20 CV was applied for eluting
the product. Elution buffer was either Phosphate 1M or Citrate 1M. This high
concentration of elution buffers were chosen in order to completely strip the
membrane assessing the percentage of virus recovered. Membrane devices were
not regenerated at the end of chromatography run, therefore a new membrane
was used for each experiments. Fraction were collected every 0.5 mL and stored
at −80◦C until further analysis.
DNA dynamic binding capacity was evaluated by using DNA salmon sperm
(Invitrogen) at the concentration of 0.05 mg/mL. In order to be similar to the
process conditions, DNA was treated with 50 U/ml of Denerase (Sartorius Stedim
Biotech).
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6.2.6 Analytics
The protocol for the quantification of total viral particles was a two-step procedure:
DNA extraction according to the instructions on the “High Pure Viral Nucleic
Acid Kit” (Roche) manual and real-time PCR. The number of viral DNA copies
was determined by real-time PCR and LightCycler system (Roche Diagnostics)
using a Fast Start DNA master SYBR Green I kit to track a specific Ad5 sequence
(Roche Diagnostics). Internal plasmid of 4.15× 109/2µl was chosen as reference
standard. The total particle concentrations were confirmed using Nanosight NS500
(NanoSight Ltd, UK), and the size distribution was determined. The average of
the two measurements was the value chosen for assessing the virus recovery yield.
The amount of host cell proteins (HCP) was determined using a commercial
available ELISA kit for HEK293 cell line (Cygnus Technologies, Inc.). The sample
was diluted in PBS and the assay was performed according to the manufacture
protocol, the 96 well plate was read by an absorbance microplate reader at
450/650 nm (SpectraMax 340). DNA was quantified by QuanT-iT Picogreen kit
(Invitrogen). After 5 minutes of incubation, the fluorescence was measured by
Luminometery (Turner BioSystems). Purified DNA was used as standard.
6.2.7 Hg Instruction Porosimetry (MIP)
MIP experiments were performed on a Micromeritics AutoPore IV instruments
which operate in the range of 0.2 to 60000 psia, with incremental pressure increase
of 0.05 psia. The PSD was determined using a surface tension of 480 dynes/cm.
The contact angle was experimental determined to be 140 degrees.
6.2.8 Sensor Chip
Biacore gold sensor chips (CM5) was purchased from Biacore/GE Healthcare,Sweden.
Polyallyalime (PAA) with a size of 17kDa and Octylamine (99%) purity grade solu-
tion were purchased from SigmaAldrich, Germany. Both compounds were function-
alized on two different sensor chips acting respectively anionic exchanger and mul-
timodal ligands. Freshly prepared solutions of 0.4 M 1-ethyl-3-(3-dimethylamino-
propyl)carbodiimide hydrochloride (EDC) and 1.0 M N-hydroxysuccinimide (NHS)
(amine coupling kit from Biacore/GE Healthcare) in water were mixed 1:1 and
injected in a pulse of 200µL at 20 µL/min to activate the terminal carboxyl group
for amide bond formation. 1.0 M PAA or 0.05M octylamine in MES running buffer
was added in serial 100µL pulses at 20µ L/min until the SPR signal stabilized. It
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should be noted that the lower concentration of octylamine compared to the PAA
is merely due to its lower water solubility, this required higher number of pulses
for signal stabilization.
6.2.9 SPR protocol
The SPR experiments were performed on a Biacore 2000 system at 25◦C. UltraPure
Salmon Sperm DNA was purchased from Invitrogen. All buffers were prepared
sterile and degassed prior to use in the equipment.
The experiments were performed at constant flow rate of running buffer and
sample injection of 100µ L/min. Each run consisted of the following sequence
of steps repeated over three or four cycles: (i) equilibration of the flow cell with
running buffer at a prescribed NaCl concentration (c0); (ii) injection of 100 µL of
DNA solution at given concentration (c0,cB); (iii) desorption and equilibration
with running buffer (again, at c0). Before starting a new run, the flow cell was
subjected to an aggressive desorption step using 100 µL of 1M NaCl in 10 mM
Tris buffer at pH 8 (c0,ref), and then cleaned/sanitized with 100 µL of 0.1 M
NaOH for complete regeneration of the surface. The experiments were conduct of
each sensor chip, with the two respectively ligand.
Sensor chips have been shown to be fully resistant to pulses of NaOH (or
HCl) up to 1 M. The baseline stability was controlled throughout the course of
each experiment. All sensorgrams were duplicated by repeating each run once for
confirmation of their reproducibility and surface regeneration.
In order to quantitatively analize SPR data one must first understand the
underlying probing mechanism of the biacore machine—the refractive index of
the medium within the sensing evanescent field depth.
The refractive index, η0, of an aqueous salt solution (0) with concentration c0
is
η0 = η̃w + (η̃0 − η̃w)v0c0, (6.1)
where c0 (M) is the salt concentration, v0 is the molar volume of the salt ions
(M−1), η̃0 is their refractive index, and η̃w is the refractive index of water.
The above equation is strictly valid if the salt solution is made as follows:
(i) weight the required amount m0m of dry salt and then add it to the flask;
(ii) slowly fill the flask with water while stirring up to a volume V ; the mass
concentration of the salt solution is then ρ0 = m0/V and the concentration is
c0 = ρ0/M0, where M0 is the molecular weight of the salt.
But there’s another way a making the salt solution: (i) fill the flask with
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water up to a volume V ; then add the mass m of salt. In this case, the mass
concentration is ρ′0 = m0/(V + (m0/M0)v0), where v0 is the molar volume of the
salt; the corresponding molar concentration will be c′0 = rho
′
0/M0. But suppose
that we still measure the concentration as c0. In this case, the refractive index
will be
η′0 = η̃w + (η̃0 − η̃w)v0c0, (6.2)
Similarly, the refractive index, ηB, of the aqueous salt solution with a given
dissolved solute (B) (this can take the form of any analyte, e.g., a protein), can
be expressed as
ηB = η0 + (η̃B − η0)vBcB, (6.3)
where cB (M), vB (M
−1) and η̃B are the solute concentration, specific volume,
and refractive index, respectively.
The Biacore signal, R(η), expressed, e.g., in resonance units (RU), is a function
of the refractive index, η, in the flow cell; if η does not vary greatly (i.e., the shift
∆η is not very large), then the corresponding change in the Biacore signal, ∆R,
will be proportional to the change in η, that is, ∆R ≈ m∆η (Jung et al., 1998).
It is also known that η is not probed uniformly throughout the depth of the flow
cell height; it is probed proportionally to the intensity of light at each point.
Thus, the effective refractive index, ηeff , measured by the Biacore system is







η(z) e−z/dp dz, (6.4)
where dp is the effective penetration depth; for the Biacore 2000 machine, dp ≈
150 nm.
Let us first consider the case of an uniform adsorbent film, of thickness ds,
attached to the metal sensor surface, under conditions where there is no adsorption
from the fluid solution flowing over its surface (e.g., when the salt concentration
is large enough to prevent it).
The refractive index, ηs, of the adsorbent film is constant unless there are
external perturbations, such as temperature changes in the flow cell, which is
not the case in the present work. Assuming that ηs is constant, Eq. 6.4 can be
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= ηs(1− φs) + η′eff , (6.5)
where φs = exp(−ds/dp). In the absence of adsorption, η(z) = η for z > ds, where
η is the refractive index of the bulk solution, hence η′eff = ηφs. Therefore, under
nonadsorbing conditions, ηeff is given by
ηeff = ηs + φs(η − ηs). (6.6)
When the salt solution has no dissolved solute (c0 > 0, cB = 0), the effective
refractive index, ηeff0 , is given by Eq. (6.6) with η replaced by η0 defined in
Eq. (6.1), that is,
ηeff0 = ηs + φs[η̃w + (η̃0 − η̃w)v0c0 − ηs] (6.7)
If the baseline (or reference) signal is established for a salt solution with
concentration c0,ref , then the change in the effective refractive index when the
salt concentration is altered to c0 is
(η0 − η0,ref)eff = φs(η̃0 − η̃w)v0(c0 − c0,ref). (6.8)
The corresponding signal shift in the Biacore system is
∆R = m(η0 − η0,ref)eff = m0(c0 − c0,ref), (6.9)
where m0 = mφs(η̃0 − η̃w)v0 is the slope of the linear fitting (with intercept set
to zero) of ∆R vs (c0 − c0,ref).
When solute is added to the reference salt solution (c0 = c0,ref , cB > 0)
and flown over the sensing surface under nonadsorbing conditions, the effective
refractive index is given by
(ηB,ref)eff = ηs + φs(ηB,ref − ηs), (6.10)
where ηB,ref is defined by Eq. (6.3) with η0 = η0,ref . The corresponding change in
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the effective refractive index is
(ηB,ref − η0,ref)eff = φs(η̃B − η0,ref)vBcB = φs[(η̃B−η̃w)−(η̃0−η̃w)v0c0,ref ]vBcB,
and the corresponding shift of the Biacore signal given by
∆R = m(ηB,ref − η0,ref)eff = (mB −m0vBc0,ref)cB, (6.11)
where mB = mφs(η̃B − η̃w)vB; note that (mB −m0vBc0,ref) will be slope of the
linear fitting (with intercept set to zero) of ∆R vs cB.
Once m0 and mB are known, we can predict the shift in the Biacore signal
due to the change in the effective refractive index, (ηB − η0,ref)eff , for an aqueous
buffer with salt concentration c0 and solute concentration cB (assuming that the
baseline was defined for the buffer salt solution with concentration c0,ref); the
expression is
∆R = (mB −m0c0vB)cB +m0(c0 − c0,ref). (6.12)
Let us now consider the more complicated case where there is solute adsorption
onto the sensor surface film. The problem is illustrated in Fig. 4.4. The aqueous
buffer solution in the bulk has salt concentration c0 and solute concentration cB;
the thickness of the adsorbed layer is dm and its inter-solute volume is filled with
buffer solution assumed to contain the same salt concentration as that of the
bulk. In Fig. 6.3, dm is assumed to be equal to the diameter of the adsorbed
solute molecules, in accordance with the formation of a single adsorbed monolayer,
though this is not a restriction imposed in our formulation.


















ηm,eff = ηs + φs(ηm − ηs) + φsφm(ηB − ηm), (6.14)
where φm = exp(−dm/dp). In these equations, ηm and ηB are the refractive indices
of the adsorbed monolayer (cm) and of the bulk solution (c0, cB), respectively.
Considering the adsorption model of Fig. 4.4, and assuming that the analyte
molecule, when adsorbed, does not change its refractive index and specific (or
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Figure 6.3: Schematic of protein monolayer adsorbed onto a surface of thickness ds
in the Biacore sensor chip flow cell. The bulk aqueous solution has salt concentration
c0, protein concentration cB, and refractive index ηB; the refractive index of the isolated
(dry) protein is η̃B; salt solution with concentration c0 and refractive index η0 is assumed
to fill the gaps between adsorbed proteins; the thickness of the adsorbed monolayer, dm,
is roughly equal to the diameter of the proteins
molar) volume, then the refractive index of the adsorbed monolayer is
ηm = η0 + (η̃B − η0)vBcm, (6.15)
where cm (M) is the protein concentration in the volume occupied by the adsorbed
monolayer; cm can be converted into a surface concentration, q (g/dm
2), through
the simple formula q = dmcm. If the baseline has a refractive index (η0,ref)eff
(obtained with a salt solution of concentration c0,ref), then the change in the
effective refractive index probed by the Biacore machine will be
(ηm − η0,ref)eff = φs(ηm − η0,ref) + φsφm(ηB − ηm). (6.16)
Expanding the two right-hand-side differences gives
(ηm − η0,ref)eff = φs(η̃B − η0)vB[cm + φm(cB − cm)] + φs(η0 − η0,ref). (6.17)
The corresponding shift of the Biacore signal is
∆R = (mB −m0c0vB)[cm + φm(cB − cm)] +m0(c0 − c0,ref). (6.18)
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Equations (6.18) and (6.19) are the most general ones since they encompass
all the cases discussed above. For example, setting φm = 1 (i.e., dm = 0)
eliminates the adsorbed monolayer; setting cm = cB sets the solute concentration
in the adsorbed phase equal to that in the bulk solution and the two phases
become optically indistinguishable. In both cases, Eq. (6.18) correctly reduces to
Eq. (6.12).
Equation (6.11) shows that mB can be determined from the slope b of the linear
fitting (with intercept equal to zero) of ∆R against cB, as mB = b+m0vBc0,ref .
These calibration experiments, however, must be carried out under conditions
where the solute does not adsorb; this may be difficult to achieve in practice.
When there is only mild solute adsorption, the adsorbed phase will quickly
reach saturation conditions, that is, cm will quickly attain a constant value.
Equation (6.18) shows that, in this case, a plot of ∆R against cB will still exhibit
a linear relationship for sufficiently large values of cB (i.e., those values of cB for
which cm ≈ const), but with slope equal to φm(mB −m0vBc0,ref) and intercept
equal to (1− φm)(mB −m0vBc0,ref)cm.
A typical SPR experiment, whose schematic is depicted in Fig. 4.2, consists
of a bind-and-elute run. In the following it is assumed that there are no mass-
transfer resistances because the system is operated at a sufficiently high flow rate
(∼ 100µL/min or higher).
Initially, the SPR cell is equilibrated with aqueous salt solute with concen-
tration c0; this establishes the baseline of the Biacore signal. The binding step
consists of injecting the SPR cell with the aqueous salt solution with the dissolved
solute (B) at concentration cB.
This step corresponds to the curve ∆Ra(t) in Fig.6.4 If the injection is large
enough, the SPR signal will attain an horizontal plateau whose value is ∆Ra.
The plateau is the visual proof that the equilibrium between the solute in the
bulk solution and in the adsorbed monolayer is really established—this plateau
corresponds to one point in the adsorption isotherm.
If we can convert the signal ∆Ra into the concentration cm of the solute in
the adsorbed monolayer, then we have the equilibrium point (c0, cB, cm): this
means that cm is the solute concentration in the adsorbed monolayer that is
in equilibrium with an aqueous solution with salt concentration c0 and solute
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Figure 6.4: Typical bind-and-elute SPR experiment in the absence of mass-transfer
resistances.
concentration cB ; we express this as cm = c
∗
m(c0, cB) and denote this function as
the adsorption isotherm.
After the binding step, we flush the SPR cell with aqueous salt solution with
concentration c0. If there are no mass-transfer resistances, there will be an abrupt
drop in the SPR signal from ∆Ra to ∆R
o
d. This happens because the bulk solution
in the SPR cell (c0, cB) is quickly replaced by the salt solution (c0, 0) while the
adsorbed phase concentration is kept at the equilibrium value cm.
Applying 6.18 to the adsorption equilibrium plateau and to the point where
the SPR signal is ∆Rod gives, respectively,
∆Ra = (mB −m0c0vB)[cm + φm(cB − cm)] (6.20)
∆Rod = (mB −m0c0vB)[cm + φm(0− cm)]. (6.21)
Therefore,
∆Ra −∆Rod = (mB −m0c0vB)φmcB. (6.22)
This equation is important: it states that if we do a series of bind-and-elute
experiments with the same salt concentration but different solute concentrations
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Table 6.1: Characteristics of the Capto
TM
Core 700
Matrix High flow agarose
Size cut-off outer layer Mr ≈ 700 000
pKa of protonated octhylamine 10.65
Functional group in the core CH3CH2CH2CH2CH2CH2CH2CH2NH-
Total ionic capacity/ml medium 40 to 85 µmol (Cl−)
Particle size (d50v)
2 90µm
Maximum operational flow 500 cm/h in columns with 20 cm bed
velocity height at < 2 bar
Binding capacity/ml of medium ≈ 13mg ovalbumin
and plot ∆Ra−∆Rod against cB, then we should get a straight line with intercept
equal to zero and slope equal to (mB −m0c0vB)φm.
The Biacore can be precalibrated for the salt effect through a couple of simple
experiments with different salt concentrations c0, where each run consists of
equilibrating the cell with water and then injecting the salt solution; the SPR
signal for each experiment should be given by
∆R = m0c0, (6.23)
and thus yield a straight line with intercept equal to zero and slope equal to m0
when plotted against c0.
6.3 Results and Discussion
6.3.1 Principle of flowthrough purification
In designing a flowthrough process the combination of membrane and bead
technology was employed. In particular Sartobind-STIC and Capto Core were
chosen. The first is characterized of having a cellulose backbone where is directly
attached a primary amine ligand, polyallylamine (Table 6.1). This ligand was
proposed for the first time by Kim and Kuga (2002), as a potential new class
of anion exchanger for proteins separation. The membrane present a pore size
distribution of 2.5µm 4.5. This was elucidated by employing two techniques for
porous material characterization: mercury porosimetry and gas liquid displasment
porometry.
Mercury porosimetry depicted a broad pore size distribution (PSD) with pore
size between between 4 and 7 µm corresponding to the mesopore range (Rouquerol
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Figure 6.5: Figures A and B display a pore size distribution of the STIC membrane
measured by mercury porosimetry in a dry state conditions. The pore size distribution
is cantered in the mesopore region with pore size between of 4–7 µm. Figures C and
D show the pore size distribution obtained by capillary flow porometry under wet state
conditions. Pore size distributions results nicely centred at 2.5 µm.
et al., 1994). However, it should be pointed out that the analysis was performed
under dry conditions and the pore size distribution may change when hydrating
the membrane with buffer or water due to a swelling effect. Therefore to assess the
real pore size under operating conditions capillary flow porometry was employed.
This method is based on the measurement of the pressure necessary to blow gas
through a liquid-filled porous membrane. As the pressure of gas increases to a
point, the applied pressure overcomes surface tension of liquid in the pore and
pushes liquid out of the pore. Figure 6.5 C, shows that when the membrane is
hydrated a narrow pore size distribution of 2.5µm is observed.
The experimentes were conducted by using a minimized column with a vol-
ume of 0.023 mL in order to identify the operational conditions suitable for a
flowthrough purification yielding higher virus recovery.
Capto core 700 is a beads based resin recently introduced in the market by GE
Healthcare for virus purification in negative mode (Fernandes et al., 2013). The
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(A) (B)
Figure 6.6: Schematic representation of the chromatographic membrane (STIC) on
figure A. Large arrows indicate the prevalence of convective flow while small arrows
indicate film diffusion. Figure B shows the structure of Capto Core 700 beads, Aden-
oviruses cannot access into the inner core of the beads and are therefore collected in the
flowthrough (FT). The exclusion limit is around 700 kDa.
ligand employed is multimodal ligand able to bind impurities under a wide range
of pHs or NaCl concentrations (Table 6.1). The structure is illustrated in Fig. 6.6
and the cut off declared by the manufactured is 700kDa, thus adenoviruses that
have a molecular weight of 1.58 Da are excluded for the pore size. Unfortunately
mercury porosimetry to better elucidate the porosimetry is not applicable for wet
resins. The pore structures are determined by the distance between the polymer
chains and crosslinks which vary with the crosslink level of the polymer, the
polarity of the solvent and the operating conditions.
6.3.2 Down scale model: SPR technology
The results of PAA and Octylamine are presented. In order to identify the best
possible scheme for a flowthrough process the two ligands, PAA and Octylamine,
respectively functional groups of STICrand Capto
TM
Core 700 were investigated.
Being DNA one of the most important impurities to separated from the target
product its binding to the two ligand was studied. The scale down was performed
in a sensor chip (CM5) where the dextran layer is roughly 100 nm thicker, thus
increasing the surface available for binding. Figure 6.7 illustrated the total binding
of DNA (cm)for both PAA and octylamine.
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Figure 6.7: Adsorbate concentration cm for DNA under 150mM NaCl for PAA and
octylamine respectively. The total amount of DNA adsorbed for PAA is 40-fold higher
then the one observed for octylamine. For both ligands the desorption is negligible
indicating a irreversible DNA binding.
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Figure 6.8: Langmuir isotherm of PAA under different Na2HPO4 concentrations
ranging from 5 to 50mM(upper figure).Fitting shows a Langmuir dependency with an R2
of 0.99 for all the phosphate concentrations evaluated. The effect of the Na2HPO4 on
the binding behavior shows a exponential decay.
The results illustrated that the binding is 40-fold higher for PAA compared
octylamine, this was also confirmed by the isotherm in figure 6.8. The desorption
of the DNA as shown in figure 6.7 indicates the irreversible adsorption mechanisms.
From the process point of view this will imply that Octylamine ligand cannot
be implemented at earlier stage of the process where the concentrations of DNA
is often greater.
Figure 6.8 depicted the binding isotherm which follow a classic Langmuir
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Figure 6.9: Figure A and B illustrated the dependency of the Henry constant (H) and
qmax(10
−6g/dm2) as function of the Na2HPO4 concentrations respectively. The fitting
show an exponential decrease up to 20mM Na2HPO4. Both Henry constant qmax show a
fairly good agreement. Above 50mM Na2HPO4 the adsorption is strongly comprised and
aspecific interactions dominate the binding
Henry constant (H) and qmax are therefore given by :




Figure 6.9 displayed a strong dependency with the Na2HPO4 up to 20mM. Both
Henry constant and qmax present,as expected, a negative slope with an excellent
R2 fitting of 0.99. Above 50mM a linear correlation is no visible, mainly because
the adsorption is strongly compromised and aspecific binding might take place.
Should be here mentioned that the aspecific binding is not due to the ligand
but most likely to the CM5 support, in particular the dextran layer.
In the light of these results PAA showed to be the ideal ligand to be used as
in first step of the chromatography train. Therefore a better characterization was
conducted under several Na2HPO4 and NaCl concentration to identify the critical
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Figure 6.10: Prediction of the qmax binding behavior for the salmon sperm DNA under
several concentration of NaCl and Na2HPO4. As the isotherm suggested above 20mM
the binding is compromised. However high salt concentration of NaCl up to 400mM do
not affect the binding is strong manner.
operational value and evaluated them in the latter scale up (Fig. 6.10).
In regard to the NaCl the PAA ligand exhibit a salt tolerant profile, the binding
is in fact maintained up to 300mM NaCl. The results obtained were used to set
condition at which STIC membrane should be evaluated by using a real feedstock.
Capto Core, was less extensively evaluated. Indeed,although the adsorption onto
octylamine for DNA is lower compared to PAA, being a multimodal ligand it is
able to maintain the binding at wider range of salt concentrations and pHs.
6.3.3 Virus recovery
The SPR experiments indicated that phosphate buffer ranking between 5 to 50
mM is a strong modulator of the impurities binding. In order to assure the
highest trade off between contaminant clearance and virus recovery concentrations
ranging between 6.25mM and 50mM of both phosphate and citrate buffer were
evaluated. HEPES 50mM and Tris 20mM were included since they are two widely
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used buffers in virus purification. Figure 6.11 shows the percentage of the virus
in flowthrough and in the elution. Interestingly in all the conditions evaluated
viruses binding to the membrane was lower than 25%,thus yielding in flow-through
mode recovery higher than 75%. The membrane ligand can explain the reasons
of the limited virus adsorption. The ligands located on the larger pore size are
then mostly occupied by contaminants mainly DNA due to the high affinity of
this biomolecule to PAA, as previously shown in the SPR experiments. The only
exception was observed by using Tris, indeed, virus in flow-though were below 10
%, nevertheless virus desorption did not occur even at 1M phosphate, indicating
the presence irreversible binding. HEPES buffer showed a similar behavior to the
multivalent anions , this may be due to the presence in the chemical structure of
a sulfonic acid group.
The mass balance for the virus , with the exception of the Tris buffer, was
easily closed reaching 100% recovery by summing up the flow-though and the
eluted peak. In the Captocore the mechanism for which the virus do not bind
is mainly size exclusion like. Therefore no investigation on the modulator of the
binding was required. HEPES 50mM with 150 mM NaCl was chosen to assess
the recovery. The NaCl of 150mM was used in order to reduce possible aspecific
interaction with the beads matrix. The bulk employed was the same used for
STIC experiments. Recovery yield is shown to be of 80.10 % (Table 6.3) slightly
lower compared to the STIC , probably due to some non-specific binding or virus
entrapment that occur in the outer shell of the beads. Therefore, unlikely to what
observed with STICr membrane mass balance could not be closed.
6.3.4 Impurities clearance
For proper assessing the feasibility of a flow-though purification process, the
removal impurities should be properly evaluated. Furthermore, this will indicate
if the prediction of the design space illustrate in 6.10 are consistent the knowledge
generate on the sensor chip can be translate to membrane chromatography system.
Table 6.2 reports the clearance for DNA and total proteins. The results suggested
that polyallylamine (PAA) ligand has higher affinity to phosphate groups, in
particular above 10mM phosphate the DNA clearance dropped to nearly 20%.
This is in line with what observed in Figure 6.8 suggested by the isotherm
determination.
However, the high affinity to the phosphate results in higher removal of DNA,
when the concentration of Na2HPO4 is reduced, since the phosphate groups are
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Figure 6.11: The recovery both in flowthrough (top plot) and after elution (bottom
plot). Orange color depicted the phosphate buffer, while in green is citrate buffer. Tris
and HEPES buffers are depicted in blue and pink respectively. Virus quantification was
performed by RT-PCR and Nanosight NS500.
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Table 6.2: DNA and total protein clearance in the flow-through under several concen-
trations of multivalent anions with the use of STICr membrane. Buffer can be rated in
regard to their clearance as: HEPES > Citrate > Tris > Phosphate
Buffers DNA clearance Total protein clearance
[%] [%]
50 mM HEPES 93.28 69.61
6.25 mM Phosphate 85.52 61.73
12.5 mM Phosphate 58.71 71.43
25 mM Phosphate 58.61 78.23
50 mM Phosphate 55.41 65.72
20 mM Tris 65.00 85.62
20 mM Tris 200 mM NaCl 79.77 27.38
6.25 mM Citrate 78.74 65.73
12.5 mM Citrate 78.73 70.35
25 mM Citrate 78.16 68.43
50 mM Citrate 74.14 67.30
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Figure 6.12: Host cell protein clearance for the flowthrough of STICr membrane.
Increasing in citrate concentration leads to reduced HCP clearance. HEPES yields the
highest clearance.
Table 6.3: DNA and host cell protein clearance in the flow-through for Capto Core.
Virus Recovery Yield DNA Clearance HCP Clearance
[%] [%] [%]
75.23 80.10 89.75
known to surround the DNA double helix. The best trade-off between DNA
and total protein clearance is given by HEPES 50mM with 100mM NaCl and
citrate buffer, with a clerance of 93.28 % and 78.74% respectively. No significance
differences are observed among the citrate concentrations evaluated.
Further analysis were carried out in order to assess the level of HCPs present in
the flow-through. Figure 6.12 displayed HCPs clearance, measured by ELISA (see
Materials and Methods). These results are complementary to the total protein
clearance, giving a more accurate determination of the amount of proteins that
do not belong to growth media, or viruses.
The HCPs clearance was similar among the citrate concentrations whereas
HEPES buffer showed a superior performance yielding a clearance of 64 %. Overall
HEPES results to be the most appropriate buffer, with a virus recovery yield
higher than 90 % coupled with a satisfactory purity level. Capto
TM
Core 700
yields a 80.10%, DNA clearance, respectively. HCPs removal compare favorably
to membrane chromatography with a 25% increased of clearance, most likely due
to the different nature of the ligand (Table6.3).
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Figure 6.13: Salmon sperm DNA breakthrough at different NaCl concentrations. As
predicted by the SPR experiments the binding is salt tolerant and a slightly decrease is
observed at 800mM.
Since HCPs are an heterogeneous pool of proteins with various size and charge
and isoeletric points, having a ligand that can adsorb impurities through ion
exchange and hydrophobic mechanism, might improve the clearance of a wide
range of proteins (Kallberg et al., 2012; Pezzini et al., 2011; Joucla et al., 2013).
In regards to the DNA removal, the results are comparable to STICr. However
dynamic binding capacity and binding isotherm using salmon sperm DNA, showed
a DBC10% of 0.84 mg/ml which is 6-fold lower compared to the 5.43 mg/ml of
the STICr membrane. Such lower DBC10% was not expected and the hypothesis
reason could be that double helix DNA is rather big molecules and could not
access the inner core of beads, therefore salmon sperm DNA was treated with
Denerase (an equivalent of the well known Benzonaze). However the results
showed a similar DBC10% (data not shown).
In the ligth of this result Capto
TM
Core 700 may be not be suitable for being
employed in the early steps of a downstream train, where high DNA concentrations
are usually observed. Breakthrough curves under various NaCl illustrated a salt
tolerant behavior for both systems.
PAA can still bind DNA until 800mM NaCl with an only slightly reduction in
the DBC (Fig. 6.13).
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Table 6.4: Residual DNA and protein that coeluted with the virus fraction. STICr
membrane
Buffers DNA Total protein Conductivity
Loading concentration [mM] [%] [%] [mS/cm]
50 mM HEPES 1.20 1.26 24.30
6.25 mM Phosphate 0.00 8.18 33.47
12.5 mM Phosphate 0.0 4.48 33.10
25 mM Phosphate 1.42 0.0 32.87
50 mM Phosphate 8.70 0.0 31.50
20 mM Tris 4.32 1.89 35.25
20 mM Tris 200 mM NaCl 9.59 60.77 30.70
6.25 mM Citrate 12.64 22.75 24.50
12.5 mM Citrate 12.65 21.59 24.31
25 mM Citrate 10.92 19.69 23.78
50 mM Citrate 13.22 20.75 23.55
However this data might be seem contradictory compared to the biacore data
prediction counterplot, where a reduction of the binding is observed above 400mM
of NaCl. Nevertheless, in a chromatographic system, the ligand salt tolerant
behaviour can be enhanced by increasing the ligand density. The overall trends
which are intrinsic in the ligand remains, although their values may raise with the
increase of ligand density. In regard to the DNA elution also on the membrane a
irreversible adsorption was observed, again indicating a good prediction of the
SPR experiments.
The analysis of the virus peak fraction shows a remarkable clearance of both
DNA and total proteins. Table 6.4 shows that the DNA eluted is below the
detection limit of the assay when the concentration of phosphate is low. Yet,
the conductivities at which virus desorption occurs are close to 25 mS/cm, thus
250mM phosphate buffer.
On the other hand, by using citrate buffer 1M as elution buffer viruses can
desorb at similar conductivity around 24 mS/cm, however impurities clearance
are reduced by 10 %.
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6.3.5 Flowthrough process
Analyzing the data showed previously it becomes clear that by only using STICr
membrane or Capto
TM
Core 700 alone would not satisfy purity constrains, in
terms of both DNA and HCP. However, implementing these two flowthrough
technologies in series as shown in Figure 6.14 lead to a platform flowthrough
process that could serve for the purification of other large biopharmaceuticals,
such as VLPs. The results from the Biacore and the proof of concept with a small
scale device, identify the following constrains in the whole process optimization.
Firstly,(i) Capto Core 700 should be placed at later stage of the process, (ii) binding
of STIC membranes can be compromised by high concentration of phosphate, (iii)
negative mode results in dilution of the product therefore UF/DF unit operations
should then integrated in the whole process. Taking into account these constrains
the process showed in Figure 6.14 top plot was developed. The first UF/DF is
mainly present to remove trace of phosphate buffer and condioniting the bulk with
HEPES buffer. Afterwards another UF/DF is employed in order to combined the
two fractions (FT and peak) and to remove remains DNA. This will help also the
purification performance of the Capto core.
The full process development showed that the DNA clearance achieved is
roughly 4 logs reduction. Also, virus recovery is boosted, especially in the first
chromatographic unit operation (STIC membranes) where summing up the virus
in FT and the virus eluted the recovery is close to 100%. As for HCP reduction
is 5 logs, however while most of the DNA clearance is achieved in the STICr




Overall by combining the two flow through technologies it is possible to design
a process that has higher productivity, more robustness, and easily scalable.
Scale up was performed by simply calculate the DBC%10 for DNA for the STIC
membrane with a full breakthrough experiments. The concentration of the bulk
was kept constant. This kind of approach in negative mode, it is more suitable
for a platform concept. Due to the high degree of uncertainty associated with
the clinical studies process development at early stage aims to produce material
for phase 1 and phase 2 clinical trials using standardized process conditions and
procedure. The use of platform process allow the acceleration of the process
development activities as already shown for mAbs application (Tugcu et al.,
2008). The similarity amongs different viruses or serotype make the platform
concept feasible although the process is not fully optimized for every complex
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Purified viruses









STIC Membrane Capto Core 700
UF/DF 100 kDa
Figure 6.14: Flowthrough purification scheme for adenovirus (top plot) and VLP
(bottom plot). The bulk after clarification is concentrated 10 times and 5 times diafiltrated
with a prototytpe 500kDa cassette. The feed is then loaded into the Sartobind STICr
membrane; flowtrough and peak contanining 85% and 15 % of the virus respectively
are collected and concentrate/diafiltrate by a factor of three. Capto
TM
Core 700 is
then loaded and the purified virus collected in the flowthrough.For the VLP flow scheme
a Vivaflow 100 kDa cassette was used for concentration and diafiltration.The STIC
membrane and the Capto Core were connected in series.
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biopharmaceuticals.
In fact, by changing virus serotype or different VLPs in a classic bind and
elute process often results in changes in the elution behavior, thus the process
should be always fine tuned. In contrast in a flowthrough process, such as the
one described here, the elution behavior is constant cause no adsorption of the
target product occurs. Scale up is easier to perform since DBC of the impurities
is the factor that has to be taken into account keep linear velocity or resident
time constant. Selectivity during gradient elution and peak tailing are not an
issue anymore.
In order to prove that the negative mode can be suitable for preliminary
purification of other large biopharmaceutical, the scheme used for adenovirus
was sligthly changed and employed for VLP purification. In contrast with the
adenovirus bulk, VLP feedstock have the following characteristic: (i) the pro-
duction occurs via budding therefore no lysis is required resulting in a cleaner
bulk,(ii) the presence of less contaminant namely DNA and host cell protein,
on one hand release the constrain for purity on the other required the use of
a modulator such as phosphate buffer in the STIC membrane (iii) VLPs are
shear stress sensitive (Negrete et al., 2014; Chalmers, 1996), therefore the use of
UF/DF should be limited. Taking into account these constrains the FT process
for adenovirus was modified by connecting in series STIC membrane and Capto
core. Only one UF/DF was unit operation was implemented at the beginning
of the chromatography train, with the aim of concentration and to condition
the bulk with a PBS containing 50mM phosphate. Also, being enveloped VLPs
relatively complex structures consisting of the host cell membrane (an envelope)
with integrated target antigens displayed on the outer surface results in high
instability. Factors such as vortexing stirring, skaking and pumping were observed
by Li shi et al, from Merck and Co to induce significant VLP aggregation and
protein concentration(Shi et al., 2005). To reduce this phenomena a small amount
of non-ionic surfactant polisorbate 80 at the concentration of 0.01 (v/v)% was
used during the entire downstream train. Overall the stabilizing effect exhibits in
two mechanisms: solubilization and replacement. The solubilization mechanism
requires the formation of a complex between between the protein and the surfac-
tant. The replacement mechanism requires the competition of surfactants with
proteins for the adsorption surfaces.
The results showed a recovery yield in the UF/DF of 50% and 45 % recovery
yield in the chromatography train. Although these results may not appear
outstanding if compared with adenovirus, in the field of enveloped VLP are
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considered in line with other purification strategies (Segura et al., 2006; McNally,
2014). The labile nature of retro VLP and their instability makes their purification
very challenging.
In regard to the purity, the two column in series achieved a log reduction for
DNA and HCP of 2.0 and 3.5 respectively. The UF/DF unit operation adds a
further 1 log reduction for both impurities. Since the bulk is obtained by budding
and cell lysis is not required, this results in having a lower initial amount of
impurities which improve the purification performance of the downstream train.
6.4 Conclusions
The work presented showed a rational development of a flowthrough process
first by understanding the behaviour of DNA (major contaminant) binding onto
the two ligands and afterwards scaling up and confirming the design space.
The flowthrough process designed is suitable for a platform concept and was
implemented for adenovirus and retro-VLP purification with minimal amount of
optimization required.
Acknowledgments
The authors thank Rute Casto and Ana Sofia Coroadinha for providing the
retro-VLP bulk. Financial support from Sartorius Stedim Biotech and from
the Portuguese Science Foundation (FCT-MCTES) (SFRH/BD/82032/2011 and
EXPL/BBB-EBB/0790/2012) is gratefully acknowledged. The authors do not




Boi, C. (2007). Membrane adsorbers as purification tools for monoclonal antibody
purification. Journal of Chromatography B , 848 , 19–27.
Burova, E., and Ioffe, E. (2005). Chromatographic purification of recombinant adenoviral
and adeno-associated viral vectors: methods and implications. Gene Ther., 12 ,
S5–S17.
Chalmers, J. (1996). Shear sensitivity of insect cells. Cytotechnology , 20 , 163–171.
Eglon, M. N., Duffy, A. M., O’Brien, T., and Strappe, P. M. (2009). Purification of
adenoviral vectors by combined anion exchange and gel filtration chromatography.
J.Gene Med., 11 , 978–989.
Fernandes, P., Peixoto, C., Santiago, V., Kremer, E., Coroadinha, A., and Alves, P.
(2013). Bioprocess development for canine adenovirus type 2 vectors. Gene therapy ,
20 , 353–360.
Gerster, P., Kopecky, E.-M., Hammerschmidt, N., Klausberger, M., Krammer, F., Grab-
herr, R., Mersich, C., Urbas, L., Kramberger, P., Paril, T. et al. (2013). Purification
of infective baculoviruses by monoliths. J. Chromatogr. A, 1290 , 36–45.
Goerke, A. R., To, B. C. S., Lee, A. L., Sagar, S. L., and Konz, J. O. (2005). Development
of a novel adenovirus purification process utilizing selective precipitation of cellular
dna. Biotechnol. Bioeng., 91 , 12–21.
Hahn, R., Tscheliessnig, A., Bauerhansl, P., and Jungbauer, A. (2007). Dispersion
effects in preparative polymethacrylate monoliths operated in radial-flow columns. J.
Biochem. Biophys. Methods, 70 , 87–94.
HOLMES-FARLEY, S. R., Mandeville, W. H., Ward, J., and Miller, K. (1999). De-
sign and characterization of sevelamer hydrochloride: a novel phosphate-binding
pharmaceutical. J. Macromol. Sci., Pure Appl. Chem., 36 , 1085–1091.
Iyer, G., Ramaswamy, S., Asher, D., Mehta, U., Leahy, A., Chung, F., and Cheng, K.-S.
(2011). Reduced surface area chromatography for flow-through purification of viruses
and virus like particles. Journal of Chromatography A, 1218 , 3973–3981.
217
REFERENCES
Jason-Moller, L., Murphy, M., and Bruno, J. (2006). Overview of biacore systems and
their applications. Curr Protoc Protein Sci , Chapter 19 , Unit 19 13. Journal Article
Review United States.
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The increasing interest in virotherapies, either gene therapy or viral vaccines, is
propelling the development of novel and more efficient bioprocesses. In particular,
advances in upstream processing (USP) have substantially increased bioreactor
yields and the bioprocess bottlenecks are now mainly in the downstream processing
(DSP) . To overcome these bottlenecks technological advances have taken place
to develop straightforward purification processes aimed to deliver a final product
fulfilling the critical quality attributes required by the authorities. Nevertheless,
the implementation of an integrated downstream purification process for virus-
like-particles or viral vectors is not yet mature; indeed, it is still difficult to achieve
a high-purity grade while keeping host cell protein (HCP) and deoxyribonucleic
acid (DNA) within the specifications set by regulatory bodies.
The work presented in this thesis aimed to develop and/or test new processes
for adenoviruses purification. This virus is considered to be one of the most
suitable platforms for producing viral vaccines and gene therapy vectors. It can
be produced using complementary cell lines in both adherent and suspension
culture systems, such as HEK–293 or PER-C6 cells, CAP or A549 for oncolytic
adenoviruses (Segura et al., 2008).
Chapter 1 offers an extended revision of the state-of-the-art by analyzing
prominent case studies and underlying the current limitations and challenges.
Part II, comprising chapters 2 and 3, focuses on the understanding and
performance improvement of some DSP unit operations, such as ultrafiltration and
anion exchange chromatography. We have successfully selected and implemented a
novel class of large cut-off ultrafiltration membranes that achieve 100% of infective
virus recovery after 10-fold concentration. In addition, we have extended the
fundamental knowledge regarding the impact of ligand density and membrane
structure providing new insights into the development of next generation membrane
chromatography.
The third part of the thesis is essentially focused on developing continuous
processes based on the simulating moving bed (SMB) technology. The result
is a remarkable increase in the productivity for the purification of adenovirus
by size-exclusion chromatography. Finally, in the last chapter a flowthrough
purification strategy was implemented by combining the salt tolerant membrane
chromatography (STIC) and the scavenger bead technology (CaptoCore). With
this new approach, we were able to design a versatile, effective, and robust
flowthrough process for adenovirus and VLP purification.
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7.1.1 Improved ultrafiltration processes
Ultrafiltration has been widely used for both concentration and buffer exchange
(diafiltration, DF), and is present in almost every virus DSP described in the
literature (Segura et al., 2013; Bandeira et al., 2012; Kamen and Henry, 2004;
Rodrigues et al., 2007; Segura et al., 2012; Wickramasinghe et al., 2005; Kalbfuss
et al., 2007; Subramanian et al., 2008) and disclosed patents (Luitjens and van
Herk, 2012; Konz et al., 2008; Weggeman and van Corven, 2005). The membranes
used in virus UF have MWCOs in the range of 100–750 kDa allowing for high virus
recoveries (70–85%). Despite the effort in developing robust DSPs and platforms,
most of the research in the field of virus purification has been focused on the
chromatographic steps. The results discussed in Chapter 2 provide an important
contribution to ultrafiltration processes for viral processing. We designed a novel
large cut-off ultrafiltration membrane (∼500kDa) based on highly cross-linked
regenerated cellulose. The membrane exhibits a remarkable virus particle recovery
yield, and higher productivity when compared to a hollow fiber (HF) (∼750kDa)
device. Most notably, this is the first study to investigate adenovirus concentration
by ultrafiltration cassette. Futhermore, our findings complement the previous
studies based on VLP and influenza (Negrete et al., 2014; Wickramasinghe et al.,
2005) where only PES membranes were evaluated. In addition, unlike the other
reported studies, important process ultrafiltration parameters, such as fouling
behavior and flux recovery before and after cleaning in place (CIP), were also
assessed.
7.1.2 Understanding anion-exchange membrane chromatog-
raphy
Convective chromatography media, such as membranes and monoliths, offer
substantial improvements in capacity, recovery, and reduction of process time
(Hahn et al., 2007). Membrane adsorbers are used in the biopharmaceutical
industry almost exclusively in flowthrough mode for mAb purification (Boi,
2007; Knudsen et al., 2001; Zhou and Tressel, 2006). More recently, membrane
adsorption chromatography has been applied to the purification of viral vectors
using a bind-and-elute mode, yielding good overall recovery rates (Lee et al.,
2009; Peixoto et al., 2006, 2008). However, two major challenges still remain:
on one hand, adequate removal of impurities (DNA and HCP) that are closely
related to the viral product, and on the other hand low binding capacity for highly
concentrated feeds. The design of new matrices with appropriate ligand density
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and degree of grafting is key to further improve the bind-and-elute purification
mode for viruses.
In Chapter 3 we complement the results obtained by Vicente et al. (2011)
for baculovirus (an enveloped virus) with adenovirus (a non-enveloped virus).
In addition we further extend our study by comparing two different membrane
platforms (direct-grafted vs hydrogel-grafted) which led to the following outcomes:
• Hydrogel-grafted membranes yield higher virus recoveries than the directly-
grafted membranes.
• Moving toward hydrogel-grafted membranes with ligand densities lower
than 2.4 µmol/cm2 led to virus recoveries higher than 70%, in line with the
findings of Vicente et al. (2011). A decreased ligand density and increased
ionic strength to a value of 150-200 mM NaCl are suitable conditions for
hydrogel-grafted membranes.
• The directly-grafted membranes show low binding for the virus and give
rise to significant percentages of viruses in the flow-through, up to 60-70%.
Increasing the ligand density and lowering the ionic strength to a maximum
of 25 mM NaCl is more suitable for directly-grafted membranes.
• An attempt is made to elucidate the shapes of the breakthrough curves by
matching the frontal analysis experiments to a simple equilibrium-dispersive
adsorption breakthrough model.
• Overall, when designing new chromatographic membrane for virus purifi-
cation, ligand density is not the only factor to consider, as the membrane
structure also plays an important role.
Finally, future work should investigate the effect of larger ligand density values
(>4.5 µmol/cm2) for improving the performance of the direct-grafted membrane
platform. This platform holds promise for replacing the current hydrogel-grafted
technology.
7.1.3 Moving towards continuous chromatography
From chapter 4 we step into the design of a semi-continuous process based on SMB
technology. The results demonstrate the feasibility of a compact and efficient,
simulated countercurrent multi-column chromatographic process for adenovirus
purification. The process is strictly operated in an open-loop configuration to
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dispense the use of an internal recirculation pump; it needs two HPLC pumps
only: one for injecting the clarified bioreaction bulk and another for injecting
fresh eluent. At any instant of the operating cycle the flow through a column is
either temporarily stopped or completely directed to one of three destinations:
the other column, the waste line, or the product line. This class of flow-path
configurations is easily implemented with simple two-way valves and gives rise to
very robust operating cycles. The experimental results show:
• a virus recovery of 86%, and a clearance of 90% and 89% for DNA and HCP,
respectively. These figures compare very favorably against single-column
batch chromatography for the same volume of size-exclusion resin.
• 6-fold productivity boost and 51% increase in Ad5 recovery, without com-
promising the impurity clearance. These are strong arguments in favor of
implementing the type of process presented here in a real production DSP
train.
The designed 2-column process is further studied by assessing its robustness
by selecting the best set of operating parameters. These operating parameters are
robust feasible and remain feasible for all parameter perturbations within their
uncertainty intervals. Our procedure successfully identifies the optimal robust
values of the step durations when both the interparticle porosity (εo)and column
volume (Vc) are subject to two types of uncertainty scenarios. In one case εo and
Vc are uncorrelated, uniformly distributed random variables, whereas in the other
case εo and Vc are uncorrelated, normally distributed random variables.
Overall the work presented in chapter 4 and chapter 5 together with the
study of Kröber et al. (2013) constitute the state-of-the-art for continuous or
quasi-continuous chromatography for viral vaccines or vectors.
Continuous processing of complex biopharmaceuticals, such as viruses or VLPs,
is still in its infancy and much more work should be done in the coming years.
The work of Nestola et al. (2014a) and Kröber et al. (2013) were both based on
isocratic elution by size exclusion chromatography (SEC); therefore future studies
should investigate a multicolumn process using an IEX matrix. IEX continuous
processes are not trivial because the development of a model able to predict
the binding and elution behavior is required. When steric mass action (SMA)
model is applied to describe the IEX mechanism of large biopharmaceuticals, it is
somewhat difficult to determine the characteristic charge, as shown by Yamamoto
et al. (2007) who studied the retention behavior of oligo-DNA onto an anionic



























Figure 7.1: Ideal flow for a fully integrated continuous processing. A close link between
upstream and downstream is required to switch from batch to continuous production.
The role of analytical tools is critical because it is essential to develop on-line or at-line
measurements to monitor a continuous processes.
quite challenging to determine this parameter experimentally. However, even more
trickier is to use the SMA model in model-based process design and optimization
due to the difficulties of numerically solving the differential material balance of
an IEX adsorber for large values of the characteristic charge. Therefore, efforts
should be made to develop a robust model that can be suitable for designing a
continuous or semi-continuous IEX process.
Overall, chromatography is only a part of the global process including upstream
and downstream, and there are really beneficial improvements when a large part
of the process is switched to continuous operation. Figure 7.1 illustrates an ideal
continuous integrated strategy where upstream and downstream are closely linked.
The development of analytical tools for on-line and at-line measurements becomes
critical for continuous processing. Nonetheless, the work presented in this thesis
is an important starting point for further studies.
7.1.4 From bind elute to flow-through process
In the last chapter of this thesis we continue our journey through the development
of new processes by focusing on a flowtrough strategy. Most of the applications
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described in the literature for virus purification are based on positive mode,
where the target product binds to the matrix. Nevertheless, negative modes are
being developed and an interesting review by Lee et al. (2014) details several
applications.
One apparent limitation of negative mode is due to the difficulty of efficiently
removing the impurities as compared to positive-mode chromatography; thus so
far, negative mode has only been implemented as a polishing step. In the process
proposed in chapter 6 we combined together two recently launched matrices, Capto
Core 700 from GE healthcare and a salt tolerant chromatographic membrane
(STIC R©) from Sartorius Stedim Biotech. The process is integrated with the
large cut-off ultrafiltration membrane selected in chapter 2. In addition, the
ligands immobilized on the two matrices were thoroughly studied using SPR
technology providing useful insights for identifying optimal operating conditions,
namely ionic strength, buffer type and phosphate concentrations. Overall, by
combining the two flowthrough technologies it was possible to design a process
with higher productivity, more robust, and easily scalable. The scale up was
performed by simply calculating the DBC%10 for DNA for the STIC membrane
from breakthrough experiments.
The negative mode strategy described herein is more suitable for a platform
concept; due to the high degree of uncertainty associated with the clinical studies
process development at early stage aims to produce material for phase 1 and
phase 2 clinical trials using standardized process conditions and procedures. The
use of platform processes allows the acceleration of the early process development
activities as already shown for the mAb applications. The similarity amongst
different viruses or serotypes make the platform concept feasible although the
process need to be optimized for each complex biopharmaceutical.
Although much work is still required to promote negative-mode chromatog-
raphy as a purification platform, its potential should not be underestimated,
especially for viral vaccines where different serotypes or strains may influence the
binding and elution behavior, leading to routine optimization for every new viral
vaccine candidate in the pipeline.
7.2 Final remarks and future perspectives
This thesis successfully contributes to the design of new processes by studying,
integrating, and validating novel matrices and materials. The overall strategy
used is shown in Fig. 7.2. A more efficient and robust process can only be
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Figure 7.2: Strategies for delivering new downstream processes applied in this thesis.
The combination of both new materials and processes is crucial, and the two aspects need
to be strongly connected for a proper process design.
achieved by the integration of new materials within new process designs. A strong
interconnection of these two aspects is therefore required to generate either new
materials from existing processes or new processes from new materials.
Current advances in material science, such as new chromatographic supports
based on nanofibers (Hardick et al., 2012) and the novel 3D printing for monolith
development (Fee et al., 2014), have the potential to revolutionize the current
processes. At the same time, better understanding of ligand density and structure
can lead to new stationary phases optimized for virus purification, where binding
site competition between viral particles and process related contaminants can
be sterically promoted; these new matrices should have high dynamic binding
capacity for virus particles and little or none for the contaminants (DNA and
HCP) (Villain et al. Oral presentation, Recovery Conference, 27-31 July 2014).
This thesis contributes to a greater extent to developing this concept further.
On the other hand, mixed-mode and biomimetic chromatography ligands
are foreseen to increase the performance of chromatographic unit operations (Li
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et al., 2014). The future of virus-ligand library screening can be as promising as
ProMetic currently is for other protein/Ab products. Materials science is also
developing stimuli-responsive polymers (known as smart polymers) with unique
properties that can be precisely modulated by a number of factors, such as light,
temperature, pH, electric or magnetic fields, etc. (Bajpai et al., 2011). These new
polymers might be employed in aqueous two phase separation (ATPS) for better
modulating two-phase partitioning (González-González and Rito-Palomares, 2013),
or even employed as mobile phase in chromatographic separations. Nevertheless,
toxicity and biocompatibility require proper assessment.
The implementation of HTPS technologies is slowly being established in
academic settings to improve process design (Nfor et al., 2012; Osberghaus et al.,
2012; Nestola et al., 2014b). Companies such as Tecan or Beckman Coulter—
industrial leaders in automation and robotic platforms—are already developing
full customizable solutions for big pharma, SMEs, or small academic groups.
HTPS tools will increase the understanding of the design space coupled with a
more mechanistic analysis of the physico-chemical properties of virus particles.
HTPS technologies are relevant not merely for the optimization of downstream
processing but also for investigating the appropriate formulation to use. For
example, Freeslate is providing a configurable, robotic laboratory automation
system for formulation and stability tests. So far, formulation has often been
regarded as the last step of the process, mainly related to the filling and finishing
processes. However, for labile viruses such as enveloped viruses, formulation
becomes critical earlier as it allows to stabilize the virus particles along the
downstream processing train, giving rise to a more robust downstream process.
The vaccine industry will most likely follow the same trend as the mAb industry
by designing new purification trains with a reduced number of unit operations.
Moreover, the implementation of numerical and scaled down tools for process
optimization will facilitate the identification of proper design spaces for both
single unit operations and integrated processes. Complex stochastic approaches,
such as the Giddings and Eyring models, or Monte Carlo models, can elucidate in
more detail the elution profile of heterogeneous viral bulks.
Furthermore, efforts to develop platform technologies, which can be used for
several virus serotypes, will be given the highest priority to allow the acceleration
of the process development.
New drag-and-drop production platforms could be developed by better un-
derstanding and modelling the different production steps. Although technology
platforms for vaccine manufacturing are indeed diverse, the diversity is seen
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mostly in the fermentation/cell culture and DSP purification. Qualified utilities,
equipment preparation areas, and buffer and media preparation areas are not
significantly different across technology platforms. With appropriate segregation
and control, it is possible to design multi-product facilities that can be used for
more than one product. This type of modular approach would improve asset usage
and minimize the impact of failure of one product. A modular design approach
requires an understanding of the pipeline of products in development and the
company’s long-term vision of the manufacturing site. Nevertheless, platform
concepts have the disadvantage and the risk of limiting somewhat the innovation
of the process by focusing all the resources to the already developed platform
(Wen et al., 2014).
Above all, the biopharmaceutical and, in particular, the vaccine industry
should embrace new changes and technologies as supported by the QbD initiative
from FDA/EMA, and the recent industry motto “If it ain’t broken don’t fix it”
should be overcome (Gottschalk et al., 2013). Process innovation will certainly be
key for delivering affordable viral vaccines and vectors. Indeed quoting Peter F.
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Kröber, T., Wolff, M., Hundt, B., Seidel-Morgenstern, A., and Reichl, U. (2013).
Continuous purification of influenza virus using simulated moving bed chromatography.
J Chromatogr A, 1307 , 99–110.
Lee, D.-S., Kim, B.-M., and Seol, D.-W. (2009). Improved purification of recombinant
adenoviral vector by metal affinity membrane chromatography. Biochem Biophys Res
Commun, 378 , 640–644.
Lee, M. F. X., Chan, E. S., and Tey, B. T. (2014). Negative chromatography: Progress,
applications and future perspectives. Process Biochem, 49 , 1005–1011.
Li, Y., Liu, X., Dong, X., Zhang, L., and Sun, Y. (2014). Biomimetic design of affinity
peptide ligand for capsomere of virus-like particle. Langmuir , 30 , 8500–8508.
Luitjens, A., and van Herk, H. (2012). Method for the production of Ad26 adenoviral
vectors. US Patent 0315696 A1 , .
Negrete, A., Pai, A., and Shiloach, J. (2014). Use of hollow fiber tangential flow filtration
for the recovery and concentration of hiv virus-like particles produced in insect cells.
J Virol Methods, 195 , 240–246.
Nestola, P., Silva, R. J., Peixoto, C., Alves, P. M., Carrondo, M. J., and Mota, J. P.
(2014a). Adenovirus purification by two-column, size-exclusion, simulated countercur-
rent chromatography. J Chromatogr A, 1347 , 111–121.
Nestola, P., Villain, L., Peixoto, C., Martins, D. L., Alves, P. M., Carrondo, M. J., and
Mota, J. P. (2014b). Impact of grafting on the design of new membrane adsorbers for
adenovirus purification. J Biotechnol , 181 , 1–11.
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